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11 General introduction
GENERAL INTRODUCTION
An adult human organism consists of trillions of cells that collectively constitute its complex 
tissues and organs. The development of those cells depends on activation or suppression 
of specific gene programs that regulate cell division, differentiation and cell death. The 
coordinated regulation of those programs occurs through among others transcriptional 
and post-transcriptional mechanisms. It has become apparent that the cellular mechanisms 
controlling normal and abnormal hematopoiesis can be profoundly regulated by microRNA’s. 
MicroRNAs (miRNAs) belong to the family of small non-coding RNAs, together with siRNAs 
and piRNAs, that post-transcriptionally suppress gene expression.1 By base pairing with 
their target mRNAs, miRNAs function as a guide for other factors that inhibit translation 
and/or induce mRNA decay.2 Considering that more than 1000 distinct miRNA genes have 
been identified and more than 60% of human protein-coding genes are thought to be under 
the control of miRNAs, these small molecules have a role not only in physiological gene 
regulatory networks but they may also have an important role in the dysregulation of these 
networks in human disease.3-5 This thesis is focused on the functional significance of micro-
RNA’s in normal hematopoiesis and the pathobiology of acute myeloid leukemia (AML).
1. MIRNAS
1.1. miRNA biogenesis
miRNA genes
miRNA gene sequences are located within various genomic contexts, such as intronic 
and exonic regions of other transcripts.6 Several miRNA loci may constitute a policistronic 
transcription unit, where a single transcript yields multiple mature miRNAs that are co-
transcribed.7 The expression of individual miRNAs can be post-transcriptionally regulated 
to provide robustness and versatility. Some miRNAs are expressed from multiple paralogous 
loci in a given genome.7 This results in increased redundancy and reflects functional 
importance of such miRNAs.
The precise location of miRNA promoters have not yet been mapped for most miRNA genes.8 
Additionally, intronic miRNAs may have their own promoters or share them with their host 
genes. The transcription of the majority of miRNA genes is carried out by RNA polymerase II 
and results into formation of long primary (pri-miRNAs) transcripts (Figure 1).6,8 Pri-miRNA 
transcription can be deregulated and can promote cancer initiation.9 This occurs when the 
pri-miRNA genomic region is deleted, amplified or translocated, but also when there is an 
aberrant transcription factor activity.
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Figure 1. Schematic overview of canonical miRNA biogenesis pathway demonstrated by miR-9/9*. miRNA genes are 
usually transcribed by RNA polymerase II (Pol II) as long primary transcripts (pri-miRNAs) that are then cleaved by 
Microprocessor complex (DROSHA and DGCR8) to release a smaller precursor miRNA (pre-miRNA). Pre-miRNA is 
transported from nucleus to the cytoplasm by exportin 5 (XPO5) and further processed by DICER1. miRNA/miRNA* 
duplex, generated by DICER1, is subsequently loaded onto AGO protein, unwinded, and one strand of the mature 
miRNA becomes a part of miRNA-induced silencing complex (miRISC). miRISC regulates target gene expression by 
transcript destabilization and/or translational repression. Chr, chromosome. 
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Pri-miRNA processing
The long pri-miRNAs (typically with a length over 1 kb) are cleaved by the Microprocessor to 
release smaller (around 65 kb) hairpin-shaped precursor miRNAs (pre-miRNAs) (Figure 1).1 
The Microprocessor is a complex that includes the double-stranded RNase III enzyme 
DROSHA and its essential cofactor DGCR8.10 The target recognition by miRNA is dependent 
on the 5’ end of its mature sequence that spans from nucleotide position 2 to 7 and is 
called the seed sequence.11 DROSHA determines the 5’ terminus of a miRNA and controls 
its abundance and activity, e.g. by post-translational modifications or interactions with 
RNA-binding proteins that selectively interact with certain pri-miRNAs.9,12,13 Following 
DROSHA processing, pre-miRNA is exported into the cytoplasm by exportin 5.14 It has been 
suggested that exportin 5 may protect pre-miRNA from nucleolytic attack in the nucleus, 
thus influencing its abundance in the cell.
Pre-miRNA processing
In the cytoplasm, pre-miRNAs are processed by another RNase III enzyme, DICER1, to 
form small ~22 nucleotide duplexes that comprise the mature miRNA and a similar-sized 
fragment derived from the opposing arm called miRNA* (Figure 1).6 DICER1 determines the 
size of miRNA. It has been proposed that it works as a ‘molecular ruler’ that binds, measures 
and cleaves a pre-miRNA.15 Genetic mutations and deregulation of DICER1 levels may result 
in tumorigenesis.15 Mutation hot spots in the RNase III domain cause defects in DICER1-
mediated processing of the 5’ side of the pre-miRNA hairpin (5p miRNA). This leads to the 
loss of 5p RNA, whereas processing of 3p RNA (derived from the 3’ side of the pre-miRNA) 
remains unaltered.16
miRNA/miRNA* duplex processing
The miRNA/miRNA* duplex, generated by DICER1, is subsequently loaded onto AGO protein, 
unwinded, and one strand of the mature miRNA becomes a part of a ribonucleoprotein 
complex called miRISC (Figure 1).6  Different miRNA duplexes may be preferentially loaded 
onto particular types of AGO proteins. At steady state, usually one of the strands from the 
duplex is retained, whereas another is peeled away and degraded. The most abundant 
(guide) strand is referred to as a miRNA and the less abundant (passenger) as a miRNA*. 
The guide strand that will be loaded onto AGO is determined based on thermodynamic 
stability of the two ends of the duplex and the first nucleotide sequence.17,18 The strand 
with relatively less tightly paired 5’ terminus and/or U at nucleotide position 1 is typically 
selected, and the other one is generally degraded. Alternative DROSHA processing 
that changes the miRNA duplex ends may result in ‘arm-switching’ and selection of less 
abundant passenger strand.13 miRNA maturation and turnover is influenced by alterations 
in RNA sequence and/or structure, such as single nucleotide polymorphisms, miRNA tailing, 
RNA editing and methylation. Single nucleotide polymorphisms may alter miRNA specificity 
and affect processing.19 Non-templated nucleotide addition to the 3’ end of RNA (miRNA 
tailing) may block DICER1 processing and lead to miRNA decay or conversely it may increase 
biogenesis.20 RNA editing and methylation interfere with DROSHA- or DICER1-mediated 
processing.21,22 miRNA abundance may be regulated also via miRNA stability.23 Several 
endoribonucleases have been shown to cleave and degrade selected miRNAs. Additionally, 
miRNAs can be stabilized or primed for degradation by binding to their mRNA targets. The 
mechanisms of target-mediated stability control remain unclear.
Beside the canonical biogenesis pathway outlined above, there are several non-
canonical pathways that include differential generation of small precursor RNA and 
processing independent of DROSHA or DICER1.24 However, the group of miRNAs that 
undergo non-canonical processing probably comprises no more than about 1% of conserved 
miRNAs.
1.2. miRNA function
miRNA-target interactions
A miRNA-induced silencing complex (miRISC) consists of the miRNA bound to AGO together 
with associated proteins (Figure 1). miRNA acts as a guide for recognition of mRNA targets 
that subsequently undergo translational repression and/or decay.2 Target recognition occurs 
through partial base pairing of the miRNA seed sequence with the 3’ untranslated region (3’ 
UTR) of an mRNA or rarely the open reading frame (Figure 2).25 Sites that are complementary 
to the miRNA seed are evolutionarily conserved and are called ‘canonical’ sites. These sites 
contain sequences that match to the seed but also may pair with position 8 and/or have 
adenine opposite position 1 of a miRNA. Canonical sites have the largest effect on mRNA 
target expression. However, more abundant miRNAs also have a large proportion of non-
canonical sites.26 Non-canonical binding sites have bulges in the miRNA seed region and are 
less effective in changing target levels.
Other factors that play a role in the target’s response to miRNA activity include 
the localization of the target site within transcript. The miRNA target sites that have the 
strongest impact on the repression of target genes are located at the beginning or the end 
of long 3’ UTRs.27 Target sites in coding regions have a smaller influence. Another important 
factor is the accessibility of the target site, that relates to the energy that is required to 
acquire a single-stranded conformation.28 Specific miRNA-target interactions are regulated 
by RNA-binding proteins that bind with sequence elements around the target sites and lead 
to mRNA stabilization or destabilization.11,29 Additionally, multiple target sites, either for a 
single miRNA or for a combination of miRNAs, may result in cooperative downregulation 
and together profoundly impact the level of target suppression.30 Finally, the response of 
one target may be influenced by the competition of miRNA binding with other targets. 
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Figure 2. Schematic overview of a miRNA function demonstrated by miR-9. miRNA acts as a guide for miRISC for a 
recognition of mRNA targets by pairing to a binding site within the 3’ untranslated region (3’ UTR) of an mRNA or the 
open reading frame (ORF). This leads to translational repression and/or mRNA decay. Figure adapted from Huntzinger 
et al.2
miRNA-dependent target regulation
miRNA-target interaction ultimately results in a decrease in the level of target protein. Each 
miRNA can target hundreds of mRNAs that in combination may exert functional effects and 
change cellular phenotypes. miRNAs have been proposed to increase the precision of target 
gene expression by counteracting ‘leaky’ transcription, defining spatial domains of target 
expression and buffering transcriptional ‘noise’.31,32
The abundance of miRNA targets is inversely correlated with the miRNA’s ability to 
repress the expression of a specific gene. Several ‘competing’ RNAs are known to sequester 
miRNAs from their protein-coding targets.29 These include pseudogenes, long non-coding 
RNAs and circular RNAs.11 If the level of miRISC is less than the target mRNA or if these two 
are at similar concentrations, then competing RNA will have little effect on the mRNA target. 
However, if miRISC is initially in high excess compared to the target, then the expression of 
competing RNA can strongly upregulate the target.
In conclusion, miRNA establish thresholds in the levels of expression of their targets, 
reduce the variability of target gene expression between cells and regulate correlations 
between the expression of various targets within individual cell.11
2. MIRNA FUNCTION IN NORMAL MYELOID CELLS
2.1. Hematopoiesis and myeloid differentiation
Hematopoiesis is a hierarchical differentiation process in which hematopoietic stem cells 
(HSCs) undergo step-wise maturation into various types of blood cells (Figure 3).33 During 
this process, HSCs lose their self-renewal and multilineage differentiation ability to develop 
into multipotent progenitors (MPPs) and subsequently give rise to lymphoid and myeloid 
progeny.34 During lymphopoiesis, MPPs develop into common lymphoid progenitors (CLPs) 
and further into dendritic cells (DCs), natural killer cells (NKs), T cells and B cells. During 
myelopoiesis, MPPs differentiate into common myeloid progenitors (CMPs). CMPs give 
rise to myeloid lineage and develop into megakaryocyte/erythroid progenitors (MEPs) and 
granulocyte/monocyte progenitors (GMPs). MEPs further differentiate into erythrocyte 
precursors (ErPs) and red blood cells or megakaryocyte precursors (MkPs) and platelets , 
whereas GMPs into macrophages, granulocytes and DCs. Granulocytes consist of neutrophils, 
basophils and eosinophils.
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Figure 3. Schematic representation of hematopoiesis. Hematopoiesis is a hierarchical differentiation process in 
which hematopoietic stem cells (HSCs) undergo step-wise maturation into various types of blood cells. These cells 
further mature into multipotent progenitors (MPPs) and differentiate into common lymphoid progenitors (CLPs) and 
common myeloid progenitors (CMPs). CLPs give rise to lymphoid lineage, i.e. dendritic cells (DCs), natural killer cells 
(NKs), T cells and B cells.  CMPs give rise to myeloid lineage and develop into megakaryocyte/erythroid progenitors 
(MEPs) and granulocyte/monocyte progenitors (GMPs). MEPs further differentiate into erythrocyte precursors (ErPs) 
and red blood cells or megakaryocyte precursors (MkPs) and platelets, whereas GMPs differentiate into macrophages 
(Macros), granulocytes (Gs) and DCs. Gs consist of neutrophils, basophils and eosinophils. Figure adapted from Reya 
et al.34 
2.2. miRNAs in normal myelopoiesis
 
The involvement of miRNAs in myeloid biology has been intensively studied.35 They are 
components of regulatory feedback loops with various transcription factors important 
for myeloid development. miRNAs that have been reported to be involved in normal and 
malignant myelopoiesis together with their regulatory networks are summarized in Table 1. 
The examples of miRNA functions in normal myelopoiesis  are given below for the three 
major players in myeloid development: miR-125 family, miR-155 and miR-223.
miR-125 family consists of miR-125a, miR-125b1 and miR-125b2.36,37 These miRNAs 
have similar functions and exert a comparable effect on the hematopoietic phenotype. 
They are highly expressed in HSCs and promote the survival of this population by targeting 
pro-apoptotic factors.36,38,39 Additionally, miR-125’s have been reported to regulate HSC self-
renewal and differentiation.40 Their level of expression is regulated in a cell type-dependent 
manner by several transcription factors, such as NF-κB, p53, MYC, AKT1.37 miR-125’s 
negatively regulate granulocytic differentiation induced by granulocyte colony-stimulating 
factor (G-CSF).37,41 They are also involved in negative regulation of inflammatory response by 
targeting tumor necrosis factor α (TNF-α) and, unusual for miRNAs, enhancing the stability 
of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) inhibitor NKIRAS2.37 
In most hematopoietic cells, miR-155 is expressed at low levels but it is rapidly 
upregulated in granulocyte-monocyte lineage during inflammatory stress,  which probably 
occurs under the control of NF-κB and activator protein 1 (AP-1).35,42-44 On the other 
hand, the expression of miR-155 is downregulated by signal transducer and activator of 
transcription 3 (STAT3) and protein kinase B (PKB/AKT1).45,46 miR-155 impacts hematopoietic 
development by targeting transcripts of genes relevant to myeloid biology, e.g. PU.1 and 
CCAAT/enhancer-binding protein β (C/EBPβ),44 and the function of mature immune cells by 
targeting genes involved in inflammatory pathways, e.g. SHIP1 and suppressor of cytokine 
signaling 1 (SOCS1).46,47
miR-223 is highly expressed in myeloid cells and its expression increases during 
granulocytic differentiation.48 The miR-223 promotor is bound by nuclear factor 1 A-type 
(NF1A) and this interaction results in low expression levels of miR-223 in progenitor cells. 
During differentiation, C/EBPα binds to the same sites and increases miR-223 expression. 
Once expressed, miR-223 targets NF1A, turns off its repressor and thereby forms a positive-
autoregulatory loop.48 Upregulation of miR-223 promotes differentiation but miR-223 is 
not absolutely required for production of granulocytes in vivo. Additionally, miR-223 forms 
a negative-autoregulatory circuit with cell-cycle regulator E2F1 to promote an exit from 
the cell cycle and to contribute to differentiation.49 It downregulates E2F1 expression, and 
conversely, E2F1 inhibits miR-223 transcription.
In conclusion, miRNAs are relevant players in hematopoiesis and specifically in myeloid 
development. They are components of crucial regulatory networks and they connect cellular 
pathways that influence hematopoietic cell fate decisions
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3. MIRNAS IN ACUTE MYELOID LEUKEMIA
3.1. Acute myeloid leukemia
Acute myeloid leukemia (AML) is a form of cancer that is characterized by the accumulation 
of abnormally differentiated myeloid cells in the bone marrow (BM).50 It has been proposed 
that impairment of differentiation and the proliferative advantage of hematopoietic cells 
are two key factors involved in the pathobiology of AML.51 The considerable heterogeneity 
in cytogenetic and molecular abnormalities that are apparent in this disease is a unique 
feature of AML. The latter variations correlate with patient outcome and may inform 
treatment strategies.50,52 Genes that are commonly mutated in AML and which normal 
function is disrupted fall into following categories: myeloid transcription factors, epigenetic 
regulators, tumor-suppressor and signaling genes. Recently, miRNAs have been recognized 
to regulate hematopoiesis and to contribute to leukemic development.
3.2. miRNAs in AML
In the past years, several studies have reported on deregulated expression of miRNAs in 
leukemia, and the relationship of patterns of deregulation with different cytogenetic and 
molecular subgroups in AML.53,54 Specific miRNA signatures may correlate with different 
cytogenetic subtypes of AML. miRNA profiling has been proposed as a useful diagnostic 
tool.55 Additionally, miRNAs may offer potential novel therapeutic agents for treatment of 
leukemia.56 As a single miRNA can regulate multiple targets and signaling pathways, the use 
of miRNAs in human-cancer therapy might theoretically downregulate oncogenic effects. 
This justifies the efforts to explore the functional role of aberrantly expressed miRNAs in 
AML and their therapeutic influence on patient survival (Table 1 and 2). Some of the most 
frequently studied miRNAs in AML are discussed below in detail.
miR-125b is upregulated in AML with the highest levels in patients carrying t(2;11) 
and t(15;17).40,53 Aberrant expression of miR-125b in normal hematopoietic progenitors 
blocks granulocytic differentiation through repression of core binding factor β (CBFβ) and 
leads to myeloproliferative disorder.57 The effect of miR-125b on cell transformation is dose 
dependent and may result in development of different kinds of leukemia.58,59 The critical 
targets of miR-125b in leukemogenesis are largely unknown but it has been proposed to 
regulate different components of p53 network.60
In patients with t(8;21) and cytogenetically normal AML, high level of miR-126 
expression is associated with worse prognosis.61,62 Both overexpression and knockout of 
miR-126 in leukemia stem cells (LSC) harboring AML1-ETO fusion protein result in enhanced 
leukemogenesis in vivo in mice.61  miR-126 confers its effect likely through targeting ERBB 
receptor feedback inhibitor 1 (ERRFI1) and sprouty-related, EVH1 domain-containing 
protein 1 (SPRED1) when overexpressed, and through frizzled-7 (FZD7) when knocked out. 
It is the first example of a miRNA playing 2-faceted role in AML. Additionally, miR-126 was 
found to inhibit cell cycle progression and differentiation, and promote self- renewal and 
chemoresistance of LSC by targeting the PI3K/AKT/MTOR signaling pathway.63 Targeting of 
miR-126 in LSCs resulted in depletion of LSC population in vitro and in vivo.62,64
miR-155 is upregulated in FLT3-ITD AML, where it is a part of transcription factor 
regulatory network involving several upstream regulators, e.g. JUN and runt-related 
transcription factor 1 (RUNX1), and two downstream targets, i.e. PU.1 and C/EBPβ.65,66 
Overexpression of miR-155 in HSC-enriched BM cells induces myeloproliferation without 
progression to overt AML.47 The effect of miR-155 may result from downregulation of its 
targets SHIP1 and C/EBPβ. Mice with global SHIP1 deficiency develop a myeloproliferative 
disorder that resembles the miR-155 phenotype and C/EBPβ is known to have a critical role 
in granulopoiesis. Downregulation of miR-155 in AML cells results in upregulation of SHIP1 
and PU.1 and leads to monocytic differentiation and apoptosis.67 Additionally, it prolongs 
the survival of mice transplanted with leukemic cells.
miR-223 regulates myeloid differentiation as part of the already mentioned 
autoregulatory feedback loops involving C/EBPα and E2F1.48,49 Additionally, it negatively 
regulates granulocytic proliferation by targeting the transcription factor myocyte-specific 
enhancer factor 2C (MEF2C), which is upregulated in highly proliferative leukemic 
progenitors.68 miR-223 is downregulated in patients with t(8;21), where it is targeted for 
epigenetic silencing by AML1-ETO.69 The loss of miR-223 in murine HSCs and human cord-
blood CD34+ cells leads to the expansion of myeloid progenitors.70,71
Other miRNAs that contribute to AML development are the miR-17~92 cluster and 
miR-29 family. The miR-17~92 cluster is overexpressed in MLL-rearranged leukemia.72 Its 
induced expression enhances the colony-forming capacity of progenitor cells in part through 
downregulation of p21, the inhibitor of cell cycle progression.72,73 The miR-29 family may 
be upregulated, i.e., in cytogenetically normal AML, or downregulated, i.e., in patients 
with t(11q23) rearrangement.54,65 Overexpression of miR-29a in hematopoietic progenitors 
enhances self-renewal and results in a myeloproliferative disorder that progresses to AML.74 
On the other hand, miR-29b that possesses the same seed region acts as a tumor suppressor 
by inducing apoptosis.75 These opposite functions of closely related miRNAs indicate the 
complexity of studying miRNA function and its targets and the importance of these studies 
in a relevant cellular context.
Variable levels of miRNA expression in leukemic cells may predict treatment outcome 
in patients with AML (Table 2). Thus, particular miRNAs  could potentially be useful for risk 
assessment of patient with AML (reference). Pediatric patients with AML with low serum 
levels of miR-370 show reduced overall survival (OS) and relapse-free survival (RFS).76 In 
adults with cytogenetically normal AML, low miR-155 and high miR-181a expression are 
associated with prolonged OS and higher complete remission (CR) rate.77,78 Additionally, 
low miR-3151 is associated with better OS and disease-free survival (DFS).79 Until today, 
miR-212 is the only microRNA which has been reported to predict for better OS and RFS 
independently of cytogenetic subtype of adult AML.80
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Table 1. miRNAs involved in normal myeloid development and AML
miRNAa Upstream 
regulators
Downstream targets Function
miR-1-2 EVI1 Proliferation97
let-7 family CXCR4, YY1 PBX2 Differentiation98
Chemosensitivity99
miR-10a KLF4, RB1CC1 Proliferation and apoptosis100
miR-15a WT1 Proliferation101,102
Enhanced differentiation103
miR-16 FLT3/ITD Pim-1, WT1 Proliferation101,102,104 
Enhanced differentiation103
miR-17 precursor family 
(miR-17~92,  
miR-106a~363, and  
miR-106b~25)
C/EBPβ, HIF-1α PHLPP2, p21, STAT3, 
SQSTM1
Differentiation105,106
Proliferation and self-renewal107
miR-21 GFI1 Differentiation108
miR-24 AML1-ETO MKP-7, (potentially BIM 
and Caspase 9)
Proliferation and differentiation109
Apoptosis110
miR-26a E2F7 Proliferation and differentiation111
miR-27a PLAG1 TNF-related apoptosis-inducing 
ligand (TRAIL) sensitivity112
miR-29 family NRF2, c-Myc, KIT, 
C/EBPα, DNA copy 
number variations
AKT2, CCND2, DNMTs, 
CDK6, SP1, KIT, FLT3, 
SKI, MLLT11
Proliferation, apoptosis and 
chemosensitivity75,113-116_
Proliferation, differentiation and 
self-renewal74,115,117-119 
miR-30c C/EBPα Notch1 Differentiation120
miR-32 BIM Apoptosis121
miR-34 family Methylation, C/
EBPα
CREB, PD-L1, E2F3, 
BMyb
Apoptosis122
Proliferation and 
differentiation123-125
Tumor-mediated 
immunosuppression126
miR-99a CTDSPL, TRIB2 Proliferation and apoptosis127
miR-100 RBSP3 Proliferation and differentiation128
miR-125 family NF-κB, p53, MYC, 
AKT1, NRF2
G-CSF signaling, TNF-α, 
NKIRAS2, CBFβ, p53 
network
Self-renewal and 
differentiation36,40,57 
Proliferation, apoptosis and 
differentiation38,39,41,58-60
Apoptosis and chemosensitivity113
miR-126 PI3K/AKT/MTOR 
signaling, ERRFI1, 
SPRED1, FZD7
Self-renewal, differentiation and 
chemosensitivity61-63
Proliferation and apoptosis64,129
miR-133 EVI1 Chemosensitivity130
miRNAa Upstream 
regulators
Downstream targets Function
miR-139-5p HDAC EIF4G2 Proliferation and differentiation131
miR-139-3p HuR Proliferation132
miR-142-3p IFN-γ signaling-related 
genes, gp130, C/EBPβ
Development and 
differentiation133,134
miR-145 p73 Differentiation135
miR-146a PU.1 CXCR4 Proliferation, differentiation and 
chemosensitivity136
Differentiation137
miR-150 KLF4 Proliferation and differentiation138
miR-155 STAT3, AKT1, AP-1, 
NF-κB,PU.1
SHIP1, SOCS1, PU.1, C/
EBPβ
Proliferation and function of 
immune cells44-47
Apoptosis and differentiation66,67,137
miR-181 family MLK2, ATM, PRKCD, 
CTDSPL, CAMKK1, 
HMGB1, MCL1, Bcl-2, 
p27Kip1
Proliferation139,140
Differentiation141,142
Apoptosis and 
chemosensitivity143,144
miR-182 HDAC RAD51 Homologous recombination repair 
and chemosensitivity145
miR-193 family Methylation, 
AML1-ETO, HOTAIR
AML1-ETO, DNMT3a, 
HDAC3, CCND1, c-KIT, 
MDM2
Proliferation, apoptosis and 
differentiation146-149
miR-196 family GFI1 ERG Differentiation108,150
miR199a-3p PRDX6, RUNX1, SUZ12 Proliferation132
miR-222/221 AML1-ETO KIT Proliferation and differentiation151
miR-223 NF1A, C/EBPα, 
E2F1, AML1-ETO
NF1A, E2F1, MEF2C Proliferation and 
differentiation48,49,68-71 
miR-299 Differentiation152
miR-370 Methylation, DNA 
copy number 
variations
NF1, FoxM1 Proliferation153,154
miR-424 PLAG1 TRAIL sensitivity112
miR-495 PBX3, MEIS1 Proliferation, apoptosis and self-
renewal155
miR-511 MLL-AF9 CCND1 Proliferation and differentiation156
miR-638 CDK2 Proliferation and differentiation157
miR-663 Differentiation158
miR-3151 SP1/NF-κB TP53 Proliferation, apoptosis and 
chemosensitivity159
a miRNAs that have been reported to be involved in normal and malignant myelopoiesis together with their 
regulatory networks.
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Table 2. Prognostic significance of miRNAs in AML
miRNA miRNA level AML subtype Prognostic relevance
Pediatric
miR-370 low All Shorter OS and RFS76
Adult
miR-155 low Normal      karyotype Longer OS and higher CR78
miR-181a high Normal karyotype Longer OS and higher CR77
miR-212 high All Longer OS and RFS80
miR-3151 low Normal karyotype Longer OS and DFS79
Abbreviations: OS, overall survival; RFS, relapse-free survival; CR, complete remission rate; DFS, disease-free 
survival.
Table 3. miR-9/9* in hematological malignancies
Type Upstream 
regulators
Downstream 
targets
Function
Lymphoid malignancies
Acute lymphoblastic leukemia Methylation FGFR1, CDK6 Proliferation and apoptosis85
Hodgkin lymphoma CD99 PRDM1 Differentiation83,87,88
Multiple myeloma HDAC IGF2BP3 Chemosensitivity89
Waldenström macroglobulinemia HDAC4, HDAC5 Proliferation, apoptosis and autophagy90
Myeloid malignancies
Acute myeloid leukemia AML1-ETO, 
MLL fusion 
proteins
UBASH3B/Sts-1, 
LIN28B/HMGA2 
axis, RYBH, 
RHOH, HES1
Proliferation and differentiation91,92
Proliferation, apoptosis and self-
renewal93,94
4. MIR-9/9* IN HEMATOLOGICAL MALIGNANCIES
4.1. miR-9/9*
miR-9 and miR-9* (miR-9/9*) are two miRNAs that originate from the same precursor 
RNA and are highly conserved during evolution from flies to humans.81 All vertebrate miR-
9/9* orthologs have the identical mature sequence. In mammals, miR-9/9* are encoded 
by three genes: MIR9-1, MIR9-2 and MIR9-3. These genes are located in humans on the 
chromosomes 1, 5 and 15, respectively (Figure 1). miR-9/9* are mainly expressed in the 
nervous system and they were first studied as regulators of neurogenesis.82 Since 2008, the 
aberrant expression of miR-9/9* has been demonstrated in various types of human cancer 
and a growing number of studies reported on their functional versatility dependent on the 
origin of the cancer cell.53,83,84 The high level of sequence conservation and the fact that miR-
9/9* are encoded at three different positions in the human genome suggest their important 
function in development and disease. 
4.2. miR-9/9* in lymphoid malignancies
In acute lymphoblastic leukemia (ALL), low miR-9 expression is associated with 
hypermethylation of MIR9 gene family (Table 3, Figure 4).85 This epigenetic downregulation 
leads to upregulation of predicted miR-9 and miR-9* targets, fibroblast growth factor 
receptor 1 (FGFR1) and cyclin-dependent kinase 6 (CDK6). FGFR1 and CDK6 are involved 
in cell proliferation and survival. Treatment with FGFR1 and CDK6 inhibitors suppresses the 
proliferation of ALL cells.85 MIR9 genes have been reported to be frequently methylated 
also in chronic lymphocytic leukemia (CLL) and overexpression of miR-9 decreased CLL cell 
proliferation.86
CD99 is a transmembrane glycoprotein that is implicated in cell migration, adhesion 
and differentiation (Table 3, Figure 4).87 It is lowly expressed in Hodgkin/Reed-Sternberg 
cells of Hodgkin lymphoma (HL). CD99 inhibits the transcription of miR-9 and upregulates 
the direct miR-9 target: positive regulatory domain 1 (PRDM1/BLIMP-1).83,87 PRDM1 is the 
master regulator of terminal B-cell differentiation. miR-9 is highly expressed in HL cells and 
its downregulation by CD99 overexpression or a direct knockdown, augments PRDM1 levels 
that triggers B-cell differentiation into plasma cells.87 During normal B-cell development 
within the germinal centers, B cells closely interact with follicular DCs.88 Only B cells that 
bind to these cells survive in the germinal centers and differentiate. It has been shown that 
direct cell-cell contact between follicular DCs and B cells leads to downregulation of miR-9 
and upregualtion of PRDM1. This subsequently may promote B-cell differentiation.
In multiple myeloma (MM), insulin-like growth factor 2 mRNA binding protein 3 
(IGF2BP3) stabilizes the expression of a cell surface glycoprotein CD44 that is involved in 
drug resistance of MM cells (Table 3, Figure 4).89 Histone deacetylase (HDAC) inhibitors are 
promising novel chemotherapeutics in MM since they downregulate CD44 expression.
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Figure 4. miR-9/9* function in lymphoid malignancies. In lymphoid malignancies, miR-9/9* have been reported to 
be differentially expressed, and to suppress or promote disease development depending on the cell of context. 
HDAC inhibitors treatment leads to upregulatation of miR-9 and downregulation of its direct 
target IGF2BP3. Subsequent downregulation of CD44 sensitizes the resistant MM cell to 
lenalidomide treatment.
A passenger strand of miR-9, miR-9*, has been reported to have a tumor suppressive 
role in Waldenström macroglobulinemia (WM) (Table 3, Figure 4).90 WM is a B-cell low-
grade lymphoma characterized by the accumulation of B cells in the BM. miR-9* is lower 
expressed in WM CD19+ cells than in normal controls. Overexpression of miR-9* in WM 
cells inhibited the unbalanced HDAC activity by downregulation of HDAC4 and 5. This 
resulted in decreased proliferation, increased apoptosis and autophagy. Neither adherence 
to primary BM stromal cells nor growth factors protected against miRNA-9*–dependent 
growth inhibition.
4.3. miR-9/9* in myeloid malignancies
In AML, miR-9 has been reported to be differentially expressed according to AML subtype. 
Dependent on the type of leukemic cell, it may suppress or promote leukemic development 
(Table 3, Figure 5). The t(8;21) rearrangement is the most common chromosomal 
translocation in AML and it results in the formation of AML1-ETO fusion protein.91 AML1-
ETO downregulates miR-9 and in this way promotes the expression of UBASH3B/Sts-1, a 
tyrosine phosphatase that inhibits CBL and enhances STAT5/AKT/ERK/Src signaling to 
promote myeloid proliferation. Forced expression of miR-9 in t(8;21) AML cells reduces 
leukemic growth and enhances monocytic differentiation induced by calcitrol by direct 
repression of the oncogenic LIN28B/HMGA2 axis.92 LIN28B and HMGA2 are expressed in 
undifferentiated proliferating cells during embryogenesis and their upregualtion in adult 
cells leads to oncogenic transformation.
miR-9 is highly upregulated in MLL-rearranged leukemic cells as compared to non-MLL-
rearranged cells and normal controls (Table 3, Figure 5).93 MLL fusion proteins may promote 
miR-9 expression since it is their direct target. Knockdown of endogenous miR-9 expression 
inhibits MLL fusion–induced immortalization/transformation of normal hematopoietic 
progenitor cell, whereas its overexpression has the opposite effect. miR-9 function may 
be mediated by the two predicted targets: RING1 and YY1-binding protein (RYBH) and Ras 
homolog family member H (RHOH). RYBP is a polycomb complex-associated protein that 
can stabilize p53 and has tumor suppressor activity. RHOH is a member of the Rho GTPase 
protein family and it can function as an oncogene or tumor suppressor depending on the 
context. 
In AML patients with normal karyotype, miR-9 is expressed at higher levels in leukemic 
stem/progenitor cells (LSPCs) than in normal HSC derived from the same patient (Table 3, 
Figure 5).94 Additionally, miR-9 expression is inversely correlated to the levels of hairy and 
enhancer of split-1 (HES1), a known tumor-suppressor.95,96 Knockdown of miR-9 decreases 
leukemic cell proliferation and survival by direct targeting of HES1 in vitro and in vivo.94
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Figure 5. miR-9/9* function in myeloid malignancies. In acute myeloid leukemia (AML), miR-9/9* have been report-
ed to be differentially expressed according to AML subtype, and to suppress or promote leukemic development 
depending on the cell of context.
SCOPE OF THIS THESIS
miR-9/9* have been shown to be deregulated in different types of human cancer including 
lymphoid and myeloid malignancies. Nevertheless, we still lack the more comprehensive 
knowledge about the impact of miR-9/9* expression on normal hematopoietic cell function 
and their possible impact in the biology of AML. 
In Chapter 2, we aim to elucidate the function of miR-9/9* in normal myeloid 
differentiation. We use murine myeloid 32D cell line model and murine primary HSPCs to 
investigate the impact of miR-9/9* overexpression on granulocytic differentiation induced by 
G-CSF. We also examine the effect of miR-9/9* expression in human primary AML samples. 
Further, we set out to identify miR-9/9* targets that are common for murine and human 
cells and that may be relevant for the observed phenotype. In Chapter 3, we broaden our 
quest for direct and indirect targets that are regulated by miR-9/9* by analyzing proteome 
changes in 32D cells. We examine the deregulated proteins and the involved pathways that 
could potentially influence different aspects of normal hematopoietic cell function. Our 
observations are further extended by in vivo and in vitro experiments presented in Chapter 4, 
we investigate the influence of miR-9/9* expression on homing of normal HSPCs in the BM.
Until now, few miRNAs have been shown to exhibit a prognostic value in AML. In 
Chapter 5, based on our results about the expression of miR-9/9* in AML patients (shown 
in Chapter 1), we set out to investigate whether the expression of miR-9/9* may predict 
patient outcome in AML. 
Finally, the results presented in this thesis are summarized and discussed in Chapter 6. 
Here we put the accumulated insights about the functions of miR-9/9* into the broader 
perspective of human cancer. 
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INTRODUCTION
Acute myeloid leukemia (AML) is a complex heterogeneous disease characterized by a 
defect in maturation and the accumulation of immature cells of the myeloid lineage. Many 
chromosomal and genetic aberrations involved in leukemogenesis have been identified. 
While the majority of them have functional or prognostic relevance,1-3 they are insufficient 
to cause AML alone and other contributing oncogenic events are required for full malignant 
transformation of hematopoietic precursors.4-5 In addition to genomic aberrations, changes 
in epigenetic regulation and post-transcriptional regulation by microRNAs (miRNAs) have 
been reported.6-9 The contribution of aberrant miRNA activities to the pathogenesis of AML 
is still largely unknown. 
MiRNAs are short non-coding RNAs (20-25 nt) that bind to specific target sequences 
within 3’untranslated regions (UTR) of mRNA transcripts.10-11 This results in transcript 
cleavage or inhibition of translation, and the subsequent downregulation of expression of 
their targets.11-12 MiRNAs have been shown to play an important role in various physiological 
processes, specific cell fate decisions, and human cancer - including different types of solid 
tumors13-14  and leukemia.15-19  Several studies have shown that cytogenetic subsets of AML 
have distinct miRNA patterns7,20-21 and that indeed, some miRNAs, such as miR-223,15-16 miR-
196b,17 miR-29b,18 and miR-125b,19 have established functions in AML.
We and others previously reported about the expression of miR-9 in human AML 
primary bone marrow cells.7,20,22-23 MiR-9-5p (miR-9) and miR-9-3p (miR-9*) are two 
highly conserved miRNAs produced from the same precursor and they are frequently 
concomitantly expressed.13,24 Depending on the type of malignancy, miR-9/9* are 
upregulated (e.g. in glioblastoma13) or downregulated (e.g. in breast cancer14). Various 
functions have been assigned to miR-9/9*.25-30 The function and mode of action of miR-9/9* 
are cell type-specific. For example, in glioblastoma, downregulation of miR-9/9* promotes 
neuronal differentiation, suggesting that miR-9/9* influence glioblastoma stem cells and 
help to maintain their stemness.13 Conversely, in oral squamous cell carcinoma and non-
small cell lung cancer cell lines, overexpression of miR-9 inhibits proliferation and promotes 
apoptosis.31-32 MiR-9 activities are cell context-dependent also in AML. Chen et al. showed 
that in MLL-rearranged AML, overexpression of miR-9 enhances MLL-AF9-mediated cell 
transformation of murine hematopoietic progenitor cells by a yet unknown mechanism.22 
However, Emmrich et al. showed that miR-9 has a function in t(8;21) AML and induces 
monocytic differentiation in KASUMI-1 cell line by targeting the LIN28B/Let-7/HMGA2 axis.23
Here, we report that enforced expression of miR-9/9* inhibited normal neutrophil 
development in both myeloid 32D cell line and in primary murine lineage negative bone 
marrow cells. Additionally, we show that miR-9/9* were significantly upregulated in most 
cases of primary human AML. Gene expression profiling of AMLs with high expression of 
miR-9/9* and 32D-miR-9/9* identified ETSrelated gene (Erg) as a potential target of miR-9. 
ABSTRACT 
Aberrant post-transcriptional regulation by miRNAs has been shown to be involved in the 
pathogenesis of acute myeloid leukemia (AML). In a previous study, we performed a large 
functional screen using a retroviral barcoded miRNA expression library. Here, we report that 
overexpression of miR-9/9* in myeloid 32D cell line (32D-miR-9/9*) had profound impact 
on GCSF induced differentiation. Further in vitro studies showed that enforced expression 
of miR-9/9* blocked normal neutrophil development in 32D and in primary murine line-
agenegative bone marrow cells. We examined the expression of miR-9/9* in a cohort of 
647 primary human AMLs. In most cases, miR9 and miR9* were significantly upregulated 
and their expression levels varied according to AML subtype; with the highest expression in 
MLL-related leukemias harboring 11q23 abnormalities, and the lowest expression in AML 
cases with t(8;21) and biallelic mutations in CEBPA. Gene expression profiling of AMLs with 
high expression of miR-9/9* and 32D-miR-9/9* identified ETS-related gene (Erg) as the only 
common potential target. Upregulation of ERG in 32D cells rescued miR-9/9*induced block 
in neutrophil differentiation. Taken together, this study demonstrates that miR-9/9* are ab-
errantly expressed in most of AML cases and interfere with normal neutrophil differentia-
tion by downregulation of ERG.
Aberrant expression of miR-9/9* in myeloid progenitors inhibits neutrophil differentiation by post- 
transcriptional regulation of ERG
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Subsequently, Erg coding sequence (without the 3’ UTR) was cloned into the pLNCX2 
retroviral expression system containing a Neomycin resistance gene (Clontech, Mountain 
View, CA, USA). Retroviral particles were produced as previously described.34 Lin- muBM, 
32D and NIH3T3 cells were transduced using RetroNectin (Takara Bio Inc., Shiga, Japan) 
according to the manufacturer’s protocol and selected for GFP expression using FACSAria 
cell sorter (BD Biosciences, Breda, the Netherlands). Cells overexpressing Erg were selected 
with Neomycin (1mg/ml; Life Technologies, Bleiswijk, the Netherlands). 
The 32D cell line was cultured as previously described.34,35 HEK239T, NIH3T3, and HL-60 
cells were cultured according to standard conditions. All cell lines were obtained from DSMZ 
GmbH (Braunschweig, Germany) and regularly tested for mycoplasma contamination.
MicroRNA LNA inhibition
HL-60 cells were transfected with microRNA LNA non-labeled inhibitors (Exiqon, Vedbaek, 
Denmark) at the final concentration of 100 nM. FAM-labeled LNA-scramble was used to 
control for transfection efficiency. At day 5, RNA and protein samples were collected and cell 
differentiation was evaluated by morphological and flow cytometric analysis. Experiments 
were performed in three independent replicates.
Methylcellulose colony-forming cell assays
Bone marrow cells were harvested from femurs and tibiae of 8- to 12-week-old C57BL/6 mice 
(Charles River, Leiden, the Netherlands) and enriched for lineage negative cells using Mouse 
Hematopoietic Progenitor (Stem) Cell Enrichment Set (BD Biosciences). Colony-forming 
unit (CFU) cell assays were performed as previously described.34 Shortly, in CFU assay, 4000 
Lin- muBM cells were plated in triplicate in methocult (M3231; StemCell Technologies, 
Grenoble, France) supplemented with IL-6 (10 ng/mL), IL-3 (supernatant 1/1000), SCF (10 
ng/mL) and GM-CSF (10 ng/mL). In CFU-granulocyte (CFU-G) assay, 10000 Lin- muBM cells 
were plated and cultured with G-CSF (100 ng/mL). For morphological evaluation 100 cells 
were scored in CFU assay and 200 cells in CFU-G assay. All experiments were performed in 
three independent biological replicates.
Flow cytometry
Immature hematopoietic progenitor population Lin-c-Kit+Sca-1- (LK) was identified by 
staining with Biotin Mouse Lineage Panel, streptavidin-APC-Cy7, c-Kit-APC (BD Biosciences) 
and Sca-1-PB (Biolegend, London, United Kingdom). LK population consists of progenitor 
cells: CMP (common myeloid), GMP (granulocyte-macrophage), and MEP (megakaryocyte-
erythroid). For apoptosis analysis, cells were stained with Annexin V:PE Apoptosis Detection 
Kit I (BD Biosciences) according to the manufacturer’s protocol. Data were collected using 
LSRII flow cytometer (BD Biosciences) and analyzed with FlowJo 7.6.5 software (Tree Star 
Inc., Ashland, OR, USA).
Upregulation of ERG in 32D cells rescued miR9/9*induced block in neutrophil differentiation. 
A block in myeloid differentiation is one of the hallmarks of AML. Hence, our findings 
uncover a novel function of aberrant expression of miR-9 in myeloid progenitors, which may 
be relevant for AML development. 
MATERIALS AND METHODS
AML and normal bone marrow samples
Patient recruitment and sample processing were performed according to protocols from 
the Dutch-Belgian-Hematology-Oncology-Cooperative group (HOVON trials 04, 04A, 29, 42, 
42A and 43) and the German-Austrian AML Study Group (AMLSG trial HD98A).7 All trails 
have been approved by the Institutional Review Board of the Erasmus University Medical 
Center and the University of Ulm. All patients had a newly diagnosed AML according to the 
2001 WHO classification and provided written informed consent in accordance with the 
Declaration of Helsinki. Mutational analysis was previously described.33
Real-time quantitative RT-PCR
Total RNA isolation and real-time quantitative RT-PCR were performed as previously 
described.7,34 Briefly, miR-9 and miR-9* expression was determined using real-time 
quantitative RT-PCR assays for miRNAs (Applied Biosystems, Nieuwerkerk a/d IJssel, the 
Netherlands). Data were normalized using RNU24 with a minimal threshold for Ct values 
above 35 set to a -dCt value of -15. MiR-9/9* expression in 32D cell line and lineage 
negative murine bone marrow progenitor cells (Lin- muBM) was determined using a set of 
endogenous controls, sno202 and sno234, with a minimal threshold for Ct values above 35 
set to a -dCt value of -13. The relative quantification method 2−(ddCt) was used to calculate 
the relative expression. Murine Erg expression was determined using real-time quantitative 
RT-PCR assays (Applied Biosystems) with Hprt as a normalization control, and human ERG 
using GAPDH.
Cell culture and transduction
A retroviral barcoded miRNA library (MSCV-BC-miRNA) was previously reported.34 Shortly, 
different miRNAs (plus ~250 bp flanking sequences) were cloned into pMCSV-BC vectors. 32D 
cells35 were transduced with MSCV-BC retroviruses and sorted for GFP expression. Different 
MSCV-BC-miRNA 32D cell populations were mixed with empty vector control infected cells 
in a 1:1 ratio and cultured in medium containing interleukin 3 (IL-3) or granulocyte colony-
stimulating factor (G-CSF). Subsequently, cells were examined as previously described.34
The mmu-miR-9-2 precursor (together with ~250 bp flanking sequence) was cloned 
into a pMSCV retroviral expression system containing GFP.34 Erg cDNA was ordered from 
the Fantom2 library of Erasmus Center for Biomics (D030036I24; ENSMUST00000077773.7). 
Aberrant expression of miR-9/9* in myeloid progenitors inhibits neutrophil differentiation by post- 
transcriptional regulation of ERG
Chapter 2
44 45
RESULTS
MiR-9/9* inhibits differentiation of early progenitor cells towards neutrophils
In a previous study, we developed a retroviral barcoded miRNA expression library (MSCV-
BC-miRNA) and overexpressed more than 130 different miRNAs and empty vector (EV) 
controls in the 32D cell line model.34 32D cells proliferate and maintain their immature 
myeloblastic morphology in IL-3 containing medium but they are capable to differentiate 
towards neutrophils within 5 days of G-CSF stimulation.35 MiR-9/9*overexpressing 32D 
cells continued to proliferate, whereas control cells and cells overexpressing other miRNAs 
stopped proliferating after 5 days of G-CSF stimulation (Figure 1a-b). This suggests that 
enforced expression of miR-9/9* interferes with normal neutrophil differentiation.
MiR-9/9* are not expressed in wild type 32D cells (Supplementary Figure 1a). To 
investigate the function of aberrant expression of miR-9/9*, we transduced 32D cells with 
miR-9/9* (32D-miR-9/9*) or empty vector (32D-EV). Expression of miR-9 and miR-9* was 
confirmed by qRT-PCR (Supplementary Figure 1a). Upon GCSF treatment, 32D-miR-9/9* 
continued to proliferate as we observed in our initial screen (Figure 1c). Additionally, they 
kept their immature myeloblastic morphology and lost their capacity to differentiate towards 
neutrophils (Figure 1d). To further validate their undifferentiated phenotype, we examined 
Cebpa expression in samples taken at different time points of G-CSF stimulation. Concordant 
with their immature morphology phenotype, 32D-miR-9/9* cells had lower levels of Cebpa 
than those of 32D-EV cells (Supplementary Figure 1b). MiR-9/9* overexpressing 32D cells 
remained cytokine dependent since withdrawal of IL-3 led to the cell death (data not shown).
To explore the effect of aberrant expression of miR-9/9* in normal early myeloid cells, 
we performed CFU assays with primary Lin- muBM. Cells were transduced with MSCV-
miR-9/9* or MSCV-EV (Supplementary Figure 2a), FACS sorted and plated in methocult. In 
the CFU assay, after 7 days of culture, miR-9/9* overexpressing cells had a significantly higher 
frequency of immature hematopoietic progenitor cells Lin-c-Kit+Sca-1- cells (LK; miR9/9* – 
26%, EV – 12%; P = 0.04; Figure 2a-b, Supplementary Figure 2c), and a significantly lower 
percentage of mature neutrophils (2 fold decrease) based on their morphology (miR-9/9* 
– 25%, EV – 44%; P = 0.01; Supplementary Figure 3a-b). Additionally, miR-9/9* expression 
did not influence apoptosis (Annexin V+ population: miR-9/9* – 41%, EV – 35%; P = 0.36; 
Supplementary Figure 2d and Supplementary Figure 3c), and no significant differences in 
colony numbers and size were noted (colony numbers per 1000 cells plated: miR-9/9* – 
28, EV – 36; P = 0.11; Supplementary Figure 3d-e). A higher frequency of LK population, 
together with a lower percentage of mature neutrophils and no differences in apoptosis, 
suggested that miR-9/9* may inhibit granulocytic differentiation. To further address this, 
we performed CFU-G assays. Again, miR-9/9* overexpressing cells had more than 2 fold less 
mature neutrophils (miR-9/9* – 11%, EV – 27%; P = 0.04; Figure 2c-d and Supplementary 
Figure 2b), and miR-9/9* expression did not influence apoptosis (Annexin V+ population: 
In microRNA LNA inhibition experiments cells were labeled using EuroFlow protocols 
with the instrument set-up for neutrophil and monocytic differentiation.36,37 Data were 
analyzed using Infinicyt software (Cytognos SL, Salamanca, Spain).
Gene expression profiling analysis 
Gene expression profiles (GEP) of 215 AML cases were derived from Human Genome U133 
plus 2.0 arrays as previously described (GSE6891).38 Raw microarray data were processed 
using MAS5 to target intensity of 100. Intensity values lower than 30 were set to 30 and 
subsequently log2 transformed. GEP data are available at www.ncbi.nlm.nih.gov/geo 
(GSE41942). GEP of 32D cells transduced with miR-9/9* (32D-miR-9/9*) or empty vector 
control (32D-EV) were derived using Mouse Genome 430 2.0 array (Affymetrix, High 
Wycombe, UK) in three independent experiments. Differentially expressed genes between 
32D-miR-9/9* and 32DEV were identified using ANOVA, with the false discovery rate 
(FDR) calculated using the Benjamini-Hochberg method (FDR<0.05).38 Only probe sets 
with standard deviations above 0.05 were included in the analysis using Partek Genomic 
suite software version 6.4. Potential miR9/9* targets were selected using TargetScan 6.2 
www.targetscan.org) web resource.
Western blot 
Nuclear extracts were prepared using standard hypotonic buffer (10 mM HEPES pH 7.9, 
1.5 mM MgCl, 10 mM KCl) and high-salt buffer (20 mM HEPES pH 7.9, 25% glycerol, 1.5 
mM MgCl, 420 mM NaCl, 0.2 mM EDTA). Specific polyclonal antibodies were used to detect 
ERG (PA529594; Life Technologies Europe BV, Bleiswijk, the Netherlands). ACTIN (A5441; 
Sigma-Aldrich, Zwijndrecht, the Netherlands) was used as loading control. Experiments 
were performed in three or more biological replicates. 
3’ UTR luciferase reporter assays
The wild-type full length 3’ UTR of ERG (NM_004449) firefly luciferase reporter construct 
was obtained from Switchgear Genomics. For site-directed mutagenesis, base pairs 3-6 of 
the three predicted binding sites targeted by miR-9 were mutated (AAA into GCG) using 
QuikChange XL Site-Directed Mutagenesis Kit (Agilent, Amstelveen, the Netherlands). 
HEK293T cells were transfected with firefly reporter constructs together with renilla control 
plasmids, and MSCV-EV or MSCV-miR-9/9*. Cells were lysed and analyzed with the Dual-Glo 
Luciferase Reporter Assay (Promega, Madison, WI, USA) according to the manufacturer’s 
protocol. Experiments were performed in three independent biological replicates.
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murine and human cell lines showed the downregulation of all ERG isoforms upon miR-9/9* 
overexpression (Figure 4c, Supplementary Figure 6a). Additionally, Western blot analysis 
and gene expression data confirmed the inverse correlation of miR-9/9* and ERG levels in 
AML patient material (Supplementary Figure 6b-c).
To validate ERG as a genuine target of miR-9, we performed luciferase reporter assays 
in HEK293T cells (Supplementary Figure 7a). Cells that were transfected with the vector 
containing the 3’ UTR of ERG together with the vector containing miR-9/9* had lower 
luciferase activity than those transfected with the empty vector control (Supplementary 
Figure 7b). The downregulation of luciferase activity by miR-9 was lost when the three 
putative miR-9 binding sites in 3’ UTR of ERG were mutated. Endogenous miR-9 is highly 
expressed in HEK293T cells. Indeed, cells transfected with the wild type 3’ UTR of ERG had a 
lower basal luciferase activity, which increased upon mutation of miR-9 binding sites.
To investigate whether Erg is involved in the block of neutrophil differentiation in 
32D-miR-9/9* cells, we performed rescue experiments using a retroviral pLNCX2 construct 
containing Erg cDNA without 3’ UTR. The overexpression was confirmed by Western blot 
(Figure 5a). Upregulation of ERG in 32D-miR-9/9* cells rescued neutrophil differentiation 
(Figure 5b-c, Supplementary Figure 7c-d). 
In order to explore the effect of in vitro miR-9 knockdown on human AML cell 
differentiation via modulation of ERG levels, we treated AML cell line HL-60 with microRNA 
LNA inhibitors. HL-60 cells express endogenous miR-9 (-dCt value of -11) and ERG (-dCt value 
of -13). All cells were effectively transfected with the inhibitors (data not shown). LNA-miR-9 
knockdown resulted in ERG protein upregulation (Supplementary Figure 8a). There were 
no signs of induction of myeloid differentiation according to morphological (Supplementary 
Figure 8b) and flow cytometric analysis of the cells (Supplementary Figure 8c).
In conclusion ERG is a validated direct target of miR-9 and it contributes to miR-9/9*-
induced block in neutrophil differentiation.
miR-9/9* – 40%, EV – 48%; P = 0.31; Figure 2e and Supplementary Figure 3f) and the 
number of colonies (colony numbers per 1000 cells plated: miR-9/9* – 16, EV – 21; P = 0.31; 
Supplementary Figure 3d-e).
Taken together, this data shows that enforced expression of miR-9/9* inhibits 
maturation of early progenitor cells towards neutrophils.
MiR-9/9* are aberrantly expressed in AML and their expression is dependent on the AML 
subtype
We examined miR-9/9* expression in a large cohort of 647 primary human AML cases. 
In most of AML subtypes, the levels of expression of miR-9/9* were significantly higher 
than the levels in normal CD34+ BM samples (Figure 3a-d; Supplementary Table 1 and 
Supplementary Figure 4a-d), and the expression of miR-9* correlated highly with miR-9 
(r = 0.806). MiR-9/9* levels were the highest in MLL-related leukemias harboring 11q23 
abnormalities (Table 1; Figure 3c-d) and in normal karyotype AML cases with mutations 
in NPM1 (Supplementary Figure 4a-b). By contrast, AML cases with t(8;21) and bi-allelic 
mutations in CEBPA had the lowest levels of miR9/9*, similar to those in normal BM controls 
(Table 1; Figures 3c-d and Supplementary Figure 4a-b).
Erg is a direct miR-9 target that contributes to a block in neutrophil differentiation
MiRNAs repress their targets by destabilization of mRNA or inhibition of translation.10-12 
To identify miR-9/9* targets that may explain the block in neutrophil differentiation, we 
analyzed the transcriptomes of AML cells that highly express miR-9/9* and 32D-miR-9/9*.
First, we searched for miR-9/9* targets by the analysis of gene expression data in a 
cohort of 215 primary AML samples.38 The cohort was split into two groups based on miR-9/9* 
levels: the group with the lowest expression (0-25% expression value; lowermost quartile) 
and with the highest expression (75100% expression value; uppermost quartile). We found 
269 probe sets to be significantly differentially expressed between these two groups with 
an absolute fold change greater than 1.5 (|FC|>1.5). Thirteen probe sets, corresponding to 
10 genes, were downregulated in the uppermost miR9/9* quartile and contained predicted 
miR-9 or miR-9* binding sites according to TargetScan (Supplementary Table 2). Next, we 
performed gene expression profiling of 32D-miR-9/9* cells and 32DEV control cells and 
found 219 differentially expressed probe sets. Twenty-six probe sets, corresponding to 20 
genes, were downregulated in 32D-miR-9/9* cells and had predicted binding sites for miR-
9 or miR-9* in their 3’ UTRs (Supplementary Table 3). A putative miR-9 target ETS-related 
gene (Erg) was the only target that was identified in both sample types, suggesting that it 
may be functionally involved in miR-9/9*-induced block in neutrophil differentiation (Figure 
4a). The downregulation of Erg transcripts by miR-9 in 32D cells was confirmed by qRT-PCR 
(Figure 4b). All Erg isoforms possess all functional domains and have miR-9 binding sites 
in their 3’ UTRs (Supplementary Figure 5a-d). In agreement, Western blot analysis in both 
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downregulated in both AML and 32D-miR-9/9*. Luciferase reporter assays confirmed that 
ERG was a genuine miR-9 target. 
Erg belongs to the ETS family of transcription factors.42 It is known that Erg is essential 
for definitive hematopoiesis. Several studies in a functionally compromised Erg mouse 
model showed that Erg is required for hematopoietic stem cell self-renewal and to maintain 
normal stem cell function.43-45 Mice homozygous for a loss-of-function Erg allele die at mid-
gestation, before the formation of the first hematopoietic stem cells.43 ERG is known to form 
homo- and heterodimers as well as ternary complexes with other hematopoietic transcription 
factors, such as GATA2, RUNX1, FLI-1 and other ETS family proteins.42,46 Formation of these 
complexes depends on the availability – relative intracellular concentration – of their 
components. Therefore, insufficient levels of ERG may influence formation and function 
of its complexes resulting in aberrant myelopoiesis. On the other side, Erg overexpression 
in a transgenic mouse model revealed promotion of T-acute lymphoblastic leukemia47 and 
erythro-megakaryocytic leukemia.48 Additionally, in a recent study Tursky et al. reported 
that overexpression of ERG in normal human CD34+ cord blood cells enhanced expansion 
of the progenitor pool but did not interfere with myeloid differentiation.49 Thus, ERG plays 
an important role in normal and malignant hematopoiesis, and ERG function depends on its 
level of expression.
Here, we show that ERG is downregulated by miR-9, and that the upregulation of ERG 
reverses miR-9/9*-induced block in normal neutrophil differentiation. This suggests that 
downregulation of ERG by miR9 interferes with normal myelopoiesis. In human AML cell 
line HL-60, LNA-based miR-9 knockdown led to upregulation of ERG protein levels but was 
insufficient to revert the block in differentiation phenotype in this malignant transformed 
in vitro model. 
In conclusion, our findings uncover a novel function of aberrant miR-9 expression in 
myeloid differentiation. However, its role in leukemogenesis remains unsettled.
DISCUSSION
AML is a heterogeneous disease that is characterized by a complex interplay of genetic 
and epigenetic abnormalities. Changes in epigenetic regulation, such as the expression 
of miRNAs, are known to contribute to the pathogenesis of AML.15-19 Our in vitro studies 
showed that in 32D and in normal primary Lin- muBM cells, upregulation of miR-9/9* 
blocked normal neutrophil development. Recently, two other studies reported on the role 
of miR-9 in AML. Chen et al. showed that overexpression of miR-9 enhanced MLL-AF9-
mediated cell transformation in murine hematopoietic progenitor cells in vitro and in vivo.22 
Mice transplanted with bone marrow progenitors that overexpressed both MLL-AF9 and 
miR-9 (MLL-AF9+miR-9) had higher frequency of c-Kit+ blast cells in the BM, spleen and 
peripheral blood than mice transplanted with cells overexpressing MLL-AF9 only. Moreover, 
morphologically, MLL-AF9+miR-9 leukemic cells had a higher frequency of immature 
blasts. In line with this, we show that miR-9/9* expression can advocate these changes 
independent of MLL-AF9. Emmrich et al. reported that overexpression of miR-9 induced 
monocytic differentiation in KASUMI-1 cell line but blocked myelomonocytic differentiation 
in normal human CD34+ cells.23 These data, together with our results, indicate that miR-9/9* 
play a role in myelopoiesis and may be involved in development of AML.
In this study, we report a high expression of miR-9/9* in the most cases of human AML, 
and their differential expression according to AML subtype; with the highest levels of miR-
9/9* in MLL-related leukemias harboring 11q23 abnormalities, and the lowest levels in AML 
cases with t(8;21) and biallelic mutations in CEBPA. There was no clear relationship between 
miR-9/9* expression and different FAB subtypes of AML. Additionally, we previously 
published that the expression of miR-9/9* is low in distinct differentiation stages of normal 
human granulopoiesis, with -dCt values similar as in CD34+ cells and ranging from -10 to -15 
(data not shown).39 It is therefore unlikely that these miRNAs are differentially expressed 
as a result of distinct maturation stages of leukemic cells. As a result, the mechanism of 
miR-9/9* overexpression in AML is still unknown. In human monocytes and neutrophils, 
miR-9 was previously reported to be induced upon proinflammatory signals and to be 
a part of a regulatory feedback loop with NF-κB, a known stress modulator.29,40-41 One could 
hypothesize that the upregulation of miR-9/9* in AML may be induced by genetic stress due 
to gene mutations, deletions or chromosomal aberrations. 
MiRNAs regulate various physiological processes and cell fate decisions by 
downregulating their targets, which may be cell-type-specific. AML is a complex disease 
that is divided into subtypes, which are characterized by different chromosomal and 
genetic aberrations. It is likely that miRNAs contribute to the heterogeneity of the disease 
by downregulating their specific targets. We compared the transcriptomes of cells with 
high levels of miR-9/9* to transcriptomes of cells with low levels, and we identified several 
potential targets. ETS-related gene (Erg) was the only common gene that was significantly 
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Table 1. AML cohort characteristics and relationships with miR-9/9* expression
Number of 
cases
miR-9 miR-9*
P Median 
difference/Rho
P Median
difference/Rho
Clinical parameters
Age (mean) 45.4 0.044 rho=0.0792 0.037 rho=0.0821
Range (min-max) 15.0-77.0
WBC, x 10 9 /L (mean) 47.4 0.038 rho=0.0819 0.091 rho=0.0666
Range (min-max) 0.3-510.0
Sex
Male 335 0.025 -0.50 0.126 -0.34
Female 312 0.025 0.50 0.089 0.38
ELN genetic risk (modified)
Favorable 234 <0.001 -1.72 <0.001 -1.13
Intermediate-I 194 <0.001 0.98 <0.001 0.95
Intermediate-II 119 0.021 0.61 0.165 0.39
Adverse 102 0.372 0.38 0.870 0.02
Cytogenetics
+8 33 0.163 0.05 0.095 0.79
-5 or -5q 3
-7 or -7q 19 0.006 -1.55 0.017 -1.49
-9q 13 0.012 -2.14 0.102 -1.28
11q23† 20 <0.001 2.42 0.048 1.45
t(8;21) 39 <0.001 -3.38 <0.001 -2.77
t(9;11) 15 <0.001 3.96 <0.001 3.94
t(15;17) 28 0.001 -1.66 0.007 -1.43
inv(3) or t(3;3) 7
inv(16) 48 0.009 -0.74 0.022 -0.82
Normal karyotype 307 <0.001 0.80 <0.001 0.95
Complex karyotype 61 0.986 0.00 0.326 -0.38
Other 71 0.192 0.46 0.948 -8.46
Molecular genetics‡
CEBPA single mutant 11 0.370 -0.57 0.824 0.29
CEBPA double mutant 34 <0.001 -3.64 <0.001 -2.46
FLT3-ITD 117 <0.001 1.07 <0.001 1.04
FLT3-TKD 39 <0.001 1.75 0.003 1.37
NPM1 166 <0.001 <0.001 <0.001 1.51
Table reports P-values of Spearman correlation test (together with Spearman correlation coefficients; positive 
rho coefficient indicates a positive relationship, negative/positive rho indicates a negative/positive relationship 
between the two continuous variables) or Wilcoxon rank sum test (together with median differences; a negative/
positive median difference indicates lower/higher miR-9 or miR-9* in the specific subtype bearing the abnormality). 
Spearman correlation test or Wilcoxon rank sum test were used to assess the association between continuous miR-9 
or miR-9* expression and different clinical and molecular parameters with more than 10 cases.
In ELN favorable risk group only patients with biallelic mutations in CEBPA were included. 
†11q23 category contains MLL-related leukemias harboring 11q23 abnormalities other than t(9;11). 
‡Molecular data only determined in patients with normal karyotype.
Abbreviations: AML, acute myeloid leukemia; WBC, white blood cell count; ELN, European LeukemiaNet; CEBPA, 
CCAAT/enhancer-binding protein α; FLT3-ITD, internal tandem duplications in the FMS-like tyrosine kinase 3;  
FLT3-TKD, FMS-like tyrosine kinase 3 with mutations in tyrosine kinase domain; NPM1, nucleophosmin.
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Figure 2. MiR9/9* inhibits maturation of Lin- muBM cells towards neutrophils. Lin- muBM cells were transduced with 
MSCVEV (EV) or MSCVmiR9/9* (miR9/9*) retroviral construct, FACS sorted, and plated in triplicate in methocult. (a) 
Representative FACS plot showing Lin-c-Kit+Sca-1- (LK)  progenitor populations in one replicate at day 7 of CFU assay. 
(b) A summary of LK populations in all three replicates at day 0 and day 7 of CFU assay. (c) Representative micrographs 
of cytospins stained with May Grünwald Giemsa at day 0 and day 7 of CFUG assay (original magnification ×100). Black 
arrows highlight immature miR-9/9* cells. (d) A summary of distinct differentiation stages scored based on 
morphology at day 7 of CFUG assay. (e) A summary of Annexin V+ populations in all three replicates at day 0 and day 
7 of CFUG assay. All experiments were performed in three independent biological replicates. Unpaired twotailed 
t-test was used for the statistical analysis. *P < 0.05.
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Figure 1. MiR9/9* inhibits granulocytic maturation in murine myeloid 32D cell line. 32D cells were transduced with 
a retroviral barcoded miRNA library (MSCVBCmiRNA), randomly assigned to separate pools and differentiated upon 
GCSF treatment. Proliferation ratios of cells cultured upon (a) IL3 or (b) GCSF in the same pool as cells overexpressing 
miR9/9* are given relatively to three empty vector (EV) controls. Data show one biological replicate. To investigate 
the phenotype of aberrant upregulation of miR9/9*, 32D cells were separately transduced with MSCVEV (EV) or 
MSCVmiR9/9* (miR9/9*) retroviral construct, FACS sorted, and differentiated upon G-CSF stimulation. (c) Average 
growth rates of cells transduced with EV control (solid line) or overexpressing miR9/9* (dashed line); upon IL3 (black) 
or GCSF (red) stimulation. Growth rates are given as number of cells at each time point divided by number of cells at 
day 0. Data show an average of five independent biological replicates. Error bars represent the standard deviation. 
Statistically significant P-values between EV and miR-9/9* transduced cells upon G-CSF treatment are marked as red 
stars. (d) Representative micrographs of cytospins stained with May Grünwald Giemsa (original magnification ×100). 
Unpaired twotailed t-test was used for the statistical analysis. *P < 0.05.
Aberrant expression of miR-9/9* in myeloid progenitors inhibits neutrophil differentiation by post- 
transcriptional regulation of ERG
Chapter 2
54 55
a
b
Gene expression profiling (GEP)
215 primary human AML cases 32D AML cell line
miR-9/9* uppermost quartile
(75-100% expression value)
miR-9/9* lowermost quartile
(0-25% expression value)
32D-EV 32D-miR-9/9*
Differentially downregulated potential miR-9/9* targets (|FC|>1.5) Differentially downregulated potential miR-9/9* targets (|FC|>1.5)
....
IKZF2
ERG
B4GALT6
ITM2C
IPO11
TNFRSF21
....
....
Ap1s2
Erg
Sntb2
Synj2bp
Ulk2
Magt1
....
Erg
0
20
40
60
80
100
120
140
32D-EV
32D-miR-9/9*
*
%
re
la
tiv
e 
ex
pr
es
si
on
 to
 E
V
ACTIN
ERG
EV mi
R-
9/9
*
c
55 kDa
40 kDa
Figure 4. MiR9/9* target identification. (a) A summary of miR9/9* target identification by transcriptome analysis. 
ETS-related gene (Erg) was the only target identified in both sample types. (b) Quantitative RTPCR and (c) Western 
blot analysis of ERG in 32DmiR-9/9*. All experiments were performed in three independent biological replicates. 
Unpaired two-tailed t-test was used for the statistical analysis. *P < 0.05.
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Figure 3. MiR9/9* are aberrantly expressed in AML and their expression is dependent on the AML subtype. 
Quantitative RTPCR of miR9 and miR9* in a cohort of primary human AML cases, normal human mononuclear cells 
(MNC), and myeloblast cells (CD34+) isolated from bone marrow. (a) MiR9 and (b) miR9* expression in all AML cases, 
and (c-d) in different cytogenetic subtypes of AML. The 11q23 category contains MLL-related leukemias harboring 
11q23 abnormalities other than t(9;11). RNU24 was used as endogenous control. Expression is given as dCt, where 
higher values represent higher expression. For measurements below detection, the minimal threshold was set to 
dCt value of 15. Unpaired two-tailed t-test was used for the statistical analysis. **P < 0.001. For detailed information 
about the miR-9/9* expression levels in different subtypes see Supplementary Table 1.
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Variable Mean Std. Dev. P (MNC)* P (CD34+)*
miR-9*
MNC -15.000 0.000
CD34+ -15.000 0.000
AML -11.598 3.294 <0.001 <0.001
+8 -10.262 3.456 <0.001 <0.001
Complex karyotype -11.708 3.240 <0.001 <0.001
-5 or -5q -12.372 3.210 <0.001 <0.001
-9q -13.115 2.609 0.023 0.023
inv(16) -12.615 2.618 <0.001 <0.001
inv(3) or t(3;3) -12.032 3.404 0.270 0.270
Normal karyotype -11.045 3.161 <0.001 <0.001
11q23 -9.515 4.325 <0.001 <0.001
t(9;11) -6.803 2.897 <0.001 <0.001
t(15;17) -13.233 2.672 0.020 0.020
t(6;9) -8.286 3.759 0.038 0.038
t(8;21) -14.697 1.129 0.090 0.090
Other -11.106 3.663 <0.001 <0.001
NPM1 wt -11.913 3.430 <0.001 <0.001
NPM1 mutant -10.341 2.741 <0.001 <0.001
FLT3 wt -11.563 3.312 <0.001 0.004
FLT3-ITD -10.659 2.908 <0.001 <0.001
FLT3-TKD -10.157 2.851 <0.001 <0.001
CEBPA wt -10.577 3.029 <0.001 <0.001
CEBPA mutant -13.617 2.566 <0.001 <0.001
CEBPA double mutant -14.257 2.112 0.002 0.002
CEBPA single mutant -11.386 2.882 0.048 0.048
Expression level is given as -dCt. RNU24 was used as endogenous control.
*P-value of unpaired two-tailed t-test. Each variable  was compared to MNC or CD34+ cells.
Abbreviations: AML, acute myeloid leukemia; MNC, mononuclear cells; WBC, white blood cell count; CEBPA, 
CCAAT/enhancer-binding protein α; NPM1, nucleophosmin; wt, wild type; FLT3-ITD, internal tandem duplications 
in the FMS-like tyrosine kinase 3; FLT3-TKD, FMS-like tyrosine kinase 3 with mutations in tyrosine kinase domain.
See also Table 1, Figure 3, and Supplementary Figure 4.    
SUPPLEMENTARY DATA 
Table S1. MiR-9/9* expression level in different AML subtypes. RNU24 was used as endogenous control. Expression 
is given as -dCt, where higher values represent higher expression. For measurements below detection, the minimal 
threshold was set to -dCt value of -15. Unpaired two-tailed t-test was used for the statistical analysis.
Variable Mean Std. Dev. P (MNC)* P (CD34+)*
miR-9
MNC -9.363 3.033
CD34+ -13.870 1.779
AML -8.122 3.748 0.298 <0.001
+8 -6.902 4.177 0.106 <0.001
Complex karyotype -7.494 3.195 0.122 <0.001
-5 or -5q -8.755 3.192 0.581 <0.001
-9q -10.852 3.768 0.320 0.022
inv(16) -9.114 2.224 0.761 <0.001
inv(3) or t(3;3) -8.314 3.847 0.628 0.121
Normal karyotype -7.542 3.555 0.110 <0.001
11q23 -4.747 3.245 0.002 <0.001
t(9;11) -2.927 2.599 <0.001 <0.001
t(15;17) -10.253 3.111 0.440 <0.001
t(6;9) -4.888 3.510 0.034 0.010
t(8;21) -12.455 2.212 0.001 0.058
Other -7.097 4.021 0.088 <0.001
NPM1 wt -8.905 4.193 0.736 <0.001
NPM1 mutant -6.449 2.530 <0.001 <0.001
FLT3 wt -8.388 3.924 0.442 <0.001
FLT3-ITD -6.944 3.024 0.017 <0.001
FLT3-TKD -5.898 2.454 <0.001 <0.001
CEBPA wt -6.787 3.022 0.009 <0.001
CEBPA mutant -11.653 3.562 0.064 0.010
CEBPA double mutant -12.457 3.435 0.014 0.103
CEBPA single mutant -8.948 2.820 0.749 <0.001
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Table S2. Significantly downregulated probe sets in AML patients with high miR-9/9* expression. 0-25% expression value 
(lowermost quartile) vs 75-100% expression value (uppermost quartile) with Padjusted < 0.05 and fold change > 1.5.
0-25% vs 75-100% Target prediction algorithm
Probe set ID Gene symbol Padjusted Fold change TargetScan (miR-9) TargetScan (miR-9*)
214953_s_at APP 3.24E-08 3.64
206622_at TRH 2.22E-07 3.55
200602_at APP 6.96E-08 3.32
202746_at ITM2A 7.87E-08 3.11
201015_s_at JUP* 1.30E-11 3.07 x
206726_at PGDS 3.47E-08 3.04
218825_at EGFL7 1.09E-11 3.00
217979_at TSPAN13 3.40E-10 2.99
241133_at --- 1.15E-06 2.96
219837_s_at CYTL1 3.13E-07 2.94
206660_at IGLL1 5.98E-06 2.89
225285_at BCAT1 1.89E-07 2.85
223708_at C1QTNF4 3.34E-05 2.77
202747_s_at ITM2A 1.79E-06 2.73
206761_at CD96 1.94E-06 2.70
227923_at SHANK3 1.40E-06 2.69
200665_s_at SPARC 4.49E-06 2.68
202947_s_at GYPC 2.99E-09 2.67
231929_at IKZF2 8.45E-08 2.66 x x
213541_s_at ERG 1.52E-11 2.65 x
202242_at TSPAN7 4.47E-08 2.59
202016_at MEST 8.20E-06 2.58
235333_at B4GALT6 5.43E-09 2.56 x
209583_s_at CD200 3.31E-06 2.53
231982_at LOC284422 6.87E-07 2.52
207550_at MPL 1.64E-08 2.48
235142_at LOC730411 /// ZBTB8 3.53E-08 2.48
208116_s_at MAN1A1 3.14E-09 2.43
226517_at BCAT1 6.62E-07 2.41
229002_at FAM69B 6.08E-09 2.40
237849_at --- 2.81E-08 2.35
221760_at MAN1A1 1.59E-08 2.32
227230_s_at KIAA1211 3.76E-08 2.32
224428_s_at CDCA7 7.63E-09 2.30
206233_at B4GALT6 1.49E-08 2.29 x
213258_at TFPI 9.12E-06 2.28
221004_s_at ITM2C 5.11E-07 2.25 x
209160_at AKR1C3 2.79E-06 2.24
238488_at IPO11 1.65E-11 2.23 x
209771_x_at CD24 5.26E-04 2.19
241926_s_at ERG 9.55E-11 2.16 x
221942_s_at GUCY1A3 1.25E-04 2.15
216379_x_at CD24 1.68E-04 2.13
227235_at --- 2.26E-04 2.10
204960_at PTPRCAP 8.87E-08 2.07
207134_x_at TPSAB1 1.80E-02 2.07
217023_x_at TPSAB1 8.99E-03 2.07
205683_x_at TPSAB1 2.37E-02 2.06
0-25% vs 75-100% Target prediction algorithm
Probe set ID Gene symbol Padjusted Fold change TargetScan (miR-9) TargetScan (miR-9*)
205051_s_at KIT 8.89E-04 2.05
266_s_at CD24 2.14E-04 2.04
210084_x_at TPSAB1 2.43E-02 2.04
215382_x_at TPSAB1 2.36E-02 2.04
216733_s_at GATM 3.19E-05 2.03
218856_at TNFRSF21 1.69E-05 2.02 x
216474_x_at TPSAB1 1.79E-02 2.01
208651_x_at CD24 5.56E-04 2.00
203178_at GATM 1.86E-04 1.97
204165_at WASF1 1.69E-04 1.97
229530_at --- 3.76E-04 1.97
232227_at --- 1.74E-09 1.97
218858_at DEPDC6 1.87E-05 1.93
235171_at --- 3.83E-04 1.90
209795_at CD69 2.59E-03 1.89
220059_at BRDG1 1.97E-05 1.88
227860_at CPXM1 7.51E-04 1.88
205240_at GPSM2 1.02E-06 1.87
212558_at SPRY1 3.20E-04 1.87 x
200953_s_at CCND2 3.15E-06 1.86
208650_s_at CD24 1.38E-03 1.85
203608_at ALDH5A1 1.50E-04 1.85
226473_at CBX2 2.53E-06 1.85
214452_at BCAT1 7.60E-07 1.84
218966_at MYO5C 7.56E-08 1.83
224759_s_at C12orf23 8.50E-06 1.82
228029_at ZNF721 1.89E-05 1.82
209560_s_at DLK1 1.84E-03 1.80
219686_at STK32B 2.01E-06 1.80
213668_s_at SOX4 1.62E-02 1.79 x
203069_at SV2A 1.60E-04 1.78
227231_at KIAA1211 2.12E-06 1.78
1555120_at CD96 5.33E-07 1.77
201416_at SOX4 6.37E-03 1.77 x
229801_at C10orf47 1.28E-08 1.76
219271_at GALNT14 1.44E-04 1.75
214390_s_at BCAT1 3.87E-05 1.73
226043_at GPSM1 2.14E-04 1.73
229390_at FAM26F 9.51E-03 1.70
201839_s_at TACSTD1 4.25E-03 1.69
210140_at CST7 2.27E-02 1.69
204529_s_at TOX 1.62E-02 1.66
201830_s_at NET1 1.20E-03 1.64
223075_s_at C9orf58 1.61E-02 1.61 x
210933_s_at FSCN1 1.65E-02 1.56
201564_s_at FSCN1 1.11E-02 1.55
225105_at OCC-1 3.60E-03 1.51
223565_at MGC29506 3.28E-02 1.50
x: Potential target of miR-9 or miR-9* that was predicted by TargetScan algorithm.
*: Potential targets of miR-9 or miR-9* that were downregulated with a fold change>1.5 are marked in red.
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Table S3. Significantly downregulated probe sets in 32D-miR-9/9*. Significantly downregulated probe sets in 
32D-miR-9/9* cells compared to those in 32D-EV cells with Padjusted < 0.05 and fold change > 1.5. 
Probe set ID Gene symbol Padjusted
Fold 
change
Target prediction 
algorithm
TargetScan 
(miR-9)
TargetScan 
(miR-9*)
1420394_s_at Gp49a /// Lilrb4 8.98E-03 3.26
1448301_s_at Serpinb1a 7.19E-03 2.95
1428478_at Reep4* 4.63E-06 2.73 x
1434940_x_at Rgs19 7.50E-05 2.55
1417588_at Galnt3 3.16E-08 2.40 x
1416318_at Serpinb1a 4.02E-02 2.39
1425469_a_at --- 5.22E-03 2.22
1425764_a_at Bcat2 8.12E-05 2.15 x
1419091_a_at Anxa2 8.43E-05 2.10 x
1425471_x_at --- 4.10E-02 2.09
1436522_at Map3k3 2.14E-06 2.08 x
1419648_at Myo1c 1.23E-04 2.06 x
1454942_at Fam129a 5.20E-04 2.02
1418448_at Rras 4.79E-04 2.00
1422861_s_at Pdlim5 2.58E-03 1.98
1420172_at --- 2.89E-03 1.96
1456179_at AU019176 2.68E-02 1.94
1429364_at 4930579G24Rik 5.36E-04 1.94
1437232_at Bpil2 1.22E-02 1.94
1451475_at Plxnd1 7.94E-04 1.91
1456150_at Jhdm1d 2.16E-03 1.90 x
1422567_at Fam129a 2.36E-03 1.89
1420827_a_at Ccng1 1.42E-03 1.87 x
1416472_at Syap1 4.06E-03 1.85 x
1449020_at Plscr3 6.20E-03 1.82
1420170_at Myh9 3.41E-03 1.82 x
1423156_at Gnpnat1 1.16E-02 1.79 x
1425122_at Fam3b 1.64E-03 1.77
1418468_at 100039484 /// 100039503 /// Anxa11 5.25E-04 1.75
1456057_x_at Tmem109 9.15E-05 1.74 x
1437008_x_at Tmem109 8.00E-04 1.74 x
1420725_at Tmlhe 7.05E-03 1.73
x: Potential target of miR-9 or miR-9* that was predicted by TargetScan algorithm.
*: Potential targets of miR-9 or miR-9* that were downregulated with a fold change>1.5 are marked in red.
Probe set ID Gene symbol Padjusted
Fold 
change
Target prediction 
algorithm
TargetScan 
(miR-9)
TargetScan 
(miR-9*)
1444015_at --- 1.70E-03 1.73
1460036_at Ap1s2 4.56E-03 1.73 x
1452254_at Mtmr9 5.64E-04 1.73
1440244_at Erg 4.08E-02 1.72 x
1417472_at Myh9 4.36E-03 1.72 x
1419455_at Il10rb 2.79E-03 1.70
1453299_a_at LOC100045567 /// Pnp1 /// Pnp2 1.15E-03 1.70
1440388_at --- 1.73E-03 1.70
1419649_s_at Myo1c 7.57E-06 1.70 x
1420372_at Sntb2 8.14E-04 1.70 x
1417786_a_at Rgs19 7.26E-04 1.69
1423707_at Tmem50b 7.25E-03 1.68
1449180_at Kcmf1 6.38E-04 1.67
1427918_a_at Rhoq 6.49E-03 1.66
1452655_at Zdhhc2 1.44E-03 1.66
1416032_at Tmem109 2.74E-02 1.65 x
1439959_at Fgf11 4.53E-03 1.63
1423614_at Lrrc8c 2.58E-03 1.62
1417471_s_at D1Ertd622e 4.73E-03 1.62
1423295_at Tm9sf2 1.99E-02 1.62
1417834_at Synj2bp 6.18E-03 1.61 x
1450786_x_at Pdlim5 6.43E-03 1.61
1438396_at Ocrl 8.53E-03 1.60
1424834_s_at Itpr2 1.03E-02 1.60
1431072_a_at Ccdc50 7.33E-04 1.60
1435867_at Jhdm1d 2.87E-02 1.59 x
1457281_at Dnajc21 9.80E-03 1.58
1417847_at Ulk2 8.19E-03 1.58 x
1427475_a_at Pdlim5 7.10E-04 1.58
1420382_at Apob48r 3.41E-02 1.58
1449383_at Adssl1 1.68E-03 1.57
1436213_a_at 1110028C15Rik 4.36E-02 1.57
x: Potential target of miR-9 or miR-9* that was predicted by TargetScan algorithm.
*: Potential targets of miR-9 or miR-9* that were downregulated with a fold change>1.5 are marked in red.
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Probe set ID Gene symbol Padjusted
Fold 
change
Target prediction 
algorithm
TargetScan 
(miR-9)
TargetScan 
(miR-9*)
1435777_at Itpripl2 1.33E-03 1.57
1441906_x_at Syap1 7.53E-03 1.56 x
1448853_at Synj2bp 6.73E-05 1.56
1419459_a_at Magt1 1.36E-03 1.55 x
1428622_at Depdc6 3.78E-02 1.55
1428633_at Twistnb 2.44E-02 1.54
1417398_at Rras2 5.87E-03 1.54
1437830_x_at Zbed3 1.94E-02 1.53
1438932_at Rasgrp2 4.76E-02 1.53
1452013_at Atp10a 7.69E-03 1.53
1419029_at Ero1l 4.35E-02 1.53
1444426_at Cass4 2.15E-02 1.52
1433571_at Serinc5 4.58E-02 1.52
1420171_s_at Myh9 5.72E-03 1.52 x
1450980_at Gtpbp3 4.55E-02 1.52
1457202_at --- 3.18E-02 1.51
1424746_at Kif1c 7.27E-03 1.51 x
1455787_x_at Minpp1 1.98E-02 1.50
1452521_a_at Plaur 1.96E-02 1.50  
x: Potential target of miR-9 or miR-9* that was predicted by TargetScan algorithm.
*: Potential targets of miR-9 or miR-9* that were downregulated with a fold change>1.5 are marked in red.
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Figure S1. MiR-9/9* inhibits granulocytic maturation in murine myeloid 32D cell line.  (a) Overexpression of miR9/9* 
showed by qRT-PCR in cells that were transduced with empty vector (32D-EV) or with vector containing miR-9/9* 
precursor (32D-miR-9/9*). Sno234 was used as endogenous control. Expression is shown as -dCt, where higher 
values represent higher expression.  (b) Cebpa expression in samples taken at different time points of G-CSF induced 
differentiation measured with Mouse Genome 430 2.0 array. All experiments were performed in three independent 
biological replicates. Unpaired two-tailed t-test was used for the statistical analysis. *P < 0.05. **P < 0.001.
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Figure S2. MiR-9/9* overexpression and FACS gating strategy in colony-forming cell assays. (a-b) qRT-PCR in lineage 
negative murine bone marrow cells (Lin- muBM) transduced with empty vector (EV) or with vector containing miR-
9/9* precursor (miR-9/9*), in (a) CFU and (b) CFU-G assay. Sno202 was used as endogenous control. Expression is 
shown as -dCt, where higher values represent higher expression. (c) FACS gating strategy for defining Lin-c-Kit+Sca-1- 
(LK) progenitor population. One biological replicate is shown at day 0 of CFU assay. (d) FACS gating strategy for 
defining Annexin V+ population. One biological replicate is shown at day 0 of CFU-G assay. Unpaired two-tailed t-test 
was used for the statistical analysis. **P < 0.001.
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Figure S3. Cell morphology, apoptosis and colony characteristic in colony-forming cell assays. (a) Representative 
micrographs of cytospins stained with May Grünwald Giemsa (original magnification ×100). Black arrows highlight 
immature miR-9/9* cells. (b) A summary of distinct differentiation stages scored based on morphology at day 7 
of CFU assay. (c) A summary of Annexin V+ populations at day 0 and day 7 of CFU assay. (d) A summary of colony 
numbers (CFUs) per 1000 cells plated at day 7 of CFU and CFU-G assays. (e) Representative micrographs of colonies 
at day 7 of CFU and CFU-G assays (original magnification ×40). (f) Representative FACS plots showing Annexin 
V+ populations in one replicate at day 0 and day 7 of CFU-G assay.  All experiments were performed in three inden-
dent biological replicates. Unpaired two-tailed t-test was used for the statistical analysis. *P < 0.05. **P < 0.001.
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Figure S4. MiR-9/9* expression in AML. (a) MiR-9 and (b) miR-9* expression in different subtypes of normal 
karyotype AML. (c) MiR-9 and (d) miR-9* expression in different FAB subtypes. RNU24 was used as endogenous 
control. Expression is given as -dCt. For measurements below detection, the minimal threshold was set to -dCt value 
of -15.
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Figure S5. Known murine and human ERG isoforms. Schematic structure of known (a) murine and (b) human ERG 
isoforms with their important functional domains. Names are given according to transcript/protein ID in Ensembl 
database. PNT – pointed domain. (cd) MiR-9 binding sites in known (c) murine Erg and (d) human ERG transcripts 
(highlighted in yellow) and miR-9 seed sequence (highlighted in grey). Position of a binding site is given from the 
beginning of a 5’ UTR of a specific transcripts. 
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Figure S6. ERG expression upon upregulation of miR-9/9* in different cell lines, and in AML with low or high miR-
9/9* levels. (a) Western blot analysis of different cell lines transduced with MSCV-EV (EV) or MSCV-miR-9/9* (miR-
9/9*). (b) Western blot analysis of AML samples with low or high miR-9/9* expression level. (c) Correlation of miR-9 
and ERG expression in AML. Plots show the expression of ERG measured with three different probe sets derived from 
Human Genome U133 plus 2.0 arrays.
Figure S7. ERG is a direct target of miR-9 and its upregulation reverses block in neutrophil differentiation induced by 
miR-9/9* overexpression. (a) A representation of ERG 3’ UTR luciferase reporter assay. Mutated miR-9 binding sites 
are marked with stars. (b) Relative luciferase activity in HEK293T cells that were transfected with the wild type or 
mutant 3’ UTR of ERG in combination with EV or miR-9/9*. (c) Average growth rates of 32DEV (no symbol) and 
32D-miR9/9* (triangle) cells that were transduced with LNCX2-EV (solid line) or LNCX2-Erg (dashed line); cultured 
upon IL-3 (black) or G-CSF (red) stimulation. Growth rates are given as number of cells at each time point divided by 
number of cells at day 0. (d) Representative micrographs of cytospins stained with May Grünwald Giemsa at different 
time points of GC-SF induced differentiation (original magnification ×100). (c-d) Data show the second of the two 
independent biological replicates.
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Figure S8. MiR-9 knockdown in HL-60 AML cell line model leads to upregulation of ERG expression. (a) Western 
blot analysis of HL-60 cells transfected with LNA-scramble or LNA-miR-9 at day 5. (b) Representative micrographs 
of cytospins stained with May Grünwald Giemsa at day 5 of LNA treatment (original magnification ×100). (c) Flow 
cytometric analysis of neutrophil and monocytic differentiation markers according to EuroFlow protocols at day 5 of 
LNA treatment. Cells treated with LNA-scramble are marked in grey and cells treated with LNA-miR-9 are marked in 
black. Circles represent median values of fluorescence intensity. All experiments were performed in three indepen-
dent replicates.
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INTRODUCTION
MiRNAs are short non-coding RNAs (20-25 nt) that post-transcriptionally regulate gene 
expression.1 They bind with their 5’ regions at position 2-8 to complementary sequences 
within the 3’ untranslated regions (3’ UTRs) of target mRNAs. In this way, they act as a 
guide for ribonucleoprotein complexes, called miRISCs, for recognition of mRNA targets. 
As a result of miRISC-mRNA interaction, the mRNA undergoes decay and/or translational 
repression that lead to decrease in the protein level. Changes in miRNA expression may 
only partially influence each individual target but significantly affect all targets as a class.2 
Each miRNA can target hundreds of transcripts, therefore miRNAs are commonly parts of 
co-regulatory networks of direct and in direct targets that function together to influence 
phenotypic outcome.3,4
MiR-9 and miR-9* (miR-9/9*) are two miRNAs that originate from the same precursor 
miRNA, pre-miR-9.5 In a previous study, we reported the aberrant expression of these 
miRNAs in acute myeloid leukemia (AML).6 MiR-9/9* are not expressed in normal murine 
hematopoietic stem and progenitor cells and overexpression of these miRNAs in the murine 
myeloid 32D cell line inhibited neutrophil differentiation. Here, we investigate the effects 
of miR-9/9* overexpression on proteome changes in 32D cells in a steady state (IL-3) and 
during granulocyte colony-stimulating factor (G-CSF) induced differentiation.
MATERIALS AND METHODS
Cell culture and transduction
The mmu-miR-9-2 precursor (together with ~250 bp flanking sequence) was cloned into 
a pMSCV retroviral expression system containing GFP.7 Retroviral particles were produced 
as previously described.7 Cells were transduced using RetroNectin (Takara Bio Inc., Shiga, 
Japan) according to the manufacturer’s protocol and selected for GFP expression using 
FACSAria cell sorter (BD Biosciences, Breda, the Netherlands). 
The 32D cell line was cultured as previously described in medium containing interleukin 
3 (IL-3) or for 48 hours in medium containing G-CSF.7,8
Real-time quantitative RT-PCR
Total RNA isolation and real-time quantitative RT-PCR were performed as previously 
described.7,9 Briefly, miR-9 and miR-9* expression was determined using real-time 
quantitative RT-PCR assays for miRNAs (Applied Biosystems, Nieuwerkerk a/d IJssel, the 
Netherlands). MiR-9/9* expression was determined using sno202 as loading control. 
A minimal threshold for Ct values above 35 were set to a dCt value of -13. The relative 
quantification method 2−(dCt) was used to calculate the relative expression.
ABSTRACT 
MiR-9 and miR-9* (miR-9/9*) are both aberrantly expressed in most cases of acute 
myeloid leukemia (AML). In a previous study, we showed that overexpression of miR-9/9* 
in normal myeloid progenitor cells inhibits neutrophil differentiation. Here, we investigate 
the proteome changes in murine myeloid 32D cells that ectopically express miR-9/9*. We 
found 29 proteins to be significantly down- or upregulated in a steady state, and 42 upon 
induction of neutrophil differentiation. The differentially expressed proteins were related to 
cell differentiation, apoptosis, migration and adhesion. Among the downregulated proteins, 
there were 5 potential miR-9/9* targets: MYO1C, ANXA2, VCL, MYH9 and ITGA6.
Expression of miR-9/9* in 32D cells induces proteome changes related to cell differentiation, 
apoptosis, migration and adhesion
Chapter 3
80 81
RESULTS
Proteome changes in 32D cells upon miR-9/9* overexpression 
MiR-9/9* are not expressed in wild type 32D cells.6 To investigate the effects of miR-
9/9* expression on the proteome, we transduced 32D cells with a retroviral construct 
containing GFP and miR-9/9* or GFP only. Subsequently, cells were FACS sorted and cultured 
in medium containing IL-3 and light or heavy amino acids under SILAC conditions (Figure 1a; 
see Materials and Methods). Ectopic expression of miR-9/9* under light and heavy culture 
conditions was confirmed by real-time quantitative RT-PCR (Figure 1b). In all 4 independent 
replicates, a total of 3043 proteins were identified (Figure 2a). Of those, 18 were significantly 
downregulated and 11 were upregulated upon miR-9/9* expression (Figure 2b). Among 
these proteins, 14 were also differentially expressed on the mRNA transcript level as shown 
by GEP analysis (n = 3; Figure 2c).
To further characterize miR-9/9* expressing 32D cells, we performed Ingenuity 
pathway analysis. The twenty-eight differentially expressed proteins could be related to the 
categories of functions, such as cell death and survival (14 proteins, P = 3.9×10-4 – 6.4×10-3), 
cellular movement (14 proteins, P = 1.2×10-5 – 2.1×10-3), cell-to-cell signaling and interaction 
(8 proteins, P = 4.9×10-6 – 1.4×10-4) (Table 1). Among differentially expressed proteins, there 
were 4 predicted downregulated miR-9 targets: MYO1C, ANXA2, VCL and MYH9 (Figure 2a, 
red dots). No predicted miR-9* targets were found to be downregulated.
Proteome changes in 32D cells upon miR-9/9* overexpression during induction of 
differentiation
32D cells are capable to differentiate from immature myeloblasts towards neutrophils within 
5 days of G-CSF stimulation.6,8 We previously showed, that miR-9/9* overexpression in 32D 
cells inhibits neutrophil differentiation.6 To investigate the influence of miR-9/9* expression 
on the proteome during early differentiation, we transferred 32D-miR-9/9* and 32D-EV cells 
to media containing G-CSF and light or heavy amino acids for 48 hours and performed SILAC 
experiments. Overall, 2793 proteins were identified in 4 independent replicates (Figure 3a).
In total, 24 proteins were significantly downregulated and 18 were upregulated upon miR-
9/9* expression (Figure 3b). We found that 31 proteins were also differentially expressed on 
the transcript level (n = 3; Figure 3c).
The Ingenuity pathway analysis revealed that the differentially expressed proteins 
could be related to the categories of functions, such as cell death and survival (27 proteins, 
P = 6.6×10-9 – 4.1×10-8), cellular movement (24 proteins, P = 7.0×10-13 – 5.3×10-7), cellular 
development (20 proteins, P = 1.5×10-7), cell-to-cell signaling and interaction (12 proteins, P 
= 7.8×10-10 – 2.8×10-6) (Table 2). Among downregulated proteins, we identified 3 predicted 
miR-9 targets: ITGA6, VCL and ANXA2 (Figure 3a, red dots). Similarly to the IL-3 culture 
condition, no predicted miR-9* targets were found.
Stable isotope labeling by amino acids in cell culture (SILAC)
32D cells that were transduced with vector containing miR-9/9* (32D-miR-9/9*) or with 
empty vector (32D-EV) were stably labeled with heavy amino acids [13C6]-L-Lysine (*Lys) 
and [13C6, 
15N4]-L-Arginine (*Arg) using SILAC
TM Protein ID & Quantitation Media Kit (Thermo 
Fischer Scientific, Bleiswijk, the Netherlands) according to manufacturer’s protocol. Full 
incorporation of heavy amino acids and arginine-to-proline conversion artifacts was 
validated after 6 doubling times using nanoflow liquid chromatography tandem mass 
spectrometry (LC-MS/MS). In the forward experiment, 32D-miR-9/9* were grown in RPMI 
medium supplemented with 10% dialyzed FBS and heavy amino acids. Simultaneously, 
32D-EV were grown in medium containing regular (light) amino acids. After six doubling 
times, cells were harvested, mixed in a 1:1 ratio (based on cell numbers) and lysed in RIPA 
buffer (Sigma-Aldrich, Zwijndrecht, the Netherlands). Subsequently, SDS-PAGE and LC-MS/
MS were performed as previously described.10 In the reversed experiment, 32D-miR-9/9* 
were grown in medium containing light amino acids and 32D-EV in medium containing 
heavy amino acids. Data obtained from forward and reversed experiments were analyzed 
using MaxQuant and Perseus software (www.maxquant.org). A list of significantly changed 
proteins was generated based on the normalized protein expression ratio < 0.8 (log2 = 
(0.322)) for downregulated or > 1.2 (log2 = (0.263)) for upregulated proteins and significance 
B < 0.05. All experiments were performed in 2 independent biological replicates, each 
including 2 technical replicates (forward and reversed; total n = 4). 
Ingenuity Pathway Analysis (IPA, www.ingenuity.com) was used to determine overrepresen-
ted pathways and functions that were related to differentially expressed proteins. Potential 
miR9/9* targets were selected using TargetScan 4.2 (www.targetscan.org) web resource. 
Gene expression profiling analysis 
Gene expression profiles (GEP) of 32D-miR-9/9* or 32D-EV were derived using Mouse 
Genome 430 2.0 array (Affymetrix, High Wycombe, UK) as published previously.6 Data 
are available at www.ncbi.nlm.nih.gov/geo (GSE41942). Down- and upregulated proteins 
that were identified in SILAC experiments were analyzed for their mRNA expression. All 
experiments were performed in 3 independent replicates.
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DISCUSSION
We previously reported that miR-9/9* are aberrantly expressed in AML. Overexpression 
of these miRNAs in normal hematopoietic stem and progenitor cells inhibited neutrophil 
differentiation.6 Since miRNAs post-transcriptionally regulate gene expression,1,2 we 
investigated the effects of miR-9/9* overexpression on the proteome in murine myeloid 
32D cell line. 
In a stady state (IL-3 conditioned medium), ectopic expression of miR-9/9* in 32D cells 
significantly changed the expression of 28 proteins. Subsequent pathway analysis revealed 
that the proteome changes induced by overexpression of miR-9/9* could be related to 
increase in apoptosis (score = 1.5), decrease in migration of hematopoietic cells (score = 
(-1.7) – (-1.2)), and decrease in adhesion of cells (score = (-2.2)) (Table 1). After induction of 
neutrophil differentiation with G-CSF, ectopic expression of miR-9/9* significantly changed 
the expression of 42 proteins. The downregulated and upregulated proteins could be related 
to decrease in apoptosis (score = (-0.5)), migration (score = (-1.9) – (1.3)), adhesion (score = 
(-1.5)) and differentiation (score = (-0.5)) (Table 2). The larger number of influenced proteins 
upon G-CSF stimulation could be potentially explained by the inhibition of neutrophil 
differentiation in 32D-miR-9/9* as compared to 32D-EV that normally differentiate.6 It is 
further supported by the pathway analysis showing that deregulated proteins relate to 
decrease in differentiation in miR-9/9* overexpressing cells.
In this study, we identified 5 potential miR-9/9* targets that are implicated in cellular 
movement and adhesion: MYO1C, ANXA2, VCL, MYH9 and ITGA6. MiR-9 was previously 
reported to influence migration and adhesion of cells in different human tumors. In 
osteosarcoma (OS), miR-9 was shown to repress genes involved in migration, differentiation 
and focal adhesion, including MYO1C, ITGA6 and VCL.4 In hepatocellular carcinoma (HCC), 
overexpression of miR-9 inhibited migration of carcinoma cell lines.11 Additionally, miR-
9 expression level was inversely correlated with the level of ANXA2 gene in primary HCC 
tissues and ANXA2 was shown to be a direct target of miR-9.11 
Our results suggest that the aberrant expression of miR-9/9*, alongside blocking 
neutrophil differentiation, may affect apoptosis, migration and adhesion of normal myeloid 
cells. Further functional studies are necessary to show the potential contribution of miR-
9/9*-induced proteome changes to aberrant apoptosis, migration and adhesion of normal 
hematopoietic stem and progenitor cells. 
Expression of miR-9/9* in 32D cells induces proteome changes related to cell differentiation, 
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Table 2. Top functions annotated to differentially expressed proteins in miR-9/9* overexpressing 32D cells after 48 
hours of G-CSF treatment
Category Functions  
annotation
P Score† No. of 
proteins‡
Protein symbol§
Cell Death and 
Survival
cell death 4.1E-08 -0.9 25
HSD17B10, FLNB, CSTA, PRDX5, IL1RL1, CTSG, 
S100A4, NFKB1, SUN2, ITGB3, TGM2, CASP6, HK2, 
S100A8, VCL, PGRMC1, LCN2, ITGA6, VIM, ANXA2, 
ITGAL, ITGAM, S100A9, PRTN3, NCF2
necrosis 6.6E-09 -1.7 23
HSD17B10, CSTA, FLNB, IL1RL1, LCN2, S100A4, 
ITGA6, CTSG, VIM, ANXA2, NFKB1, ITGAL, SUN2, 
ITGB3, TGM2, CASP6, HK2, ITGAM, S100A9, PRTN3, 
NCF2, S100A8, PGRMC1
apoptosis 1.2E-08 -0.5 23
HSD17B10, CSTA, FLNB, IL1RL1, PRDX5, LCN2, 
S100A4, ITGA6, CTSG, VIM, ANXA2, NFKB1, SUN2, 
ITGB3, TGM2, CASP6, HK2, ITGAM, S100A9, PRTN3, 
NCF2, S100A8, VCL
cell survival 1.5E-08 1.8 17
CCR1, HSD17B10, LCN2, S100A4, VIM, NFKB1, ITGAL, 
PREP, TGM2, CASP6, ITGAM, HK2, S100A9, NCF2, 
S100A8, VCL, PGRMC1
Cellular Move-
ment
migration of 
cells 9.9E-13 -1.2 24
CCR1, FLNB, LCP1, IL1RL1, LCN2, S100A4, ITGA6, 
CTSG, VIM, ANXA2, NCF4, NFKB1, ITGAL, SUN2, 
ITGB3, TGM2, ITGAM, S100A9, PRTN3, NCF2, ANXA3, 
TRPV2, S100A8, VCL
chemotaxis of 
cells 1.0E-11 -1.9 14
CCR1, LCP1, LCN2, CTSG, ITGA6, S100A4, ANXA2, IT-
GAL, ITGB3, ITGAM, S100A9, PRTN3, TRPV2, S100A8
cell movement 
of tumor cell 
lines
5.3E-07 0.2 12 TGM2, FLNB, LCP1, S100A9, S100A4, ITGA6, CTSG, 
VIM, S100A8, ANXA2, VCL, ITGB3
Cellular Develop-
ment
differentiation 
of cells 1.5E-07 -0.5 20
CCR1, CSTA, FLNB, LCP1, IL1RL1, LCN2, CTSG, ITGA6, 
S100A4, VIM, ANXA2, NFKB1, ITGAL, ITGB3, PREP, 
TGM2, ITGAM, PRTN3, S100A8, ACADM
Cellular Move-
ment, Hemato-
logical System 
Development 
and Function, 
Immune Cell 
Trafficking,  
Inflammatory 
Response,  Tissue 
Development
leukocyte 
migration
7.0E-13 -1.3 18
CCR1, LCP1, IL1RL1, LCN2, CTSG, ITGA6, S100A4, 
ANXA2, NCF4, NFKB1, ITGAL, ITGB3, TGM2, ITGAM, 
S100A9, PRTN3, TRPV2, S100A8
cell movement 
of myeloid cells 1.3E-11 -1.2 14
CCR1, IL1RL1, LCN2, CTSG, S100A4, ANXA2, ITGAL, 
ITGB3, TGM2, ITGAM, S100A9, PRTN3, TRPV2, 
S100A8
migration of 
phagocytes 1.3E-07 -1.9 8
CCR1, ITGAM, S100A9, CTSG, S100A8, ANXA2, ITGAL, 
ITGB3
accumulation of 
neutrophils 1.0E-10 -1.6 7 ITGAM, S100A9, PRTN3, LCN2, ITGA6, CTSG, S100A8
Inflammatory 
Response
inflammatory 
response 1.2E-12 -1.6 17
CCR1, LCP1, IL1RL1, PRDX5, LCN2, CTSG, S100A4, 
ANXA2, NFKB1, ITGAL, ITGB3, TGM2, ITGAM, 
S100A9, PRTN3, TRPV2, S100A8
Tissue Morpho-
logy quantity of cells 9.4E-05 0.6 14
CCR1, IL1RL1, LCN2, ITGA6, NFKB1, ITGAL, ITGB3, 
PREP, TGM2, ITGAM, S100A9, PRTN3, S100A8, VCL
Cell-To-Cell 
Signaling and 
Interaction
binding of cells 7.8E-10 -0.9 12 CCR1, TGM2, ITGAM, S100A9, PRTN3, ITGA6, CTSG, 
TRPV2, ANXA2, VCL, ITGAL, ITGB3
adhesion of 
tumor cell lines 2.8E-06 -1.5 7 TGM2, ITGAM, ITGA6, ANXA2, VCL, ITGAL, ITGB3
Cancer, Organis-
mal Injury and 
Abnormalities
metastasis 8.5E-05 1.9 9 TGM2, IL1RL1, LCN2, S100A4, ITGA6, VIM, CST7, 
ITGAL, ITGB3
†Activation score provides an information whether experimentally observed protein expression is associated with 
a literature-derived direction of regulation, which can be either “activating” (score > 0) or “inhibiting” (score < 0).
‡Number of differentially expressed proteins that were annotated to a particular function.  
§Predicted miR-9/9* targets that were downregulated upon miR-9/9* overexpression are marked in red.
Table 1. Top functions annotated to differentially expressed proteins in miR-9/9* overexpressing 32D cells upon 
IL-3 treatment
Category Functions 
annotation
P Score† No. of
proteins‡
Protein symbol§
Cell Death and Survival
cell death 3.9E-04 1.6 14
MYH9, GNG2, S100A4, ANXA2, ITGAL, 
SERPINB9B, POR, CSF2RB, MPO, ANXA1, PNP, 
ZYX, VCL, ARL11
necrosis 5.1E-03 1.5 10 CSF2RB, MPO, ANXA1, GNG2, S100A4, PNP, 
ZYX, ANXA2, ITGAL, ARL11
apoptosis 6.4E-03 1.5 10 POR, CSF2RB, MPO, ANXA1, GNG2, S100A4, PNP, ANXA2, VCL, ARL11
Cellular Movement
migration of 
cells 1.2E-05 0.3 13
SERPINB1, MYH9, S100A4, ANXA2, MYO1C, 
ITGAL, CSF2RB, IFITM3, MPO, ANXA1, ZYX, 
VCL, MYL12A
cell movement 
of tumor cell 
lines
5.4E-04 2.0 7 IFITM3, MYH9, ANXA1, S100A4, ZYX, ANXA2, 
VCL
chemotaxis of 
cells 2.5E-04 -0.4 6
SERPINB1, ANXA1, S100A4, ANXA2, BIN2, 
ITGAL
Tissue Morphology quantity of cells 4.0E-03 -0.8 8
SERPINB1, CSF2RB, MYH9, MPO, ANXA1, PNP, 
VCL, ITGAL
Cellular Movement, 
Hematological System 
Development and 
Function, Immune Cell 
Trafficking, Inflammatory 
Response
leukocyte 
migration
1.2E-04 -1.2 8 SERPINB1, CSF2RB, MYH9, MPO, ANXA1, S100A4, ANXA2, ITGAL
cell movement 
of myeloid cells 2.1E-03 -1.3 5 SERPINB1, ANXA1, S100A4, ANXA2, ITGAL
migration of 
phagocytes 9.0E-04 -1.7 4 MPO, ANXA1, ANXA2, ITGAL
Cell-To-Cell Signaling and 
Interaction
adhesion of 
tumor cell lines 4.9E-06 -2.2 6 MYH9, ANXA1, ZYX, ANXA2, VCL, ITGAL
binding of cells 1.4E-04 -1.6 6 CSF2RB, MYH9, MPO, ANXA2, VCL, ITGAL
Inflammatory Response
inflammatory 
response 2.3E-03 -0.7 6
SERPINB1, MPO, ANXA1, S100A4, ANXA2, 
ITGAL
†Activation score provides an information whether experimentally observed protein expression is associated with 
a literature-derived direction of regulation, which can be either “activating” (score > 0) or “inhibiting” (score < 0).
‡Number of differentially expressed proteins that were annotated to a particular function.  
§Predicted miR-9/9* targets that were downregulated upon miR-9/9* overexpression are marked in red.
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Figure 2. Proteome changes in 32D cells upon miR-9/9* overexpression. 32D cells were transduced with MSCVEV 
or MSCVmiR9/9* retroviral construct, FACS sorted, and cultured in media containing IL-3 upon SILAC conditions. 
Subsequently, a mass spectrometric analysis was performed. (a) A plot summarizing all identified proteins in 
2 biological replicates, each including 2 technical replicates. Horizontal and vertical axes represent logarithms of 
normalized protein expression ratios. Proteins that were upregulated upon miR-9/9* overexpression are situated 
in the upper right corner and those that were downregulated in the bottom left. Significantly changed proteins 
upon miR-9/9* expression are shown in detail per replicate. (b) A plot showing the logarithms of normalized protein 
expression ratios of significantly upregulated or downregulated proteins upon miR-9/9* expression. (c) mRNA 
transcript levels of differentially expressed proteins. Gene expression ratios were calculated relative to empty vector 
in 3 independent replicates. Error bars represent the standard deviation. Potential downregulated miR-9/9* targets 
are marked in red.
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Figure 1. SILAC experimental strategy and overexpression of miR-9/9* in 32D cell line. To investigate the influence of 
miR-9/9* expression on the proteome changes in 32D cell line, cells were transduced with MSCVEV (EV) or MSCV-
miR9/9* (miR9/9*) retroviral construct, FACS sorted, and cultured in media containing light (black) or heavy (red) 
amino acids. (a) A summary of SILAC experimental strategy. LS-MS/MS – nanoflow liquid chromatography tandem 
mass spectrometry. All experiments were performed in 2 independent biological replicates, each including 2 tech-
nical replicates: forward and reversed (total n = 4). (b) Quantitative RTPCR of miR-9 and miR-9* in cells that were 
transduced with empty vector (EV) or with vector containing miR-9/9* precursor (miR-9/9*) and grown in medium 
containing light (L) or heavy amino acids (H). Sno202 was used as endogenous control. Expression is shown as -dCt, 
where higher values represent higher expression. Error bars represent the standard deviation. Unpaired two-tailed 
t-test was used for the statistical analysis. **P <  0.001.
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Figure 3. Proteome changes in 32D cells upon miR-9/9* overexpression during induction of differentiation. 32D cells 
were transduced with MSCVEV or MSCVmiR9/9* retroviral construct, FACS sorted, and cultured in media containing 
granulocyte colony-stimulating factor (G-CSF) for 48 hours upon SILAC conditions. Subsequently, a mass spectrometric 
analysis was performed. (a) A plot summarizing all identified proteins in 2 biological replicates, each including 2 
technical replicates. Horizontal and vertical axes represent logarithms of normalized protein expression ratios. 
Proteins that were upregulated upon miR-9/9* overexpression are situated in the upper right corner and those that 
were downregulated in the bottom left. Significantly changed proteins upon miR-9/9* expression are shown in detail 
per replicate. (b) A plot showing the logarithms of normalized protein expression ratios of significantly upregulated 
or downregulated proteins upon miR-9/9* expression. (c) mRNA transcript levels of differentially expressed proteins. 
Gene expression ratios were calculated relative to empty vector in 3 independent replicates. Error bars represent the 
standard deviation. Potential downregulated miR-9/9* targets are marked in red.
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ABSTRACT
MiR-9/9* are highly conserved miRNAs that are aberrantly upregulated in most cases of 
acute myeloid leukemia (AML). We previously showed that aberrant expression of miR-9/9* 
in normal hematopoietic stem and progenitor cells (HSPCs) inhibits myeloid differentiation 
in vitro and leads to proteome changes related to differentiation, apoptosis, migration 
and adhesion. Here we report that in bone marrow transplantation experiments in mice, 
miR-9/9* overexpressing HSPCs had a reduced homing ability. We observed no differences 
in apoptosis and proliferative potential of these cells. Our preliminary data suggest that 
expression of miR-9/9* impairs different aspects  of normal hematopoietic cells function.
INTRODUCTION
Hematopoiesis is a lineage-specification process that involves step-wise maturation of 
hematopoietic stem and progenitor cells (HSPCs). The ability of these cells to differentiate 
and to contribute to normal hematopoiesis depends on their clonogenic properties and the 
interaction with the bone marrow (BM) compartment.1 Different hematopoietic cell types 
express a unique spectrum of adhesion and signaling molecules that convey their propensity 
to migrate and to interact with stromal cells in the hematopoietic niche.2 Several epigenetic 
factors have been shown to regulate function of hematopoietic cells, among which miRNAs 
are recognized to play a significant role.3,4 Altered miRNA expression has been reported to 
contribute to the development of acute myeloid leukemia (AML), a complex heterogeneous 
disease characterized by the accumulation of immature myeloid cells in the bone marrow 
(BM).5 
MiRNAs are short non-coding RNAs (20-25 nt) that post-transcriptionally suppress gene 
expression. In this way they regulate specific molecular networks in tissue development and 
disease.6 MiR-9 and miR-9* (miR-9/9*) are two highly conserved miRNAs that are produced 
from the miR-9 precursor RNA.7,8 Their expression and mode of action are cell-type specific 
and they have been shown to be deregulated in different types of tumors.9-11 In normal 
human HSPCs, miR-9 is expressed at low levels and miR-9* is not detectable.11 However, 
they are both aberrantly upregulated in most cases of AML.11,12 Our preliminary experiments 
in myeloid 32D cell line model indicated that miR-9/9* induce changes in expression of 
proteins involved in cellular movement and adhesion (unpublished data, Chapter 3 of this 
thesis). Here, we investigate the effect of miR-9/9* overexpression on homing of normal 
HSPCs in a murine in vivo bone marrow transplantation model.
MATERIALS AND METHODS
Cell culture and transduction
The mmu-miR-9-2 precursor (together with ~250 bp flanking sequence) was cloned into 
a pMSCV retroviral expression system containing GFP.13 Murine BM cells were harvested 
from femurs and tibiae of 8- to 12-week-old C57BL/6 mice, enriched for lineage negative 
stem and progenitor cells (HSPCs), retrovirally transduced, selected for GFP expression and 
cultured as previously described.11,14
Real-time quantitative RT-PCR
Total RNA isolation and real-time quantitative RT-PCR were performed as previously 
described.11 MiR-9/9* expression in HSPCs was determined using sno202 as a loading 
control with a minimal threshold for Ct values above 35 set to a -dCt value of -13 when a 
miRNA is not expressed. 
Hematopoietic stem and progenitor cells that express miR-9/9* have a decreased potential to home to the 
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Flow cytometry
Hematopoietic progenitor population Lin-c-Kit+Sca-1- (LK) and hematopoietic stem/
progenitor population Lin-Sca-1+c-Kit+ (LSK) were identified by staining with Biotin Mouse 
Lineage Panel, streptavidin-APC-Cy7, c-Kit-APC (BD Biosciences, Breda, the Netherlands) 
and Sca-1-PE-Cy5 (eBioscience, Vienna, Austria). Hematopoietic stem cells (HSC) Lin-Sca-
1+c-Kit+CD150+CD48- and multipotent progenitor cells (MPP) Lin-Sca-1+c-Kit+CD150-CD48- 
were identified by staining with CD150-PerCP/Cy5.5 and CD48-PB (Biolegend, London, 
United Kingdom). For apoptosis analysis, cells were stained with Annexin V:PE Apoptosis 
Detection Kit I (BD Biosciences). Data were collected and analyzed as previously described.11 
All experiments were performed in three independent biological replicates.
Bone marrow transplantation experiments
In homing experiments, recipient mice were lethally irradiated (8.5 Gy) and tail-vein injected 
with 1.5×105 miR-9/9* (n = 8) or EV (n = 8) transduced GFP+ HSPCs. Cells overexpressing 
miR-9/9* and EV controls were transplanted at the same time point. BM was analyzed 20 
hours after transplantation. The percent of transplanted GFP+ cells that had homed to BM 
was calculated as previously described:2 % homing = [(A×B×C)/D]×100%, where A equals the 
percent of GFP+ cells and B equals the percent of living cells determined by flow cytometry, 
C equals the total organ cellularity, and D equals the number of cells transplanted. 
The absolute number of GFP+ cells was calculated from the formula: no. of GFP+ cells = 
(A×B×C)/100. The results were multiplied by 4 since cells from both femurs and tibiae are 
assumed to represent 25% of the entire BM.2 All animal experiments were approved by the 
Animal Welfare/Ethics Committee of the Erasmus University Medical Center. 
Colony-forming unit (CFU) cell assays
4×103 HSPCs were plated in triplicate in methocult (M3231; StemCell Technologies, Grenoble, 
France) supplemented with IL-3 (supernatant 1/1000), IL-6 (10 ng/mL) and SCF (10 ng/
mL).13 After 7 days 5×104 cells were replated under the same conditions. All experiments 
were performed in three independent biological replicates.
RESULTS
MiR-9/9* overexpressing HSPCs home less efficiently to the BM 
To investigate the influence of miR-9/9* expression on the function of hematopoietic cells in 
vivo, we transduced normal HSPCs with retroviral construct containing GFP and miR-9/9* or 
GFP only. Subsequently, cells were FACS sorted and ectopic expression of these miRNAs was 
confirmed by real-time quantitative RT-PCR (dCt: miR-9/miR-9* = (-3.0 ± 0.5)/(-6.7 ± 0.9); see 
Materials and Methods). The frequencies of successfully transduced LK and LSK populations 
were the same for miR-9/9* (n = 3; LK: 81.4 ± 2.0%; LSK: 7.1 ± 2.6%) and EV (n = 3; LK: 82.7 
± 3.5%; LSK: 6.8 ± 2.0%; Figure 1a-b), and further flow cytometric analysis indicated similar 
distribution of HSCs and MPPs (Figure 1a). Cells overexpressing miR-9/9* (n = 8) and EV 
controls (n = 8) were transplanted into lethally irradiated C57BL/6 recipient mice and the 
homing of GFP+ cells was assessed at 20 hours post-transplantation. We observed that miR-
9/9* HSPCs were able to home to the BM (Figure 2a-c). However, the percent of homing 
(0.9 ± 0.4%) and the absolute number of GFP+ cells (1246 ± 526) in miR-9/9* transplanted 
animals were significantly lower than those in EV controls (% homing: 2.9 ± 0.5%; no. of GFP+ 
cells: 4438 ± 482; Figure 2b-c).
MiR-9/9* overexpressing HSPCs have normal level of apoptosis and colony-forming 
capacity
In order to gain more insight into decreased ability of miR-9/9* overexpressing HSPCs to 
home to the BM, we assessed early apoptosis in vitro. HSPCs transduced with miR-9/9* 
or EV were FACS sorted and the level of apoptosis was evaluated at 0 and 24 hours after 
transduction. We observed no differences in frequencies of Annexin V+ populations between 
miR-9/9* HSPCs (n = 3; 0 hours: 30.2 ± 3.5%; 24 hours: 25.0 ± 5.0%) and EV control cells (n 
= 3; 0 hours: 31.8 ± 5.0%; 24 hours: 26.4 ± 7.3%; Figure 3a-b). Next, we performed CFU 
assays to explore the effect of aberrant expression of miR-9/9* on colony-forming capacity 
of normal HSPCs. Cells overexpressing miR-9/9* and EV controls were plated in triplicate in 
methocult containing IL-3, IL-6 and SCF. After 7 days, there were no differences in colony 
numbers and size between miR-9/9* and EV transduced cells (n = 3; colony numbers per 
1000 cells plated: miR-9/9* – 50.6 ± 7.8, EV – 63.9 ± 10.3; Figure 3c-d). Additionally, both 
formed no colonies after replating (Figure 3c). Stable overexpression of miR-9/9* in time 
was confirmed by real-time quantitative RT-PCR (Figure 3e).
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DISCUSSION
In a previous study, we reported that miR-9/9* are aberrantly upregulated in human AML and 
that ectopic expression of miR-9/9* in normal murine HSPCs inhibits myeloid differentiation 
in vitro.11 In addition, we observed that miR-9/9* induce changes in expression of proteins 
involved in cellular movement and adhesion in myeloid 32D cell line model (unpublished 
data, Chapter 3 of this thesis). This provides the rationale for further investigation of the 
effect of miR-9/9* overexpression on the function of normal HSPCs in vivo.
The ability of hematopoietic cells to contribute to normal hematopoiesis relate to 
their potential to interact with the BM compartment. Here, we report that HSPCs that 
overexpressed miR-9/9* seed in the BM three times less efficiently than EV control cells. This 
reduction in the ability of the hematopoietic cells to home may be potentially explained by the 
increased apoptosis and/or decreased proliferation. However, we observed no differences 
in apoptosis and colony-forming potential between miR-9/9* and EV transduced cells. This 
indicates that the decreased homing ability may be a result of aberrant cell migration and 
adhesion. Overexpression of miR-9/9* in 32D cells results in proteome changes related 
to reduced cellular movement and adhesion (unpublished data, Chapter 3 of this thesis). 
Furthermore, miR-9 has been previously reported to influence cell migration and adhesion in 
different types of tumors, e.g. in hepatocellular carcinoma9 and osteosarcoma.10 Additional 
experiments are needed to evaluate whether the identified proteome changes contribute 
to decreased migration, adhesion and in vivo homing of primary murine HSPCS and whether 
they would affect the ability of normal cells to reconstitute hematopoiesis in vivo.
In conclusion, these preliminary data suggest that expression of miR-9/9* impairs 
different aspects of normal hematopoietic cell function.
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Figure 1. Flow cytometric analysis of cell populations in bone marrow transplantation assay. (a) Representative plots 
of flow cytometric analysis of HSPCs that were transduced with EV or miR-9/9*. Arrows below the graphs show the 
direction of gating. (b) Summary of frequencies of LK and LSK populations in HSPCs that were transduced with EV 
or miR-9/9*. All experiments were performed in three independent biological replicates. Unpaired two-tailed t-test 
was used for statistical analysis.
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Figure 3. MiR-9/9* overexpressing HSPCs have normal level of apoptosis and colony-forming capacity. (a) Gating 
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after transduction. (b) A summary of Annexin V+ populations in all replicates at 0 and 24 hours after transduction 
with EV or miR-9/9* expression construct. (c) Representative micrographs of colonies at day 7 of CFU assay. (d) 
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miR-9/9* measured by real-time quantitative RT-PCR in HSPCs that were transduced EV or with vector containing 
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ABSTRACT
In double-stranded miRNA/miRNA* duplexes, one of the strands represents an active 
miRNA whereas another, known as a passenger strand (miRNA*), is typically degraded. MiR-
9* is not detectable in normal myeloid cells. Here, we show that miR-9* is expressed in 59% 
of acute myeloid leukemia (AML) cases, and we investigate its clinical impact in 567 adults 
with de novo AML (age ≤ 60 years). AML cases with detectable miR-9* included a lower 
percentage of cases with favorable risk (P < 0.001) as compared to those with no detectable 
miR-9*. High levels of miR-9* expression independently predicted for higher CR (OR = 1.28, 
P = 0.013), and better EFS (HR = 0.86, P = 0.001), RFS (HR = 0.84, P = 0.008) and OS (HR = 
0.86, P = 0.002). Among the subgroup of adverse risk patients, high miR-9* expressers had 
strikingly longer median survival than low miR-9* expressers (EFS: 16 vs. 5 months, P = 
0.020; RFS: 12 vs. 4, P = 0.060; OS: 23 vs. 8, P = 0.021). Comparative transcriptome analysis 
suggests that miR-9* regulates genes involved in leukemogenesis, e.g., MN1 and MLLT3. 
This is the first report showing that a miRNA* has prognostic value in AML.
INTRODUCTION
MiRNAs are short non-coding RNAs that specifically bind to their target mRNAs and 
decrease protein levels by destabilization of transcripts or inhibition of translation.1 In this 
way they regulate crucial cellular mechanisms, such as cell differentiation and survival.2-4 
MiRNAs are expressed as primary miRNAs (pri-miRNAs) that undergo stepwise maturation.1 
Those transcripts are processed in the nucleus and in the cytoplasm, what results in the 
formation of double-stranded miRNA/miRNA* duplexes. At steady state, the two strands are 
asymmetrically expressed.5-6 One of them, referred as miRNA, is loaded into RNA-induced 
silencing complex (RISC), whereas another, known as the passenger miRNA (miRNA*), is 
typically degraded. Nevertheless, miRNA* can be stabilized and become functional.6 There 
is still relatively little known about the functions of miRNA*s in hematopoiesis but they have 
been proposed to have complementary roles to their related miRNAs.6-7
In recent years, the role of miRNAs in acute myeloid leukemia (AML) has been 
extensively investigated. Several miRNA-expression profiling studies have revealed that 
miRNA expression patterns can discriminate between different cytogenetic subtypes.8-10 
Particular miRNAs have been shown to be associated with clinical outcome. For example, 
high expression of miR-181a and low expression of miR-155 correlate with improved survival 
in cytogenetically normal AML.11-12 Recently, we have reported about miR-212,13 which was 
associated with better outcome independently of cytogenetic subtype. The prognostic 
relevance of miRNA*s expression in AML remains unexplored.
The three genes of MIR9-1, MIR9-2 and MIR9-3 are located at chromosomes 1, 5, and 
15, respectively. They encode a highly conserved miRNA-9-5p (miR-9) and its passenger 
strand, miRNA-9-3p (miR-9*).14 In normal myeloid cells, miRNA-9 is expressed at low levels, 
whereas miR-9* is not detectable.15-16 Recently, we have reported that miR-9 and miR-9* 
are both aberrantly upregulated in AML.16 Additionally, miR-9 has been shown to contribute 
to the development of MLL-rearranged leukemia17 while the function of miR-9* remains 
unknown. Here, we report on the clinical significance of the expression of miR-9 and its 
passenger strand, miR-9*, in a large series of newly diagnosed well characterized patients 
with AML.
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MATERIALS AND METHODS
Patient, treatment, and cytogenetic analysis
All 567 patients (age ≤ 60 years) included in this study had newly diagnosed AML according 
to the 2001 WHO classification and provided written informed consent in accordance with 
the Declaration of Helsinki. Patient recruitment was performed according to protocols 
from the Dutch-Belgian-Hematology-Oncology-Cooperative group (HOVON trials 4/4A,18 
29,19 42/42A20; www.hovon.nl) and the German-Austrian AML Study Group (AMLSG trial 
HD98A).21 All trials had been approved by the Institutional Review Board of the Erasmus 
University Medical Center and the University of Ulm. Sample processing and mutational 
analysis has been previously described.13
Real-time quantitative RT-PCR
Total RNA isolation and real-time quantitative RT-PCR were performed as previously 
described.8,22 Briefly, miR-9 and miR-9* expression was determined in a singleplex manner 
using real-time quantitative RT-PCR assays for miRNAs (Applied Biosystems, Nieuwekerk a/d 
IJssel, the Netherlands). Data was normalized using RNU24 with a minimal threshold for Ct 
values above 35 set to a -dCt value of -15. MiR-9 and miR-9* expression was determined 
centrally at one location. The relative quantification method 2−(dCt) was used to calculate 
the relative expression.23 The expression data was log transformed to obtain symmetrical 
distribution.
Gene expression profiling
Gene expression profiles (GEP) of 242 AML cases were derived from Human Genome U133 
plus 2.0 arrays as previously described.24 Raw microarray data were processed using MAS5 
to target intensity of 100. Intensity values lower than 30 were set to 30 and subsequently 
log2 transformed. GEP data are available at www.ncbi.nlm.nih.gov/geo (GSE6891). To 
identify differentially expressed genes, two-sided t-test analysis was performed controlling 
for the false discovery rate (FDR) by Benjamini-Hochberg procedure (FDR < 0.05). The 
analysis was done using GenePattern platform www.broadinstitute.org/cancer/software/
genepattern/).25 Ingenuity systems was used to determine overrepresented pathways and 
functions www.ingenuity.com/). Potential miRNA targets were selected using TargetScan 
5.2 www.targetscan.org/) web resource.
Definition of clinical endpoints and statistical analysis
Complete remission (CR), event-free survival (EFS), relapse-free survival (RFS), and overall 
survival (OS) were defined according to the recommendations of European LeukemiaNet 
(ELN) guidelines.26 Genetic risk groups were distinguished according to the ELN criteria with 
one minor modification concerning CEBPA mutations, i.e., only cases with biallelic mutations 
in CEBPA (instead of any CEBPA gene mutation) were considered favorable. Favorable risk 
group includes inv(16)(p13.1q22), t(16;16)(p13.1;q22), t(8;21)(q22;q22), cytogenetically 
normal karyotype (NK)-AML with mutation in NPM1 without FLT3-ITD mutation, and NK-
AML with biallelic mutations in CEBPA. Intermediate-I group contains the remainder of 
the NK-AML. Intermediate-II consists of t(9;11)(p22;q23) and various other cytogenetic 
abnormalities not classified as favorable or adverse. Inv(3)(q21q26.2) or t(3;3)(q21;q26.2), 
t(v;11q23), t(6;9)(p23;q34), -5 or 5q-, -7, abn(17p), and complex karyotype are designated 
as adverse risk. Only young adults (age ≤ 60) with primary AML and without t(15;17) were 
included into the analysis.
In univariable and multivariable analysis, logarithm of miRNA expression was used 
as a continuous linear variable. Cox proportional hazards model was used to evaluate 
the association of miRNA expression with EFS, RFS, and OS. The association with CR was 
tested using logistic regression. Known prognostic factors and non-correlated variables, 
that were significant in univariable analysis at P ≤ 0.20, were included into multivariable 
model. Age and logarithm of white blood cell count (WBC) were used as continuous linear 
variables, whereas ELN prognostic risk and treatment protocol as categorical variables. The 
proportional-hazards assumption was tested using scaled Schoenfeld residuals. Linearity 
of miRNA expression function and an optimal cutoff were assessed using martingale 
residuals.27-28 The optimal cutoff was close to commonly used cutoff of 75% expression 
value, therefore patients were dichotomized at the 75th percentile of miRNA expression. 
Kaplan-Meier plots were used to illustrate the predictive value of miRNA, and log-rank test 
was used to test for differences in survival distributions. 
Mann-Whitney test was used to determine the association between two continuous 
variables. Fisher’s exact and chi-square tests were used for categorical variables. All statistical 
tests were two-sided. The analysis was done using Stata/Se v11.1 (College Station, TX, USA).
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RESULTS
MiR-9* is differentially expressed in AML subsets
We assessed miR-9 and miR-9* expression in AML. Measurable levels of miR-9 are present 
in 89% of AML cases (median -dCt: -7.9, standard deviation: 3.7; within the expressers 
median -dCt: -7.5, standard deviation: 3.0), whereas miR-9* is measurably expressed in 
59% (median -dCt: -11.5, standard deviation: 3.3; within the expressers median -dCt: -9.7, 
standard deviation: 2.3) (Figure 1a; Supplementary Figure 1a-b; Supplementary Table 1). 
Furthermore, miR-9* expression appears highly correlated with that of miR-9 (Pearson 
r = 0.779, P < 0.001; Supplementary Figure 1c). According their clinical and molecular 
characteristics, AML cases with measurable levels of miR-9* (miR9*-positive; n = 336) are 
different than those with no expression (miR-9*-negative; n = 231) (Table 1). MiR9*-positive 
included a smaller number of cases with favorable risk (27% vs. 44%, P < 0.001), but more 
intermediate-I risk cases of AML (40% vs. 21%, P < 0.001), as compared to miR-9*-negative. 
There were no differences in distribution of miR-9*-negative and miR-9*-positive among 
intermediate-II and adverse risk groups. Furthermore, miR-9*-negative AMLs included 92% 
(33/36) of all t(8;21) cases, and 90% (28/31) of all cases with biallelic mutations in CEBPA. On 
the other hand, miR-9*-positive subset included almost all AMLs with t(9;11) (92%, 11/12), 
and AMLs with mutation in the gene NPM1 (82%, 128/156). The underlying differences 
in patient composition make it difficult to directly compare miR-9*-positive and miR-9*-
negative cases with respect to patient outcome. MiR-9*-positive subgroup included mostly 
unfavorable risk AMLs. However, the comparative analysis revealed that miR-9*-positive 
cases had similar OS as miR-9*-negative (Supplementary Figure 2a). This suggested that 
miR-9* expression may have a positive impact on patient outcome. 
MiR-9* is independently associated with better outcome in AML 
To investigate the clinical impact of miR-9 and miR-9* expression in AML, we performed 
a univariable analysis in the patient cohorts that express those miRNAs. MiR-9 expression 
had no prognostic value, whereas miR-9* was significantly associated with improved EFS 
(hazard ratio (HR) = 0.889, 95% confidence interval (CI) = 0.815-0.969, P = 0.007), and OS (HR 
= 0.868, 95% CI = 0.791-0.951, P = 0.002) (Supplementary Table 2). Additionally, patients 
with AML expressing measurable miR-9* had a trend for a better CR rate (odds ratio (OR) 
= 1.159, 95% CI = 0.976-1.376, P = 0.092), and prolonged RFS (HR = 0.906, 95% CI = 0.806-
1.018, P = 0.096). To illustrate the predictive value of miR-9*, Kaplan-Meier curves and log-
rank test were used to test for differences in survival distributions. First, AML cases were 
split into quartiles based on miR-9* expression. Patient outcome improved with increasing 
levels of miR-9* (Supplementary Figure 2b-d). In order to define clinically relevant cutoff of 
miR-9* expression to characterize subgroup of patients with improved survival, we searched 
for the optimal cutoff using martingale residuals method. This analysis revealed that the 
optimal cutoff was close to the 75% expression value (data not shown). Therefore, AML 
patients were split into the low (n = 252) or high (n = 84) miR-9* group based on the 75th 
percentile (Supplementary Table 3). High miR-9* expressers had significantly better EFS 
(median survival: 18 vs. 9 months, P = 0.038; Figure 1b), OS (62 vs. 17 months, P = 0.020; 
Supplementary Figure 3a), and RFS (12 vs. 8 months, P = 0.043; Supplementary Figure 
4a) than low miR-9* expressers. Detailed analysis among the distinct ELN prognostic risk 
groups showed that patients with high miR-9* have overall better outcomes (Figure 2a-d; 
Supplementary Figure 3b-e, and Supplementary Figure 4b-e). Patients in favorable risk 
group had improved EFS (P = 0.024; Figure 2a) and OS (P = 0.038; Supplementary Figure 3b). 
Patients in the intermediate-II risk category had better EFS (P = 0.050; Figure 2c) and RFS (P 
= 0.010; Supplementary Figure 4d). Among adverse risk patients, we observed improved 
outcomes for each of the survival end points; with median survival of 16 vs. 5 months for 
EFS (P = 0.020; Figure 2d), 23 vs. 8 months for OS (P = 0.021; Supplementary Figure 3e), 
and 12 vs. 4 months for RFS (P = 0.060; Supplementary Figure 4e). There were no notable 
differences in prognosis among intermediate-I risk group. Clinical and genetic characteristics 
of high and low miR-9* expressers were the same (Supplementary Table 2), with exception 
concerning cases with t(9;11) of which the majority (91%, 10/11, P < 0.001) belonged to the 
high miR-9* group.
To account for established prognostic factors and theoretical differences in treatment 
protocols, we performed multivariable analysis using Cox proportional hazards model for 
survival outcomes and logistic regression for achieving complete remission. MiR-9*, age, 
WBC, ELN prognostic risk, and treatment protocol were included into the model. The overall 
test of proportional-hazards assumption was not significant (data not shown). MiR-9* was 
independently predictive for better CR rate (OR = 1.284, 95% CI = 1.054-1.563, P = 0.013), 
as well as better EFS (HR = 0.861, 95% CI = 0.786-0.944, P = 0.001), better RFS (HR = 0.843, 
95% CI = 0.744-0.956, P = 0.008) and better OS (HR = 0.855, 95% CI = 0.775-0.943, P = 0.002) 
(Table 2).
Biological insights of miR-9* expression in AML
To further characterize miR-9*-positive AML, we performed transcriptome analysis of 
miR-9*-positive and miR-9*-negative cases. Gene expression profiles revealed 548 probe 
sets, corresponding to 454 genes, to be differentially expressed (Supplementary Table 4). 
Ingenuity pathway analysis subsequently showed that these genes could be related to the 
categories of diseases or functions, such as cancer (P = 9.4×10-3 – 1.6×10-9), cell death and 
survival (P = 9.2×10-3 – 1.9×10-7), hematological system development and function (P = 
8.7×10-3 – 2.7×10-7) (Table 3). Among differentially expressed genes, there were 12 predicted 
downregulated miR-9* targets that included genes known to be involved in leukemogenesis, 
such as MN12932 and MLLT3 (AF9).17,33-34
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DISCUSSION
MiRNAs are short non-coding RNAs that are processed into double-stranded duplexes 
containing a guide miRNA and its passenger strand, miRNA*.1 MiRNAs are functionally 
implicated into leukemogenesis,24 and some of these have prognostic value.11-13 MiRNA*s 
are typically degraded and there is not much known about their roles in hematopoiesis.5-7 
MiR-9* is not detectable in normal myeloid cells.15-16 Here, for the first time, we report that 
the passenger miRNA, miR-9*, is expressed in AML (59% of cases) and has a positive impact 
on patient outcome.
The patient characteristics of miR-9*-positive and miR-9*-negative AML were 
significantly different. MiR-9*-positive included a lower percentage of favorable and a 
higher percentage of intermediate-I risk patients than miR-9*-negative. Percentages 
of intermediate-II and adverse risk groups were the same. The mechanisms of miRNA*s 
retained expression are largely unknown. Recently, it has been reported that various post-
transcriptional mechanisms, such as RNA methylation, differential expression of RISC 
components, and expression of mRNA targets, may selectively prevent miRNA strand 
degradation.35-37 It remains speculative whether or how various genetic abnormalities might 
contribute to differential miRNAs processing and lead to sustained miR-9* expression in 
particular subgroups of AML. Further studies of mechanisms of differential processing of 
miR9/miR9* duplex leading to miR-9* accumulation in AML may contribute to understanding 
of its preferential expression in unfavorable risk leukemias. 
MiR-9 has been proposed to be part of 3-microRNA scoring system for prognostication 
in de novo AML as an independent marker of poor OS.38 In our study, miR-9 was not 
significantly associated with any of the clinical response/survival endpoints. The reasons 
for discrepancy between our results and those previously reported are not evident but may 
be due to the significant differences in patient cohorts. Chuang et al. included in their study 
a substantial amount of elderly patients (41% of age > 60), as well as patients with acute 
promyelocytic leukemia (APL).38 Older patients have a distinctly different prognosis and often 
do not receive or tolerate intensive treatment strategies. The current investigation focuses 
on young adults (age ≤ 60) with AML excluding APL, as patient outcome varies substantially 
as a function of age, and there are major differences in the treatment protocols between 
APL39 and AML cases.26 In contrast to miR-9, we found that its passenger strand, miR-9*, has a 
positive impact on patient outcome. High miR-9* expression was independently associated 
with increased CR rate and longer EFS, RFS, and OS. The increased CR rate and improved EFS 
may suggest that high miR-9* patients may be more sensitive to induction therapy. Indeed, 
there have been reports about the relationship of other miRNA*s and  chemosensitivity in 
cancer, i.e., miR-21-3p40 and miR-126-5p.41 
We observed that patients with high miR-9* had overall better outcomes in a 
heterogeneous cohort of AML. Subsequent analysis of different ELN prognostic risk groups 
revealed that in favorable and intermediate-II groups, patients with high miR-9* expression 
had generally better survival than low miR-9* expressers. We did not note any differences in 
outcome among the intermediate-I risk cases and for the time being the lack of prognostic 
value in the latter remains unexplained. In this study, the influence of miR-9* expression 
did not prevail over other potential prognostic factors. Interestingly, we observed large 
differences in survival outcomes between cases that expressed high and low miR-9* levels in 
adverse risk group of AML. Our results, for the first time, show that a single miRNA can have 
a clinical impact in adverse risk leukemias. In order to externally validate our findings, we 
have explored The Cancer Genome Atlas (TCGA) database that contains miRNA expression 
data of a different panel of AML patients. In 97 AML cases that matched our criteria (age ≤ 
60 years, excluding APL), miR-9* was detected with the low number of 2 reads per million 
miRNA mapped on average. This discrepancy between our database and TCGA may largely 
be explained by the fact that miRNA sequencing is less sensitive in detecting low abundant 
transcripts than quantitative PCR if the depth of sequencing is not sufficient, as previously 
reported by Mestdagh et al.42
To gain more insight into the biological contribution of miR-9* expression on patient 
outcome and response to treatment, we compared transcriptomes of miR-9*-positive and 
miR-9*-negative cases. We found 12 downregulated predicted targets of miR-9* that were 
differentially expressed. These included genes known to be involved in leukemogenesis, 
such as MN12932 and MLLT3 (AF9).17,33-34 The relation of these findings with prognosis remains 
unsettled.
In conclusion, here we report that passenger miRNA, miR-9*, is expressed in 59% of 
AML cases,  and has an independent positive prognostic value. Furthermore, this is the first 
report showing that a single miRNA has an impact on patient outcome in adverse risk group. 
Transcriptome analysis revealed that miR-9* may regulate genes involved in leukemogenesis. 
Our findings provide a rational for further studies of miRNA*s in AML.
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Table 1. Clinical and genetic characteristics of AML cohort by  miR-9* expression status
Whole cohort miR-9*-negative miR-9*-positive
No. of cases % No. of cases % No. of cases % P
Clinical parameters
Age (mean) 43.9 42.9 44.6
Range (min-max) 15.0-60.0 15.0-60.0 17.0-60.0
WBC, x 109/L (mean) 48.1 45.3 50.0
Range (min-max) 0.8-427.0 0.9-427.0 0.8-371.0
Sex
    Total 567 100 231 100 336 100
Male 292 52 125 54 167 50
Female 275 49 106 46 169 50
ELN prognostic risk† <0.001
Favorable 193 34 101 44 92 27 <0.001
Intermediate-I 181 32 48 21 133 40 <0.001
Intermediate-II 99 18 45 20 54 16
Adverse 94 17 37 16 57 17
Cytogenetics
+8 21 4 7 3 14 4
-5 or -5q 3 0.5 1 0.4 2 0.6
-7 or -7q 16 3 10 4 6 2
-9q 12 2 8 4 4 1
11q23‡ 14 3 3 1 11 3
t(9;11) 12 2 1 0.4 11 3 0.033
t(8;21) 36 6 33 14 3 1 <0.001
inv(3) or t(3;3) 4 1 1 0.4 3 1
inv(16) 43 8 22 10 21 6
NK 287 51 90 39 197 59 <0.001
Complex karyotype 57 10 25 11 32 10
Other 62 11 30 13 32 10
Molecular genetics in NK
CEBPA double 31 6 28 12 3 1 <0.001
FLT3-ITD 110 19 24 10 86 26 <0.001
FLT3-TKD 16 3 1 0.4 15 5 0.004
NPM1 156 28 28 12 128 38 <0.001
Whole cohort miR-9*-negative miR-9*-positive
No. of cases % No. of cases % No. of cases % P
Treatment protocol <0.001
HOVON04 9 2 2 1 7 2
HOVON04A 14 3 8 4 6 2
HOVON29 61 11 25 11 36 11
HOVON42 83 15 19 8 64 19 <0.001
HOVON42A 180 32 98 42 82 24 <0.001
HD98A 220 39 79 34 141 42
Mann-Whitney test was used for continuous variables. Fisher’s exact and chi-square tests were used for categorical 
variables.
†Only patients with biallelic mutations in CEBPA were included in favorable risk group (instead of any CEBPA gene 
mutation).
‡11q23 category contains MLL-related leukemias harboring 11q23 abnormalities other than t(9;11).
NOTE. Percentages may add up >100% because of rounding.
Abbreviations: AML, acute myeloid leukemia; WBC, white blood cell count; ELN, European LeukemiaNet; NK, 
normal karyotype; CEBPA, CCAAT/enhancer-binding protein α; FLT3-ITD, internal tandem duplications in the FMS-
like tyrosine kinase 3; FLT3-TKD, FMS-like tyrosine kinase 3 with mutations in tyrosine kinase domain; NPM1, 
nucleophosmin.
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Figure 1. MiR-9* is expressed in 59% of AML cases, and it is associated with better outcome. (a) Percentage of AML 
cases that express miR-9, and miR-9*. (b) Event-free survival (EFS) of AML patients according to miR-9* expression. 
Patients were dichotomized into high and low expression groups based on the 75th percentile of miR-9* expression 
value (see Materials and Methods).
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Figure 2. Patients with high miR-9* have overall better outcomes in different ELN prognostic risk groups. Event-free 
survival (EFS) of AML patients belonging to (a) favorable, (b) intermediate-I, (c) intermediate-II, and (d) adverse risk 
group according to miR-9* expression. Patients were dichotomized into high and low expression groups based on the 
75th percentile of miR-9* expression value (see Materials and Methods).
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SUPPLEMENTARY DATA 
Table S1. MiR-9 and miR-9* expression in patients with AML. Raw Ct data and normalized expression values (see 
Materials and Methods) from real-time quantitative RT-PCR.
Assay name hsa-miR-9 hsa-miR-9*
miRBase ID hsa-miR-9-5p hsa-miR-9-3p
Target Sequence UCUUUGGUUAUCUAGCUGUAUGA AUAAAGCUAGAUAACCGAAAGU
Sample Raw Ct Log(2^(-dCt)) Raw Ct Log(2^(-dCt))
AML 1 27.06 -2.51 30.40 -4.82
AML 2 35.00 -11.44 35.00 -11.44
AML 3 28.90 -3.63 32.05 -5.82
AML 4 27.78 -2.84 30.71 -4.87
AML 5 34.06 -7.72 35.00 -11.44
AML 6 31.91 -6.17 34.46 -7.93
AML 7 30.29 -5.48 33.25 -7.53
AML 8 31.09 -6.03 34.45 -8.36
AML 9 30.62 -1.94 32.80 -3.45
AML 10 33.57 -7.51 35.00 -11.44
AML 11 32.78 -7.15 35.00 -11.44
AML 12 35.00 -11.44 34.71 -6.64
AML 13 35.00 -11.44 35.00 -11.44
AML 14 33.64 -5.38 34.32 -5.84
AML 15 34.50 -4.41 34.29 -4.26
AML 16 30.92 -5.01 33.20 -6.58
AML 17 35.00 -11.44 35.00 -11.44
AML 18 29.13 -3.47 31.42 -5.06
AML 19 27.35 -2.75 31.16 -5.39
AML 20 29.76 -4.04 32.52 -5.96
AML 21 26.80 -1.66 28.45 -2.80
AML 24 34.00 -4.88 35.00 -11.44
AML 25 33.91 -7.22 34.35 -7.53
AML 26 35.00 -11.44 35.00 -11.44
AML 27 29.62 -5.05 32.80 -7.25
AML 28 34.50 -7.92 35.00 -11.44
AML 29 29.62 -4.51 33.05 -6.89
AML 30 35.00 -11.44 35.00 -11.44
AML 32 28.52 -3.59 31.75 -5.83
AML 33 31.57 -4.80 34.90 -7.11
AML 34 28.93 -4.51 31.67 -6.41
AML 35 30.34 -5.48 33.61 -7.75
AML 36 30.52 -2.38 33.31 -4.32
AML 37 28.72 -3.68 31.64 -5.70
AML 38 23.24 -0.13 26.82 -2.61
AML 40 32.71 -7.17 34.23 -8.23
AML 42 27.59 -3.42 30.75 -5.61
AML 43 31.59 -6.11 34.38 -8.04
Assay name hsa-miR-9 hsa-miR-9*
miRBase ID hsa-miR-9-5p hsa-miR-9-3p
Target Sequence UCUUUGGUUAUCUAGCUGUAUGA AUAAAGCUAGAUAACCGAAAGU
Sample Raw Ct Log(2^(-dCt)) Raw Ct Log(2^(-dCt))
AML 44 28.80 -3.76 31.28 -5.48
AML 45 30.34 -4.92 33.58 -7.17
AML 46 33.15 -6.86 35.00 -11.44
AML 47 29.69 -4.21 33.14 -6.60
AML 48 32.23 -6.32 34.88 -8.16
AML 49 35.00 -11.44 35.00 -11.44
AML 50 34.63 -5.96 35.00 -11.44
AML 51 30.87 -5.61 33.42 -7.37
AML 52 30.67 -4.40 34.38 -6.97
AML 53 33.38 -7.26 35.00 -11.44
AML 54 35.00 -11.44 35.00 -11.44
AML 55 23.64 -0.22 27.07 -2.60
AML 56 30.45 -4.57 32.88 -6.26
AML 57 29.62 -4.51 33.05 -6.89
AML 58 33.51 -7.17 34.79 -8.06
AML 59 29.18 -4.02 32.43 -6.28
AML 60 26.46 -1.16 29.65 -3.38
AML 61 29.72 0.08 32.73 -2.00
AML 62 35.00 -11.44 35.00 -11.44
AML 63 33.69 -6.81 35.00 -11.44
AML 64 32.28 -4.48 35.00 -11.44
AML 65 31.67 -5.53 33.47 -6.78
AML 66 35.00 -11.44 35.00 -11.44
AML 67 30.26 -4.45 32.99 -6.34
AML 68 25.99 -1.66 29.00 -3.75
AML 69 26.55 -2.40 30.43 -5.09
AML 70 27.43 -3.61 30.37 -5.65
AML 72 25.09 -1.43 28.64 -3.89
AML 73 25.32 -1.55 28.58 -3.81
AML 74 29.98 -4.61 32.54 -6.38
AML 75 31.11 -5.42 34.68 -7.89
AML 76 23.47 -0.34 27.16 -2.90
AML 77 29.33 -4.40 31.92 -6.20
AML 78 26.82 -2.85 29.90 -4.99
AML 79 32.69 -6.58 35.00 -11.44
AML 80 27.64 -3.33 31.20 -5.80
AML 81 29.39 -4.07 32.72 -6.37
AML 82 26.91 -3.15 30.25 -5.46
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Assay name hsa-miR-9 hsa-miR-9*
miRBase ID hsa-miR-9-5p hsa-miR-9-3p
Target Sequence UCUUUGGUUAUCUAGCUGUAUGA AUAAAGCUAGAUAACCGAAAGU
Sample Raw Ct Log(2^(-dCt)) Raw Ct Log(2^(-dCt))
AML 83 30.86 -5.74 33.22 -7.38
AML 84 25.37 -1.68 28.81 -4.06
AML 85 32.40 -7.06 34.42 -8.46
AML 86 29.15 -4.09 31.74 -5.89
AML 87 30.51 -5.14 33.49 -7.20
AML 88 30.27 -5.37 32.91 -7.20
AML 89 26.24 -1.80 29.47 -4.04
AML 90 30.56 -5.11 33.29 -7.01
AML 91 31.07 -6.18 32.63 -7.26
AML 92 27.17 -2.51 29.85 -4.37
AML 93 34.20 -8.62 35.00 -11.44
AML 94 27.30 -3.41 31.67 -6.43
AML 95 28.07 -3.49 31.71 -6.01
AML 96 28.83 -3.61 32.52 -6.17
AML 97 33.23 -6.69 35.00 -11.44
AML 98 35.00 -11.44 35.00 -11.44
AML 99 22.64 0.06 26.09 -2.34
AML 100 33.62 -6.98 35.00 -11.44
AML 101 33.37 -7.41 35.00 -11.44
AML 102 23.29 2.57 26.80 0.14
AML 103 31.26 -5.72 33.42 -7.22
AML 104 33.45 -6.95 34.57 -7.73
AML 105 35.00 -11.44 35.00 -11.44
AML 106 28.91 -4.19 32.40 -6.61
AML 107 34.03 -7.30 35.00 -11.44
AML 108 30.90 -5.01 33.52 -6.83
AML 109 31.62 -6.16 35.00 -11.44
AML 110 28.65 -3.75 31.56 -5.77
AML 111 26.31 -2.30 29.86 -4.75
AML 112 26.88 -2.85 30.52 -5.37
AML 113 29.77 -4.36 32.62 -6.34
AML 114 26.98 -2.40 30.41 -4.78
AML 115 33.91 -7.59 35.00 -11.44
AML 116 32.33 -6.12 34.20 -7.42
AML 117 26.21 -1.77 29.51 -4.06
AML 118 30.14 -4.14 35.00 -11.44
AML 119 34.22 -7.14 35.00 -11.44
AML 120 35.00 -11.44 35.00 -11.44
AML 121 32.17 -5.61 35.00 -11.44
AML 122 35.00 -11.44 35.00 -11.44
AML 123 32.39 -6.56 35.00 -11.44
AML 124 34.59 -7.66 35.00 -11.44
AML 125 30.95 -5.91 34.35 -8.28
Assay name hsa-miR-9 hsa-miR-9*
miRBase ID hsa-miR-9-5p hsa-miR-9-3p
Target Sequence UCUUUGGUUAUCUAGCUGUAUGA AUAAAGCUAGAUAACCGAAAGU
Sample Raw Ct Log(2^(-dCt)) Raw Ct Log(2^(-dCt))
AML 126 34.43 -7.95 35.00 -11.44
AML 128 34.39 -7.87 35.00 -11.44
AML 129 34.86 -7.54 35.00 -11.44
AML 130 35.00 -11.44 35.00 -11.44
AML 131 30.49 -5.43 33.23 -7.33
AML 132 32.67 -6.45 34.92 -8.01
AML 133 33.51 -6.90 35.00 -11.44
AML 135 33.61 -6.84 35.00 -11.44
AML 136 34.64 -7.95 35.00 -11.44
AML 137 26.28 -1.80 30.07 -4.42
AML 138 28.98 -3.94 33.04 -6.76
AML 139 33.84 -6.81 35.00 -11.44
AML 142 35.00 -11.44 35.00 -11.44
AML 144 35.00 -11.44 35.00 -11.44
AML 149 31.35 -5.63 35.00 -11.44
AML 150 31.62 -5.34 35.00 -11.44
AML 151 33.00 -6.51 35.00 -11.44
AML 152 35.00 -11.44 35.00 -11.44
AML 153 32.25 -6.65 34.86 -8.46
AML 154 35.00 -11.44 35.00 -11.44
AML 155 33.66 -6.04 33.87 -6.19
AML 156 26.04 0.00 27.63 -1.10
AML 157 24.83 -1.45 27.30 -3.17
AML 158 30.82 -3.89 33.09 -5.46
AML 159 29.38 -4.01 32.38 -6.09
AML 160 34.29 -5.95 33.68 -5.53
AML 161 28.71 -3.33 32.47 -5.94
AML 162 33.87 -7.93 35.00 -11.44
AML 163 32.11 -6.05 35.00 -11.44
AML 164 35.00 -11.44 35.00 -11.44
AML 165 26.07 -2.31 28.99 -4.33
AML 166 29.21 -4.57 32.20 -6.64
AML 167 35.00 -11.44 35.00 -11.44
AML 168 26.37 -1.21 29.76 -3.56
AML 170 32.14 -7.39 35.00 -11.44
AML 171 25.67 -2.30 28.44 -4.22
AML 172 30.88 -4.77 34.30 -7.14
AML 174 34.84 -7.36 35.00 -11.44
AML 175 34.96 -6.23 35.00 -11.44
AML 176 32.31 -5.73 34.06 -6.94
AML 179 28.67 -4.07 31.37 -5.95
AML 180 31.07 -4.90 33.31 -6.45
AML 181 35.00 -11.44 35.00 -11.44
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Assay name hsa-miR-9 hsa-miR-9*
miRBase ID hsa-miR-9-5p hsa-miR-9-3p
Target Sequence UCUUUGGUUAUCUAGCUGUAUGA AUAAAGCUAGAUAACCGAAAGU
Sample Raw Ct Log(2^(-dCt)) Raw Ct Log(2^(-dCt))
AML 182 33.96 -6.78 35.00 -11.44
AML 183 29.35 -5.54 30.91 -6.62
AML 184 28.93 -4.15 30.30 -5.10
AML 185 29.43 -4.70 30.98 -5.78
AML 186 31.52 -6.50 33.49 -7.87
AML 187 32.51 -7.04 33.85 -7.97
AML 188 29.23 -3.54 30.19 -4.21
AML 189 31.50 -5.97 32.59 -6.73
AML 190 31.95 -6.36 33.33 -7.32
AML 192 26.48 -2.73 28.80 -4.34
AML 193 32.15 -7.23 34.51 -8.86
AML 195 25.82 -2.89 27.80 -4.27
AML 196 29.31 -4.15 31.50 -5.68
AML 198 35.00 -11.44 35.00 -11.44
AML 199 31.06 -5.64 33.42 -7.28
AML 200 32.53 -6.56 33.99 -7.58
AML 201 35.00 -11.44 35.00 -11.44
AML 202 32.17 -6.41 33.52 -7.35
AML 203 25.89 -1.83 29.44 -4.29
AML 204 30.69 -5.23 32.37 -6.40
AML 205 35.00 -11.44 35.00 -11.44
AML 206 30.35 -4.97 31.90 -6.05
AML 207 30.53 -5.49 33.93 -7.84
AML 208 34.28 -7.68 35.00 -11.44
AML 209 34.72 -8.13 35.00 -11.44
AML 210 32.77 -6.66 34.85 -8.11
AML 211 32.15 -6.36 33.55 -7.33
AML 212 32.67 -6.73 34.34 -7.89
AML 213 30.30 -5.25 32.94 -7.08
AML 215 33.33 -7.15 35.00 -11.44
AML 216 33.70 -0.97 35.00 -11.44
AML 217 29.17 -4.70 32.20 -6.80
AML 218 35.00 -11.44 35.00 -11.44
AML 220 24.99 -1.34 27.89 -3.35
AML 221 33.82 -7.56 34.36 -7.93
AML 222 33.61 -7.12 34.81 -7.95
AML 223 31.22 -5.62 33.17 -6.97
AML 225 30.49 -5.42 32.81 -7.02
AML 226 25.41 -1.58 28.53 -3.75
AML 227 34.10 -7.31 35.00 -11.44
AML 229 30.52 -5.75 32.39 -7.05
AML 230 34.93 -8.78 35.00 -11.44
AML 231 23.97 -0.80 26.91 -2.84
Assay name hsa-miR-9 hsa-miR-9*
miRBase ID hsa-miR-9-5p hsa-miR-9-3p
Target Sequence UCUUUGGUUAUCUAGCUGUAUGA AUAAAGCUAGAUAACCGAAAGU
Sample Raw Ct Log(2^(-dCt)) Raw Ct Log(2^(-dCt))
AML 232 32.91 -7.14 35.00 -11.44
AML 233 34.69 -8.31 35.00 -11.44
AML 235 26.93 -2.61 31.81 -5.99
AML 236 35.00 -11.44 35.00 -11.44
AML 237 34.93 -7.78 35.00 -11.44
AML 239 29.76 -4.95 31.50 -6.15
AML 240 34.03 -7.57 35.00 -11.44
AML 241 29.18 -5.24 31.54 -6.87
AML 242 34.18 -7.97 35.00 -11.44
AML 243 32.02 -6.78 33.88 -8.06
AML 246 34.49 -7.64 34.49 -7.65
AML 247 35.00 -11.44 35.00 -11.44
AML 249 34.68 -6.98 35.00 -11.44
AML 250 31.54 -5.69 34.11 -7.47
AML 252 35.00 -11.44 35.00 -11.44
AML 322 33.00 -7.66 35.00 -11.44
AML 1174 29.89 -5.44 33.41 -8.12
AML 1188 31.62 -6.55 34.54 -8.44
AML 1299 30.04 -6.25 33.44 -7.84
AML 1316 35.00 -11.44 35.00 -11.44
AML 1551 28.58 -5.52 35.00 -11.44
AML 1595 29.23 -5.55 33.52 -7.66
AML 1747 26.63 -4.31 35.00 -11.44
AML 1766 35.00 -11.44 35.00 -11.44
AML 2169 26.07 -2.08 30.18 -5.12
AML 2171 32.95 -7.13 32.59 -8.26
AML 2172 22.20 0.10 34.56 -9.25
AML 2175 28.17 -3.06 31.56 -6.68
AML 2176 29.64 -4.27 33.02 -7.60
AML 2184 25.58 -2.77 27.41 -5.78
AML 2186 35.00 -11.44 35.00 -11.44
AML 2188 27.21 -4.14 30.22 -6.20
AML 2189 31.28 -6.18 35.00 -11.44
AML 2190 33.21 -8.09 35.00 -11.44
AML 2192 35.00 -11.44 35.00 -11.44
AML 2194 32.50 -7.56 35.00 -11.44
AML 2195 32.39 -5.20 33.56 -7.87
AML 2197 35.00 -11.44 34.44 -9.74
AML 2199 26.43 -4.18 30.05 -5.94
AML 2200 33.09 -8.11 35.00 -11.44
AML 2201 29.34 -4.85 30.74 -7.08
AML 2203 26.91 -4.07 35.00 -11.44
AML 2205 29.87 -5.01 32.75 -7.81
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Assay name hsa-miR-9 hsa-miR-9*
miRBase ID hsa-miR-9-5p hsa-miR-9-3p
Target Sequence UCUUUGGUUAUCUAGCUGUAUGA AUAAAGCUAGAUAACCGAAAGU
Sample Raw Ct Log(2^(-dCt)) Raw Ct Log(2^(-dCt))
AML 2207 25.95 -3.59 29.08 -6.09
AML 2208 35.00 -11.44 35.00 -11.44
AML 2210 35.00 -11.44 35.00 -11.44
AML 2212 28.87 -5.16 32.73 -7.23
AML 2215 30.03 -5.57 35.00 -11.44
AML 2216 35.00 -11.44 35.00 -11.44
AML 2217 24.35 -1.62 30.56 -5.11
AML 2218 35.00 -11.44 35.00 -11.44
AML 2220 26.15 -2.60 35.00 -11.44
AML 2222 32.54 -7.42 33.56 -8.12
AML 2223 32.70 -7.69 33.79 -8.36
AML 2224 32.23 -6.08 33.89 -7.88
AML 2226 25.99 -2.84 31.60 -6.21
AML 2227 30.16 -3.83 35.00 -11.44
AML 2228 32.31 -4.68 35.00 -11.44
AML 2229 30.59 -4.54 29.85 -5.50
AML 2230 35.00 -11.44 35.00 -11.44
AML 2231 28.94 -2.69 31.02 -5.76
AML 2234 34.22 -9.38 34.14 -9.06
AML 2235 33.50 -7.53 32.53 -8.47
AML 2236 30.77 -5.33 32.29 -7.51
AML 2238 35.00 -11.44 35.00 -11.44
AML 2239 29.90 -3.81 33.93 -8.31
AML 2240 35.00 -11.44 35.00 -11.44
AML 2241 31.86 -7.23 35.00 -11.44
AML 2242 34.85 -9.01 35.00 -11.44
AML 2243 31.88 -6.21 35.00 -11.44
AML 2244 24.72 -1.82 27.95 -4.21
AML 2245 32.36 -7.28 31.97 -7.03
AML 2246 28.03 -4.55 29.68 -6.75
AML 2247 25.18 -2.57 32.65 -7.96
AML 2248 26.28 -3.83 29.78 -5.43
AML 2250 35.00 -11.44 35.00 -11.44
AML 2253 35.00 -11.44 35.00 -11.44
AML 2254 35.00 -11.44 33.85 -8.31
AML 2256 31.33 -5.45 31.70 -7.50
AML 2257 29.98 -5.44 30.94 -7.13
AML 2260 27.26 -3.57 28.05 -4.94
AML 2261 30.85 -6.30 32.79 -6.87
AML 2268 31.73 -7.65 33.40 -8.43
AML 2271 26.03 -2.71 28.97 -4.91
AML 2273 35.00 -11.44 35.00 -11.44
AML 2275 29.87 -5.02 35.00 -11.44
Assay name hsa-miR-9 hsa-miR-9*
miRBase ID hsa-miR-9-5p hsa-miR-9-3p
Target Sequence UCUUUGGUUAUCUAGCUGUAUGA AUAAAGCUAGAUAACCGAAAGU
Sample Raw Ct Log(2^(-dCt)) Raw Ct Log(2^(-dCt))
AML 2276 23.55 -1.27 27.50 -4.01
AML 2278 30.89 -5.09 33.73 -7.26
AML 2283 31.22 -4.94 35.00 -11.44
AML 2285 27.95 -3.60 31.03 -6.46
AML 2286 30.84 -5.36 35.00 -11.44
AML 2288 32.08 -6.60 30.48 -5.05
AML 2289 28.77 -4.36 35.00 -11.44
AML 2291 26.33 -3.37 29.40 -4.75
AML 2292 27.48 -2.65 30.91 -5.93
AML 2296 28.76 -4.83 31.44 -6.90
AML 2326 29.13 -5.51 35.00 -11.44
AML 2327 35.00 -11.44 35.00 -11.44
AML 2747 31.89 -6.41 33.70 -8.63
AML 3308 25.25 -2.13 28.97 -4.75
AML 3309 29.26 -4.95 31.75 -6.91
AML 3310 27.18 -3.51 31.41 -5.84
AML 3311 29.34 -4.75 34.67 -9.12
AML 3312 24.61 -2.25 32.07 -5.87
AML 3313 35.00 -11.44 35.00 -11.44
AML 3314 30.43 -5.96 31.82 -6.94
AML 3316 25.39 -2.15 29.47 -5.12
AML 3319 29.16 -4.47 33.06 -7.44
AML 3321 26.61 -3.27 29.19 -5.80
AML 3322 21.75 -0.36 24.32 -2.72
AML 3323 33.76 -8.11 35.00 -11.44
AML 3324 32.46 -6.45 35.00 -11.44
AML 3326 25.08 -2.32 35.00 -11.44
AML 3327 35.00 -11.44 35.00 -11.44
AML 3482 30.69 -6.19 33.20 -7.49
AML 3483 28.38 -4.07 31.64 -6.92
AML 3484 25.02 -2.19 28.87 -5.00
AML 4333 35.00 -11.44 35.00 -11.44
AML 4334 31.08 -5.75 34.62 -8.41
AML 4335 30.74 -5.94 34.55 -7.65
AML 4336 35.00 -11.44 35.00 -11.44
AML 4337 29.99 -5.24 33.42 -7.62
AML 4338 29.86 -5.21 35.00 -11.44
AML 4339 25.86 -1.86 29.54 -4.05
AML 4340 26.55 -2.79 30.22 -4.87
AML 4341 30.54 -5.49 34.53 -7.70
AML 5282 28.49 -5.17 33.42 -7.89
AML 5283 35.00 -11.44 35.00 -11.44
AML 5284 31.97 -6.64 34.63 -9.06
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Assay name hsa-miR-9 hsa-miR-9*
miRBase ID hsa-miR-9-5p hsa-miR-9-3p
Target Sequence UCUUUGGUUAUCUAGCUGUAUGA AUAAAGCUAGAUAACCGAAAGU
Sample Raw Ct Log(2^(-dCt)) Raw Ct Log(2^(-dCt))
AML 5285 27.99 -4.32 31.45 -6.34
AML 5286 28.55 -5.09 33.48 -8.40
AML 5357 34.03 -9.07 35.00 -11.44
AML 5358 22.69 -0.80 27.14 -3.40
AML 5359 29.87 -5.14 33.32 -7.15
AML 5360 25.69 -2.57 29.96 -4.87
AML 5361 26.89 -3.99 31.78 -6.32
AML 5362 35.00 -11.44 35.00 -11.44
AML 5363 28.43 -3.46 31.60 -5.81
AML 5364 32.39 -7.40 35.00 -11.44
AML 5365 29.27 -4.49 33.06 -7.48
AML 6237 26.15 -3.06 30.89 -5.68
AML 6238 29.13 -4.20 32.95 -7.35
AML 6239 30.53 -5.39 33.98 -8.13
AML 6240 30.89 -7.06 34.39 -8.67
AML 6241 26.08 -2.97 31.13 -5.93
AML 6243 33.76 -8.51 35.00 -11.44
AML 6245 23.74 -1.41 28.58 -4.17
AML 6246 22.68 -0.29 26.74 -3.13
AML 6247 32.99 -6.78 34.92 -8.15
AML 6359 33.72 -6.95 34.24 -7.89
AML 6363 30.00 -4.82 33.36 -7.37
AML 6364 23.71 -0.77 27.91 -2.90
AML 6365 35.00 -11.44 35.00 -11.44
AML 6368 29.33 -4.65 32.47 -6.83
AML 6370 27.08 -3.87 32.22 -6.86
AML 6371 23.73 -1.92 27.43 -4.08
AML 6372 35.00 -11.44 35.00 -11.44
AML 6373 30.81 -5.46 33.61 -7.39
AML 6374 28.71 -4.69 33.60 -7.79
AML 6376 35.00 -11.44 35.00 -11.44
AML 6379 29.14 -5.24 33.71 -7.97
AML 6448 32.15 -5.74 35.00 -11.44
AML 7301 27.11 -3.82 31.31 -5.93
AML 7302 25.33 -2.73 30.97 -5.43
AML 7303 35.00 -11.44 35.00 -11.44
AML 7304 29.06 -4.79 32.73 -7.53
AML 7305 27.90 -3.49 31.39 -6.23
AML 7306 25.49 -2.13 30.15 -4.73
AML 7307 24.74 -2.69 29.06 -4.59
AML 7308 30.93 -6.29 33.78 -8.57
AML 7309 28.03 -4.06 31.73 -6.24
AML 7310 28.64 -4.95 33.94 -8.08
Assay name hsa-miR-9 hsa-miR-9*
miRBase ID hsa-miR-9-5p hsa-miR-9-3p
Target Sequence UCUUUGGUUAUCUAGCUGUAUGA AUAAAGCUAGAUAACCGAAAGU
Sample Raw Ct Log(2^(-dCt)) Raw Ct Log(2^(-dCt))
AML 7311 29.31 -4.54 32.41 -5.77
AML 7312 29.73 -4.64 32.88 -6.43
AML 7313 33.33 -7.98 35.00 -11.44
AML 7314 29.52 -4.86 34.15 -7.64
AML 7315 30.35 -5.77 34.72 -7.56
AML 7316 29.88 -4.82 34.04 -7.75
AML 7317 29.44 -4.54 33.68 -6.51
AML 7318 31.79 -5.95 33.34 -7.43
AML 7319 26.54 -3.14 31.06 -5.72
AML 7320 26.06 -2.92 30.24 -5.02
AML 12500 30.13 -5.58 34.33 -8.50
AML 12501 33.77 -8.16 35.00 -11.44
AML 12502 33.24 -7.34 35.00 -11.44
AML 12503 32.61 -7.84 35.00 -11.44
AML 12504 25.45 -2.55 29.81 -5.57
AML 12505 26.66 -3.00 30.98 -5.99
AML 12506 27.39 -3.28 30.72 -5.59
AML 12507 34.76 -8.43 35.00 -11.44
AML 12509 34.79 -7.87 35.00 -11.44
AML 12510 32.22 -6.56 35.00 -11.44
AML 12511 26.28 -2.54 31.04 -5.84
AML 12512 31.23 -5.54 35.00 -11.44
AML 12513 29.26 -4.86 33.32 -7.66
AML 12514 28.82 -4.80 33.11 -7.76
AML 12515 28.20 -4.04 31.88 -6.60
AML 12516 33.48 -7.44 35.00 -11.44
AML 12517 31.75 -6.07 35.00 -11.44
AML 12518 33.40 -7.64 35.00 -11.44
AML 12519 29.44 -4.54 34.35 -7.94
AML 12520 29.51 -4.40 34.23 -7.67
AML 12521 28.25 -3.34 32.88 -6.55
AML 12522 32.24 -7.17 35.00 -11.44
AML 12523 28.55 -4.14 32.34 -6.77
AML 12524 31.75 -6.66 35.00 -11.44
AML 12525 29.09 -5.03 32.23 -7.21
AML 12526 25.85 -2.68 30.30 -5.76
AML 12527 34.18 -8.54 35.00 -11.44
AML 12528 27.38 -3.01 30.73 -5.34
AML 12529 26.82 -2.75 30.34 -5.19
AML 12530 29.30 -2.96 33.26 -5.70
AML 12531 34.49 -7.84 35.00 -11.44
AML 12532 32.77 -5.96 35.00 -11.44
AML 12534 32.27 -7.48 35.00 -9.37
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Assay name hsa-miR-9 hsa-miR-9*
miRBase ID hsa-miR-9-5p hsa-miR-9-3p
Target Sequence UCUUUGGUUAUCUAGCUGUAUGA AUAAAGCUAGAUAACCGAAAGU
Sample Raw Ct Log(2^(-dCt)) Raw Ct Log(2^(-dCt))
AML 12535 23.27 -0.95 27.12 -3.62
AML 12536 30.22 -4.60 33.39 -6.80
AML 12554 23.46 -1.21 28.04 -4.39
AML 12555 29.89 -5.36 32.35 -7.06
AML 12556 33.18 -7.13 35.00 -11.44
AML 12557 30.13 -5.34 34.59 -8.43
AML 12558 28.23 -4.45 33.76 -8.29
AML 12560 34.72 -8.88 35.00 -11.44
AML 12561 23.90 -1.03 28.28 -4.06
AML 12562 29.20 -5.28 34.98 -9.28
AML 12563 28.52 -3.56 33.60 -7.08
AML 12564 30.70 -5.39 33.81 -7.54
AML 12565 26.90 -3.06 30.65 -5.66
AML 12566 29.18 -4.85 32.69 -7.29
AML 12567 32.45 -6.55 35.00 -11.44
AML 13960 33.98 -8.53 35.00 -11.44
AML 13960 33.98 -8.53 35.00 -11.44
AML 13961 30.73 -6.23 34.85 -9.08
AML 13962 34.59 -8.58 35.00 -11.44
AML 13963 33.29 -7.73 35.00 -11.44
AML 13963 33.29 -7.73 35.00 -11.44
AML 13964 31.38 -6.39 35.00 -11.44
AML 13968 23.61 -1.59 27.84 -4.52
AML 13970 31.72 -7.14 35.00 -11.44
AML 13972 31.59 -6.74 33.97 -8.39
AML 13973 32.69 -6.64 35.00 -11.44
AML 13975 33.61 -8.13 35.00 -11.44
AML 13976 29.60 -4.84 34.78 -8.43
AML 13977 29.61 -4.76 33.38 -7.38
AML 13978 35.00 -11.44 35.00 -11.44
AML 13981 33.57 -8.17 35.00 -11.44
AML 13982 27.08 -2.80 32.23 -6.37
AML 13983 23.26 -1.36 27.57 -4.35
AML 13984 31.54 -7.27 35.00 -11.44
AML 13986 30.23 -5.45 33.88 -7.98
AML 13986 30.23 -5.45 33.88 -7.98
AML 13988 33.69 -8.48 35.00 -11.44
AML 13989 23.47 -1.13 28.15 -4.37
AML 13993 28.67 -4.34 32.84 -7.23
AML 13995 32.76 -7.32 35.00 -11.44
AML 13996 31.78 -6.05 35.00 -11.44
AML 13997 29.57 -4.65 33.97 -7.70
AML 13999 30.58 -5.71 35.00 -11.44
Assay name hsa-miR-9 hsa-miR-9*
miRBase ID hsa-miR-9-5p hsa-miR-9-3p
Target Sequence UCUUUGGUUAUCUAGCUGUAUGA AUAAAGCUAGAUAACCGAAAGU
Sample Raw Ct Log(2^(-dCt)) Raw Ct Log(2^(-dCt))
AML 14001 29.44 -5.36 34.19 -8.65
AML 14003 27.40 -3.59 32.76 -7.31
AML 14004 29.71 -4.78 33.82 -7.63
AML 14005 31.71 -6.51 35.00 -11.44
AML 14006 32.19 -7.27 35.00 -11.44
AML 14007 32.65 -7.19 35.00 -11.44
AML 14008 25.94 -2.60 30.98 -6.10
AML 14009 30.81 -5.96 35.00 -11.44
AML 14010 26.40 -2.04 31.93 -5.88
AML 14011 28.57 -4.02 33.82 -7.66
AML 14012 28.18 -4.29 34.00 -8.32
AML 14013 34.68 -8.17 35.00 -11.44
AML 14014 27.90 -3.37 32.99 -6.89
AML 14016 34.43 -8.45 35.00 -11.44
AML 14017 25.71 -2.40 31.39 -6.33
AML 14018 28.58 -4.03 34.22 -7.94
AML 14019 31.41 -6.66 35.00 -11.44
AML 14020 29.83 -5.66 35.00 -11.44
AML 14021 34.67 -8.26 35.00 -11.44
AML 14022 32.54 -6.42 35.00 -11.44
AML 14023 31.30 -5.94 35.00 -11.44
AML 14024 32.13 -6.80 35.00 -11.44
AML 14025 32.10 -6.67 35.00 -11.44
AML 14026 30.23 -4.75 35.00 -11.44
AML 14027 33.20 -7.45 35.00 -11.44
AML 14028 35.00 -11.44 35.00 -11.44
AML 14030 27.41 -3.85 33.57 -8.12
AML 14031 29.02 -4.45 35.00 -11.44
AML 14032 32.20 -6.35 35.00 -11.44
AML 14033 26.94 -2.95 31.00 -5.77
AML 14034 27.63 -3.38 33.36 -7.36
AML 14035 33.39 -7.77 35.00 -11.44
AML 14036 32.41 -6.10 35.00 -11.44
AML 14037 31.83 -6.06 35.00 -11.44
AML 14039 30.79 -5.64 35.00 -11.44
AML 14296 33.83 -7.55 35.00 -11.44
AML 14298 31.08 -5.55 35.00 -11.44
AML 14300 29.11 -3.92 34.72 -7.81
AML 14302 30.64 -5.34 34.81 -8.23
AML 14304 31.41 -6.72 35.00 -11.44
AML 14306 29.94 -4.92 34.77 -8.27
AML 14307 31.19 -6.20 35.00 -11.44
AML 14308 32.73 -6.99 35.00 -11.44
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Assay name hsa-miR-9 hsa-miR-9*
miRBase ID hsa-miR-9-5p hsa-miR-9-3p
Target Sequence UCUUUGGUUAUCUAGCUGUAUGA AUAAAGCUAGAUAACCGAAAGU
Sample Raw Ct Log(2^(-dCt)) Raw Ct Log(2^(-dCt))
AML 14309 32.95 -7.00 35.00 -11.44
AML 14310 27.57 -2.56 32.79 -6.17
AML 14311 32.10 -6.70 35.00 -11.44
AML 14312 32.28 -7.06 35.00 -11.44
AML 14313 33.60 -7.16 35.00 -11.44
AML 14314 31.52 -5.90 35.00 -11.44
AML 14315 28.46 -4.01 34.10 -7.92
AML 14316 33.64 -7.38 35.00 -11.44
AML 14319 29.35 -4.80 33.78 -7.87
AML 14321 32.51 -6.60 35.00 -11.44
AML 14323 32.65 -4.60 35.00 -11.44
AML 14324 25.40 -1.62 30.14 -4.90
AML 14326 35.00 -11.44 35.00 -11.44
AML 14329 35.00 -11.44 35.00 -11.44
AML 14331 31.39 -5.86 35.00 -11.44
AML 14334 29.11 -4.44 35.00 -11.44
AML 14335 32.79 -6.93 35.00 -11.44
AML 14338 29.85 -5.07 34.49 -8.29
AML 14340 27.48 -2.56 33.25 -6.56
AML 14341 33.10 -7.36 35.00 -11.44
AML 14342 27.41 -2.93 32.94 -6.77
AML 14343 27.93 -3.74 33.43 -7.55
AML 14344 34.26 -7.93 35.00 -11.44
AML 14345 27.04 -2.90 31.80 -6.20
AML 14348 31.57 -6.16 35.00 -11.44
AML 14349 30.67 -6.46 35.00 -11.44
AML 14351 34.58 -7.39 35.00 -11.44
AML 14354 27.70 -3.54 32.74 -7.04
AML 14355 28.60 -3.24 33.34 -6.53
AML 14356 31.15 -5.71 35.00 -11.44
AML 14359 30.67 -6.00 35.00 -11.44
AML 14361 30.54 -5.69 35.00 -11.44
AML 14362 23.39 -0.70 29.11 -4.67
AML 14363 35.00 -11.44 35.00 -11.44
AML 14364 27.52 -3.46 32.80 -7.12
AML 14365 29.62 -5.01 35.00 -11.44
AML 14366 34.24 -8.02 35.00 -11.44
AML 14368 25.17 -1.96 30.48 -5.64
AML 14369 31.81 -6.29 35.00 -11.44
Table S2. Univariable analysis of association of miR-9 and miR-9* expression with achievement of complete 
remission and survival in AML.
Univariable analysis HR/OR s.e. z P 95%  CI
miR-9
CR 1.018 0.055 0.33 0.739 0.915- 1.133
EFS 0.983 0.025 -0.67 0.506 0.935-1.034
RFS 0.978 0.033 -0.65 0.518 0.914-1.046
OS 0.985 0.027 -0.55 0.585 0.933-1.040
miR-9*
CR 1.159 0.102 1.68 0.092 0.976-1.376
EFS 0.889 0.039 -2.69 0.007 0.815-0.969
RFS 0.906 0.054 -1.66 0.096 0.806-1.018
OS 0.868 0.041 -3.03 0.002 0.791-0.951
Logistic regression was used for CR, and Cox proportional hazards model was used for EFS, RFS, and OS. HR < 1 
or HR > 1 indicate a decreased or increased risk. OR < 1 or OR > 1 indicated a decreased or increased odds for 
reaching CR.
Abbreviations: AML, acute myeloid leukemia; CR, complete remission; EFS, event-free survival; RSF, relapse-free 
survival; OS, overall survival; HR, hazard ratio; OR, odds ratio; CI, confidence interval.
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Table S3. Clinical and genetic characteristics of AML patients that express miR-9* by the level of expression. 
Patients were dichotomized into high and low expression groups based on the 75th percentile of miR-9* expression 
value (see Materials and Methods).
Low  miR-9* High miR-9*
No. of cases % No. of cases % P
Clinical parameters
Age (mean) 44.9 43.8
Range (min-max) 17.0-60.0 18.0-60.0
WBC, x 109/L (mean) 50.6 48.2
Range (min-max) 0.8-263.4 0.8-371.0
Sex
    Total 252 84
Male 126 50 41 49
Female 126 50 43 51
ELN prognostic risk†
Favorable 73 29 19 23
Intermediate-I 100 40 33 39
Intermediate-II 34 13 20 24 0.038
Adverse 45 18 12 14
Cytogenetics
+8 10 4 4 5
-5 or -5q 2 1 0 0
-7 or -7q 5 2 1 1
-9q 3 1 1 1
11q23‡ 7 3 4 5
t(9;11) 1 0 10 12 <0.001
t(8;21) 3 1 0 0
inv(3) or t(3;3) 3 1 0 0
inv(16) 19 8 2 2
Normal karyotype 147 58 50 60
Complex karyotype 27 11 5 6
Other 25 10 7 8
Molecular genetics in NK
CEBPA double 2 1 1 1
FLT3-ITD 67 27 19 23
FLT3-TKD 9 4 6 7
NPM1 101 40 27 32
Low  miR-9* High miR-9*
No. of cases % No. of cases % P
Treatment protocol
HOVON04 6 2 1 1
HOVON04A 6 2 0 0
HOVON29 27 11 9 11
HOVON42 48 19 16 19
HOVON42A 69 27 13 15 0.028
HD98A 96 38 45 54 0.015
Mann-Whitney test was used for continuous variables. Fisher’s exact and chi-square tests were used for categorical 
variables. †Only patients with biallelic mutations in CEBPA were included in favorable risk group (instead of any 
CEBPA gene mutation). ‡11q23 category contains MLL-related leukemias harboring 11q23 abnormalities other 
than t(9;11). NOTE. Percentages may add up >100% because of rounding.
Abbreviations: AML, acute myeloid leukemia; WBC, white blood cell count; ELN, European LeukemiaNet; NK, 
normal karyotype; CEBPA, CCAAT/enhancer-binding protein α; FLT3-ITD, internal tandem duplications in the FMS-
like tyrosine kinase 3; FLT3-TKD, FMS-like tyrosine kinase 3 with mutations in tyrosine kinase domain; NPM1, 
nucleophosmin.
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Figure S1. MiR-9 and miR-9* expression in AML. Distribution of (a) miR-9 and (b) miR-9* expression, and (c) the 
correlation between them. RNU24 was used as endogenous control. Expression is given as logarithm of 2(dCt). 
For measurements below detection, the minimal threshold was set to -dCt value of -15.
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Figure S2. Patient outcome improves with increasing levels of miR-9* expression. (a) Overall survival (OS) of AML 
patients that express measurable levels of miR-9* (miR-9*-positive) and those with no expression (miR-9*-negative). 
(b) Event-free survival (EFS), (c) overall survival (OS), and (d) relapse-free survival (RFS) of miR-9*-positive cases 
according to the quartiles of miR-9* expression. 
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Figure S3. Patients with high miR-9* have better overall survival. (a) Overall survival (OS) of AML patients according 
to miR-9* expression. (b-e) OS of AML patients belonging to (b) favorable, (c) intermediate-I, (d) intermediate-II, 
and (e) adverse risk group according to miR-9* expression. Patients were dichotomized into high and low expression 
groups based on the 75th percentile of miR-9* expression value (see Materials and Methods).
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Figure S4. Patients with high miR-9* have better relapse-free survival. (a) Relapse-free survival (RFS) of AML 
patients according to miR-9* expression. (b-e) RFS of AML patients belonging to (b) favorable, (c) intermediate-I, 
(d) intermediate-II, and (e) adverse risk group according to miR-9* expression. Patients were dichotomized into high 
and low expression groups based on the 75th percentile of miR-9* expression value (see Materials and Methods). 
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Here we will place the findings reported in this thesis on miR-9/9* into a broader perspective 
and discuss the implications for our understanding of the biology of leukemia and future 
research.
1. At which stage of myeloid development do miR-9/9* block myeloid differentiation and 
does the observed in vitro  block in differentiation translate into aberrant hematopoiesis 
in vivo?
miR-9 has been reported to influence cell differentiation in various types of human cancer. 
In cervical squamous cell carcinoma, a chromosomal gain of 1q is linked with malignant 
progression and results in upregulation of miR-9 (1q23.3) (Figure 1).1 Overexpression of miR-9 
in normal keratinocytes cell line blocks epithelial differentiation. In Hodgkin lymphoma cells, 
miR-9 is highly expressed and its downregulation triggers B-cell differentiation into plasma 
cells.2 In line with these findings, in Chapter 2 we show that the expression of miR-9/9* 
disrupts normal neutrophil differentiation in the myeloid 32D cell line model and in primary 
HSPCs in vitro. In our murine miR-9/9* bone marrow overexpression model, we observed 
an increase in the frequency of Lin-c-Kit+Sca-1- (LK) progenitor population in cells expressing 
miR-9/9*. Since the frequencies of more immature Lin-Sca-1+c-Kit+ (LSK) populations were 
similar, our data suggest that the observed block in differentiation may occur at the later 
stages of myeloid development. In order to investigate the effect of overexpression of miR-
9/9* on the function of different cell populations further in vivo hematopoietic repopulation 
studies would be useful. In such experiments, HSPCs that overexpress miR-9/9* should 
be transplanted into recipient animals in order to evaluate  their ability to repopulate 
different cellular compartments of the hematopoietic system in short-term and long-term 
repopulation experiments. Moreover, proposed transplantation experiments may help to 
elucidate whether our in vitro findings can be extrapolated into miR-9/9* induced aberrant 
hematopoiesis in vivo. 
2. How do miR-9/9* influence adhesion and migration of hematopoietic cells?
In Chapter 4, we report that HSPCs that overexpress miR-9/9* have decreased potential 
to home to the BM. Data presented in Chapter 3 revealed that miR-9/9* may regulate 
genes that are involved in decreased adhesion and migration of cells. Our results suggest 
that miR-9/9* may not only impact myeloid differentiation but also affect other aspects 
of HSPC function, such as adhesion, migration, engraftment and metastasis. In the past 
years, several studies have reported on the relationship of miR-9/9* expression with 
different processes in human cancer, e.g. migration and metastasis (Table 1, Figure 1). In 
glioblastoma multiforme, miR-9 has been reported to play a critical role in determination of 
the so-called “go or grow” phenotype.3 miR-9 is part of a feedback minicircuitry that allows 
a tight control of the expression levels of target genes that coordinate the proliferation 
and migration of glioblastoma cell lines. In 2010, Ma et al. reported that miR-9 plays 
an important role in metastasis of MYC-driven breast tumor.4 By targeting E-cadherin in 
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breast tumor cells, miR-9 enables dissociation of carcinoma cells and leads to formation 
of pulmonary micrometastasis.4,5 Retention and movement of HSPCs within the BM and 
periphery are important biologic processes that are crucial to the maintenance of the stem 
cell pool in the BM.6,7 The detailed ability of miR-9/9* to influence adhesion and migration 
of HSPCs warrants further study for example using in vitro assays that measure adhesion to 
fibronectin and migration of HSPCs towards various ligands (e.g. CXCL2).8
3. Do miR-9 and miR-9* exert synergistic or antagonistic functions?
The data presented in this thesis are derived from experiments with concomitant 
overexpression of both mature miRNA strands, miR-9 and miR-9*. This implies that we are 
unable to distinguish the effects of either one separately and therefore we cannot make 
specific interpretations regarding their independent roles nor about potentially synergistic 
or antagonistic roles of miR-9 and miR-9*. In CD133+ glioblastoma stem cells, both miRNAs 
are highly expressed and needed for stem cell renewal (Figure 1).9 In claudin-low triple-
negative breast cancer cells, overexpression of miR-9* has been reported to synergize with 
mitogen-activated protein kinase enzymes 1 and 2 (MEK1/2) inhibitor and to suppress 
growth, migration and invasion of tumor cells.10 Interestingly, miR-9 has a reverse effect 
and its overexpression together with MEK1/2 inhibitor increases cell proliferation. These 
findings suggest that miRNAs co-expressed following generation from the same precursor 
may fulfill different and opposing functions and that there may be regulatory mechanisms 
specific of miR-9 or miR-9* expression. In Chapter 2, we show that miR-9 and miR-9* are 
both highly expressed in most cases of AML. The functions of individual miR-9 and miR-9* in 
hematopoietic system remain to be studied using models with specific overexpression and/
or silencing of either one of these miRNAs.
4. Which targets of miR-9/9* contribute to their functions observed in myeloid cells?
In Chapter 2, using GEP assay we identified ERG as a miR-9 target in murine 32D cells and 
human AML samples. Reintroduction of Erg into miR-9/9* overexpressing 32D cells restored 
normal neutrophil differentiation. The proteomics data presented in Chapter 3 indicate 
other potential miR-9 targets that may influence differentiation, adhesion and migration 
of myeloid cells. These include MYH9, MYO1C, ITGA6, VCL and ANXA2. Until today, 4 of 
them have been reported in relation to miR-9 in different types of human cancer. MYO1C, 
ITGA6 and VCL are repressed by miR-9 in osteosarcoma, and ANXA2 in hepatocellular 
carcinoma.11,12 Functions of these potential targets have been linked to the hematopoietic 
system. MYO1C and VCL are involved in cytoskeleton rearrangements and they may 
influence cell motility in B cells and monocytes, respectively.13,14 ITGA 6 is associated with 
resistance of leukemia and lymphoma cells against gamma T cell-mediated cytotoxicity 
and ANXA2 may affect adhesion, homing and chemosensitivity of acute lymphoblastic 
leukemia cells.15,16 Whether the proteins reported in Chapter 3 are direct targets of miR-
9 and influence normal myeloid cell functions needs to be further investigated. miRNAs Ta
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fine-tune cell-specific gene regulatory networks by influencing the expression of multiple 
genes. These genes may interplay with each other by fulfilling separate functions. Therefore, 
deconstructing the weighted contribution of each of these separate targets to the observed 
phenotypes may be a challenging task.
5. What are the mechanisms that regulate miR-9/9* expression in AML?
The reasons for aberrant expression of miR-9/9* in AML are unknown. Since miR-9/9* genes 
contain their own promoters, one could speculate that it is a result of deregulated control by 
aberrant levels of transcription factors that regulate miR-9/9* expression. In fact, miR-9/9* 
expression has been reported to be regulated by transcription factors commonly upregulated 
in AML, such as Nf-κB.17,18 The mechanisms that control miR-9/9* levels may be different in 
various subtypes of AML since it has been shown that various aberrantly expressed fusion 
proteins can influence miR-9 expression. In example, the leukemic fusion protein AML1-ETO 
downregulates miR-9 in t(8;21) rearranged leukemias and MLL-AF9 upregulates miR-9 in 
MLL-rearranged cases.19,20 The existence of various mechanisms that may regulate miR-9/9* 
within one malignancy has been shown in other types of human cancer where miR-9/9* are 
differentially expressed according to the cellular context (Figure 1).
In Chapters 2, we reported that miR-9 is expressed at low levels in normal CD34+ cells, 
while miR-9* is not expressed. Furthermore, miR-9 is expressed in 89% and miR-9* in 59% of 
patients with AML as shown in Chapter 5. The molecular and mechanistic basis of low miR-
9* expression in such a high percentage of AML cases remains the subject of future studies. 
The existence of specific post-transcriptional modulation mechanisms that regulate miR-9* 
expression separately from miR-9 may play a role, e.g. RNA methylation and differential 
expression of RNA-induced silencing complex components.21-23
6. Can the prognostic value of miR-9* expression be incorporated in algorithms with 
clinical utility that predict patient outcome in AML?
Few miRNAs have been shown to impact patient outcome in AML, e.g. miR-155, miR-181a 
and miR-212.24-28 In Chapter 5, we show that although miR-9 has no prognostic significance, 
its passenger strand miRNA-9* predicts improved survival. Until today, it is the first report 
showing that the preservation of a miRNA* expression has prognostic significance. Most 
miRNA*s are thought to be degraded during the strand selection by miRISC complexes.29,30 
Therefore, our results support further research focused on miRNA*s in AML. 
The use of miRNAs as biomarkers of a disease is still hindered by technical obstacles and 
no miRNA has yet been incorporated into clinical algorithms. Before we can apply miRNAs 
in the clinical setting, the measurement of their expression levels should be standardized 
and robust.31 Additionally, the prognostic value of miRNAs is usually reported for “high 
versus low” expressers, unlike “yes versus no” for gene mutations, e.g. NPM1 and C/EBPα.32 
This brings difficulties in establishing universal cut-offs of miRNA expression that would be 
clinically applicable. 
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ENGLISH SUMMARY
miRNAs are small non-coding RNAs that as a part of miRISC complexes bind to the target 
mRNAs and lead to translational repression and/or transcript decay. In this way, they post-
transcriptionally suppress gene expression. miRNAs are known to control the expression 
of genes involved in normal myelopoiesis and AML, a disease that is characterized by the 
accumulation of abnormally differentiated myeloid cells in the BM. 
In Chapter 2, a screen using retroviral barcoded miRNA expression library in murine 32D 
cell line model revealed that miR-9/9* may interfere with normal neutrophil differentiation. 
This was further confirmed by the overexpression of miR-9/9* in 32D cells and in murine 
primary HSPCs. In human CD34+ cells, miR-9 is expressed at low levels and miR-9* is not 
expressed. However, they are both aberrantly upregulated in most cases of AML. In order to 
identify the miR-9/9* targets that may be involved in the observed phenotype, we analyzed 
the transcriptomes of AML cells that highly express miR-9/9* and 32D cells that were 
transduced with these miRNAs. We found ERG to be the only potential target common for 
both sample types. ERG was further shown to be direct miR-9 target and its overexpression 
in 32D cells recued miR-9/9*-induced block in neutrophil differentiation.
To unravel other potential miR-9/9* targets that may be involved in normal myeloid 
cell function, in Chapter 3 we performed proteome studies in 32D cells that ectopically 
expressed miR-9/9*. Twenty-nine proteins were significantly down- or upregulated in 
a steady state between miR-9/9* transduced and control cells, and 42 upon induction 
of neutrophil differentiation. Subsequent pathway analysis showed that these proteins 
could be related to cell differentiation, apoptosis, migration and adhesion. Among the 
downregulated proteins, we found 5 potential miR-9 targets: MYO1C, ANXA2, VCL, MYH9 
and ITGA6. No miR-9* targets were found to be differentially expressed.
In order to explore potential influence of miR-9/9* on migration and adhesion 
of normal hematopoietic cells, in Chapter 4 we examined the function of HSPCs that 
ectopically expressed miR-9/9* using in vivo homing assay. We observed that HSPCs that 
were transduced with miR-9/9* seed in the BM three times less efficiently than control 
cells. The observed phenotype was not related to the increased apoptosis and/or decreased 
colony-forming potential of these cells. These preliminary results suggest that miR-9/9* may 
influence adhesion and migration of HSPCs.
The differential expression of miRNAs has been associated with various subtypes of AML 
and linked with clinical outcome. In Chapter 5, we investigated the prognostic significance 
of miR-9/9* in a large cohort of primary AML cases. Although, the expression of miR-9 had 
no clinical impact, high expression of its passenger strand miR-9* independently predicted 
improved patient survival. Furthermore, transcriptome analysis revealed that miR-9* may 
regulate genes involved in leukemogenesis, such as MN1 and MLLT3.
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DUTCH SUMMARY (NEDERLANDSE SAMENVATTING)
MiRNAs zijn kleine niet-eiwit coderende RNA’s die als onderdeel van het miRISC complex 
binden aan target mRNAs, wat resulteert in translatie onderdrukking en of transcriptie 
blokkade. miRNAs reguleren de expressie van genen die betrokken zijn bij de normale 
myelopoiese en bij AML, een ziekte die wordt gekenmerkt door de accumulatie van 
abnormaal gedifferentieerde myeloïde cellen in het beenmerg.  
In Hoofdstuk 2 met behulp van een retrovirale barcode-miRNA expression-library in 
een muizen 32D-cellijn model bleek dat miR-9/9* kunnen interfereren met de normale 
neutrofiele differentiatie. Dit werd bevestigd door overexpressie van miR-9/9* in 32D-cellen 
en in primaire humane pluripotente stamcellen (HSPCs). In humane CD34+ cellen, komt 
miR-9 in geringe mate en miR-9 * niet tot expressie. Echter, beiden komen tot expressie 
in de meerderheid van AML patiënten. Om de miR-9/9* targets die betrokken zijn bij het 
waargenomen fenotype te kunnen identificeren, analyseerden we het transcriptoom van 
AML cellen en 32D cellen die waren getransduceerd met deze miR-9/9* en identificeerden 
we ERG als een potentieel target. Vervolgens hebben we aangetoond dat ERG een directe 
miR-9 target is en dat over-expressie van ERG in 32D cellen een miR-9/9*-geïnduceerde blok 
in neutrofielen differentiatie kan herstellen.  
Om nieuwe potentiële miR-9/9* targets die betrokken zijn bij normale myeloïde 
celfunctie te kunnen identificeren, in Hoofdstuk 3 voerden we proteomics-studies uit in 32D 
cellen met ectopisch expressie van miR-9/9*. In de steady state toestand waren 29 eiwitten 
significant up- of down-gereguleerd in miR-9/9* cellen te opzichte van controle cellen en 
bij in-vitro inductie van neutrofielen differentiatie waren dat er 42.  Een daaropvolgende 
pathway analyse toonde aan dat deze eiwitten te maken hebben met celdifferentiatie, 
apoptose, migratie en adhesie. Onder de down-gereguleerde eiwitten vonden we 5 
mogelijke miR-9 targets: MYO1C, ANXA2, VCL, MYH9 en ITGA6. miR-9 * targets bleken niet 
verschillend tot expressie te komen. 
Met behulp van een in vivo homing assay in Hoofdstuk 4 hebben we de potentiele 
invloed van miR-9/9* op de migratie en adhesie van normale hematopoietische cellen 
onderzocht in HSPCs met ectopische expressie van miR-9/9* We vonden dat HSPCs die 
waren getransduceerd met miR-9/9* driemaal minder efficiënt konden nestelen in het 
beenmerg dan controle cellen. Het waargenomen fenotype was niet gerelateerd aan 
verhoogde apoptose of aan een verminderd kolonievormend vermogen van deze cellen. 
Deze voorlopige resultaten suggereren dat miR-9/9 * de adhesie en migratie van HSPCs 
kunnen beïnvloeden. 
Tenslotte in Hoofdstuk 5 hebben we beschreven dat de differentiële expressie van 
miRNAs is geassocieerd met verschillende subtypes van AML en gekoppeld aan de klinische 
uitkomst. We onderzochten de prognostische betekenis van miR-9/9* in een groot cohort 
van primaire AML casus. Hoewel, de expressie van miR-9 niet was geassocieerd met de uit-
komst, voorspelde een hoge expressie van miR-9* een verbeterde overleving van patiënten. 
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POLISH SUMMARY (POLSKIE PODSUMOWANIE)
miRNA to małe niekodujące RNA, które jako część kompleksów miRISC wiążą się z 
docelowymi mRNA i blokują ich translację oraz/albo prowadzą do rozpadu docelowych 
transkryptów. W ten sposób potranslacyjnie obniżają ekspresję genów. Wiadomo, że miRNA 
kontrolują ekspresję genów zaangażowanych w leukopoezę i ostrą białaczke szpiku, chorobę 
charakteryzującą się nowotworowym rozrostem w szpiku wadliwie zróżnicowanych komórek 
krwi.
W Rozdziale 2 skrining z użyciem retrowirusowej oznakowanej biblioteki miRNA w mysiej 
linii komórkowej 32D ujwnił, że miR-9/9* mogą interferować z normalnym różnicowaniem 
się neutrofilów. To zostało dalej potwierdzone przez nadekspresję miR-9/9* w komórkach 
32D i w mysich pierwotnych komórkach macierzystych i prekursorowych. W ludzkich 
normalnych komórkach macierzystch krwi (CD34+) miR-9 ulega ekspresji na niskim poziomie 
i miR-9* nie ulega ekspresji. Jednakże oba miRNA występują na anormalnie wysokim 
poziomie w większości przypadków ostrej białaczki szpiku. Aby zidentyfikowć docelowe 
dla miR-9/9* transkrypty, które mogą być zaangażowane w zaobserwowany fenotyp 
przeanalizowaliśmy transkryptomy komórek ostrej białaczki szpiku, które charakteryzowały 
się wysokim poziomem miR-9/9* oraz transkryptomy komórek 32D, w których miR-9/9* 
były ekpresjonowane za pomocą transdukcji. Odkryliśmy, że ERG był jedynym potencjalnym 
kandydatem w obu typach komórek. Białko ERG zostało dalej potwierdzone jako bezpośredni 
cel regulwany przez miR-9 i jego nadekspresja w komórkach 32D odwróciła spowodowaną 
przez miR-9/9* blokadę w różnicowaniu się neutrofilów.
Aby ujawnić inne potencjalne cele miR-9/9*, które mogą być zaangażowane w normalne 
funkcjonowanie leukocytów w Rozdziale 3 przeprowadziliśmy badania nad proteomem 
w komórkach 32D z użyciem ektopowej ekspresji miR-9/9*. W normalnym stanie 29 
białek było ekspresjonowanych na znacząco niższym lub wyższym poziomie w komórkach 
transdukowanych miR-9/9* w porównaniu z komórkami kontrolnymi oraz 42 białka były 
ekspresjonowane na anormalnym poziomie podczas indukcji różnicowania się neutrofilów. 
Późniejsza analiza wykazała, że te białka mogą być związane z różnicowaniem się komórek, 
apoptozą, migracją i adhezją. Wśród białek, które ulegały ekspresji na zredukowanym 
poziomie odkryliśmy 5 potencjalnych celów dla miR-9: MYO1C, ANXA2, VCL, MYH9 and 
ITGA6. Nie odkryliśmy żadnych potencjalnych celów dla miR-9*.
W celu zbadania czy miR-9/9* mogą potencjalnie wpływać na migrację i adhezję 
normalnych komórek krwi, w Rozdziale 4 zbadaliśmy funkcję komórek macierzystych 
i prekursorowych, które ektopowo ekspresjonowały te miRNA, z użyciem badania in 
vivo zasiedlania szpiku po przeszczepie. Zaobserwowaliśmy, że komórki macierzyste i 
prekursorowe, które ekspresjonowały miR-9/9* zasiedlają szpik trzy razy mniej wydajnie niż 
komórki kontrolne. Zaobserwowany fenotyp nie był związany ze zwiększoną apoptozą oraz/
albo zmniejszonym potencjałem do tworzenia kolonii. Te wstępne wyniki sugerują, że miR-
9/9* mogą mieć wpływ na adhezję i migrację komórek macierzystych i prekursorowych krwi.
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Zróżnicowana ekspresja miRNA jest związana z różnymi rodzajami ostrej białaczki 
szpiku i wskaźnikiem przeżywalności pacjentów. W Rozdziale 5 badaliśmy prognostyczne 
znaczenie miR-9/9* w dużej kohorcie pierwotnych przypadków ostrej białaczki szpiku. 
Mimo, że ekspresja miR-9 nie miała znaczenia klinicznego, wysoka ekspresja miR-9* była 
niezależnie związana z lepszą przewidywaną przeżywalnością pacjentów. Ponadto analiza 
transkryptomu ujawniła, że miR-9* może regulować geny zaangażowane w rozwój białaczki, 
takie jak MN1 i MLLT3.
GLOSSARY OF ABBREVIATIONS
(in alphabetic order)
AC adenocarcinoma
AKT protein kinase B
ALL acute lymphoblastic leukemia
AML acute myeloid leukemia
AMLSG German-Austrian AML Study Group
AP-1 activator protein 1
APL acute promyelocytic leukemia
BC breast cancer
BM bone marrow
CBFβ  core binding factor β
CDK6  cyclin-dependent kinase 1
C/EBPα  CCAAT/enhancer-binding protein α
C/EBPβ  CCAAT/enhancer-binding protein β
CFU  colony-forming unit
CFU-G CFU-granulocyte assay
CI confidence interval
CLL  chronic lymphocytic leukemia
CLP common lymphoid progenitor
CMP common myeloid progenitor
CR complete remission
DC dendtritic cell
ΔEGFR mutant epidermal growth factor receptor
DFS disease-free survival
EFS event-free survival
ELN European LeukemiaNet
ERG ETS-related gene
ErP erythrocyte precursor
ERRFI1 ERBB receptor feedback inhibitor 1
EV empty vector
FACS fluorescence-activated cell sorting
FDR false discovery rate
FGFR1  fibroblast growth factor receptor 1
FZD7  frizzled-7
GBM glioblastoma multiforme
G-CSF granulocyte colony-stimulating factor
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GEP gene expression profile
GMP granulocyte/monocyte progenitor
HCC hepatocellular carcinoma
HDAC histone deacetylase
HES1 hairy and enhancer of split-1
HL Hodgkin lymphoma
HOVON Dutch-Belgian-Hematology-Oncology-Cooperative group
HPV E6 human papillomavirus E6 oncoprotein
HR hazard ratio 
HSC hematopoietic stem cell
HSPC  hematopoietic stem/progenitor cell
IGF2BP3  insulin-like growth factor 2 mRNA binding protein 3
IL-3 interleukin 3
IPA Ingenuity Pathway Analysis
LC-MS/MS liquid chromatography tandem mass spectrometry
Lin- lineage negative cells
LK Lin-c-Kit+Sca-1-
LNA locked nucleic acid
LSK Lin-Sca-1+c-Kit+
LSC leukemia stem cell
LSPC leukemic stem/progenitor cell
MEF2C  myocyte-specific enhancer factor 2C
MEK1/2(i) mitogen-activated protein kinase enzymes 1 and 2 (inhibitors)
MEP megakaryocyte/erythroid progenitor
miRISC  miRNA-induced silencing complex
miR(NA) microRNA
miR-9/9*  miR-9 and miR-9*
MkP megakaryocyte precursor
MLL mixed-lineage leukemia
MM multiple myeloma
MNC mononuclear cells
MPP multipotent progenitor
muBM murine bone marrow cells
NF-κB  nuclear factor kappa-light-chain-enhancer of activated B cells 
NF1A  nuclear factor 1 A-type
NK natural killer cell
NK-AML normal karyotype AML
NPM1 nucleophosmin gene
OR odds ratio
OS  overall survival 
PI3K phosphatidylinositol-4,5-bisphosphate 3-kinase
PRDM1/BLIMP-1 positive regulatory domain 1
pre-miRNA precursor miRNA
pri-miRNA primary miRNA 
PKB/AKT1 protein kinase B
RFS  relapse-free survival
RHOH  Ras homolog family member H
RNA ribonucleic acid
RUNX1  runt-related transcription factor 1
RYBH  YY1-binding protein
SCC squamous cell carcinoma
SILAC stable isotope labeling by amino acids in cell culture
SOCS1 suppressor of cytokine signaling 1
SPRED1 sprouty-related, EVH1 domain-containing protein 1
STAT3  signal transducer and activator of transcription 3 
TNF-α  tumor necrosis factor α
WBC white blood cells
WM Waldenström macroglobulinemia
TCGA The Cancer Genome Atlas
3’UTR  3’ untranslated region
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